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 Several polymer systems including P(MAA-g-EG) and P(MAA-co-NVP) with 
crosslinking agents TEGDMA and PEGDMA1000, monomer-to-solvent ratios of 67:33, 
60:40, and 50:50, and particle sizes of <75 microns, 90-150 microns, and 150-212 
microns were synthesized for use with protein-transporter conjugates.  All synthesized 
systems were characterized by SEM which demonstrated the visual size, surface 
features, and surface textures of the polymer microparticles. 
 Insulin-transferrin and calcitonin-transferrin conjugates were successfully 
synthesized using the protein crosslinker SPDP, binding the two proteins with a disulfide 
bond.  The multi-step conjugation reactions used to create the conjugates were 
analyzed by the use of UV spectroscopy and HPLC to ensure the quality of the final 
products.  In both conjugation reactions, the final product yield was found to be over 
70%. 
 The in vitro loading and release characteristics for insulin-transferrin and 
calcitonin-transferrin were separately investigated.  By testing loading and release using 
a number of different polymer systems with different synthesis parameters, it was 
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possible to optimize the hydrogel carriers for use with each of the conjugates 
independently.  Upon optimization, the ideal system for use with insulin-transferrin and 
calcitonin-transferrin was found to be P(MAA-g-EG) microparticles of <75 microns 
formed using a PEGDMA1000 crosslinker and a 50:50 monomer-to-solvent ratio for both 
conjugates through separate optimization processes.  This optimized polymer carrier 
was found to release upwards of 50% of loaded insulin-transferrin conjugate and near 
90% of loaded calcitonin-transferrin conjugate. 
 The insulin-transferrin conjugate was further evaluated through the use of 
cellular and animal models.  Using cellular models, the insulin-transferrin conjugate was 
shown to increase transport relative to insulin by a factor of 7, achieving an apparent 
permeability of 37 x 109 cm/s.  Also, in the presence of polymer microparticles, the 
insulin-transferrin conjugate increased transport by a factor of 14 times relative to 
insulin, achieve an apparent permeability of 72.8 x 109 cm/s.  The presence of the 
microparticles near the cells was found to improve conjugate transport by nearly 100%.  
The preliminary animal studies verified the successful synthesis of the insulin-transferrin 
conjugate as well as demonstrated the bioactivity of the insulin portion of the molecule 
by achieving a drop in blood glucose level upon subcutaneous injection. 
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CHAPTER 1 
INTRODUCTION 
   
  Due to the recent growth in the fields of biomedical and pharmaceutical 
research, an increasing portion of current therapeutic agents is comprised of 
macromolecules such as proteins.  Because of the low solubility and low permeability of 
most therapeutic proteins, it has been exceedingly difficult to formulate successful oral 
dosage forms for administering protein drugs.  While the oral route remains the 
preferred route of therapeutic administration, the nature of most protein drugs requires 
administration through injection to ensure high bioavailability and high efficacy.  Insulin, 
which is used to treat diabetes, is an example of a therapeutic protein which has 
traditionally been injected.  Many patients consider insulin injections to be painful, 
generally leading to a decrease in patient compliance [1].   
  Lack of patient compliance in treating diabetes can lead to many serious 
complications such as blindness, kidney failure, amputations, cardiovascular disease, 
and even death [2].  Similar consequences also can occur from noncompliance issues 
with other illnesses treated by protein drugs.  In an effort to decrease injections and 
increase patient compliance, there has been a strong emphasis in recent years on the 
development of alternative formulations for the delivery of therapeutic proteins [3-5].   
  Each route of administration for therapeutic agents has its inherent advantages 
and disadvantages [3].  For therapeutic proteins, the possibility of pulmonary delivery, 
or delivery through the lungs, has been investigated [6].  While pulmonary delivery 
allows for rapid drug absorption through the very thin (0.1-0.5 μm) alveolar epithelium 
with a large surface area (~75 m2) for absorption in the lung, it also has barriers to 
effective delivery such as delivery device inefficiency and rapid clearance of the drug 
from the lungs through enzymatic degradation, mucocilliary clearance, and phagocytosis 
[7].   
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  Another alternative route for protein delivery is through the skin, or transdermal 
delivery.  Transdermal delivery systems are simple to administer and are relatively 
painless, but such systems typically suffer from low bioavailability and protein size 
limitations [8].  It has been shown that iontophoresis, a common enhancement 
technology for transdermal delivery, can effectively transport a 12.4 kDa protein across 
the skin [9].  Other enhancement technologies for transdermal delivery are being 
investigated in an attempt to increase the size limitation of this type of delivery.   
  Rectal delivery and ocular delivery of proteins have also been considered, but 
the patient acceptability and discomfort associated with rectal delivery and the effective 
defense mechanisms of the eye leading to low bioavailability for ocular delivery exclude 
either from becoming a viable mainstream option [10].  Intravaginal delivery has also 
received some consideration [4], but the patient discomfort and obvious gender 
limitations prevent the possibility of its widespread use.  The oral route of 
administration for therapeutic proteins remains the most attractive route of drug 
delivery for investigation, despite several inherent challenges [11].  This body of work 
will focus on the development of an effective oral delivery system which utilizes natural 
transport pathways in an effort to increase bioavailability of the therapeutic protein 
being delivered. 
  Oral delivery of proteins is beneficial due to the increased patient compliance, 
low cost, ease of administration, and the overall increased quality of life for the patient 
in comparison to injection therapy.  To achieve an effective oral delivery system, several 
physiological barriers must be overcome.  For the protein to reach the absorption site of 
the small intestine, it must first resist proteolytic degradation and the low pH 
environment of the stomach.   
  Due to their sensitive nature, most proteins will be degraded or denatured by 
the enzymes in the stomach [12].  The protein-enzyme interaction can be minimized 
with the introduction of a protective carrier for the therapeutic protein.  By 
encapsulating the protein in a pH-sensitive hydrogel carrier, it can be protected in the 
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harsh environment of the stomach and then released in the small intestine based on the 
physical pH change [13].  As the hydrogel carrier reaches the small intestine, it needs an 
appropriate residence time at the site of absorption to effectively release the loaded 
protein.  In an effort to increase residence time, tethers consisting of polymer chains can 
be grafted onto the hydrogel to promote adhesion to the mucosa lining the small 
intestine [14].  The addition of polymer tethers mitigates the effect of intestinal motility, 
allowing additional time for the protein to be released. 
  The primary biological barrier investigated in this work exists as the site of 
absorption.  Due to the large molecular weight of most proteins, transport across the 
intestinal epithelium into the bloodstream is often extremely difficult.  Increased 
protein transport through the paracellular route can be achieved by a reversible 
opening of the tight junctions in the presence of polymer hydrogels [15].  The 
transcellular route of protein transport through the epithelium by conjugation to a 
transporter ligand has also been investigated [16].  Transcellular protein transport is 
advantageous for use in a drug delivery system because of less viral risk due to the tight 
junctions not being opened and the selective targeting of the transporter ligand to its 
specific receptor on the cell. 
 This thesis focuses on utilizing the transcellular mechanism of absorption in an 
attempt to increase overall protein transport across the epithelium.  Multiple protein-
transporter conjugates were synthesized and characterized for incorporation into 
polymer hydrogel carriers developed in this lab as drug delivery systems [17].  The 
hydrogel systems were also optimized for maximum efficiency in the loading and release 
of each conjugate synthesized.  Cellular and animal studies were performed to 
determine the effect of the conjugate systems on overall protein transport and 
bioactivity. 
 Within this body of work, the completed thesis is split into several chapters.  
Chapter 2 gives in-depth background information on diabetes, insulin, osteoporosis, 
calcitonin, alternative routes for protein delivery, physiology of the GI tract, and oral 
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delivery design strategies.  Chapter 3 outlines the objectives of this work.  The synthesis 
and modification of the different polymer hydrogel systems is covered in Chapter 4.  The 
synthesis and characterization of multiple protein-transporter conjugates is discussed in 
Chapter 5.  Chapter 6 details the encapsulation and release procedures for in vitro 
analysis of insulin-transferrin conjugates.  Loading and release studies performed on 
calcitonin-transferrin conjugates is discussed in Chapter 7.  Chapter 8 contains cellular 
evaluations of the potential of some of the synthesized conjugate formulations as well 
as preliminary animal studies conducted using the conjugate.  The thesis ends with 
Chapter 9 which will be comprised of several conclusions about the work performed as a 
whole. 
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CHAPTER 2 
BACKGROUND 
   
  Recent advances in the field of biotechnology have led to increased usage of 
pharmaceutical formulations involving therapeutic proteins.  There is a wide variety of 
therapeutic proteins that are used to treat a wide variety of illnesses.  One of the most 
prevalent therapeutic proteins based on medical need is insulin, which is used to treat 
diabetes.  Another prevalent therapeutic protein is calcitonin, which is administered to 
treat Paget’s disease, bone metastases, hypercalcemia, and postmenopausal 
osteoporosis.   
  Due to the sensitive nature of these proteins, they are typically administered 
through injection as to ensure high bioavailability and biological activity.  However, 
injection therapy often causes patient discomfort, leading to a lack of patient 
compliance and the complications which can occur as a result.  Because of the nature of 
injection therapy, an alternative route of administration for the therapeutic proteins is 
highly desired to increase patient compliance and improve overall quality of life.  Among 
the alternative routes of administration, oral delivery of therapeutic proteins is typically 
considered the most desired route due to its ease of administration, low cost, and high 
patient compliance.  However, designing an effective oral protein delivery formulation is 
difficult due to protein degradation by digestive enzymes in the stomach, a narrow 
absorption window in the small intestine, and the epithelial cell barrier lining the villi of 
the small intestine. 
 This chapter covers diseases such as diabetes, Paget’s disease, hypercalcemia, 
and others as well as the therapeutic proteins used to treat these illnesses.  Also, several 
alternatives routes of administration for the delivery of proteins will be explored such as 
transdermal delivery and pulmonary delivery among several others.  Then, oral protein 
delivery is investigated by first discussing the physiological conditions of the 
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gastrointestinal tract and then discussing strategies to circumvent the natural biological 
barriers to effective oral protein delivery that are present in the body.  The chapter will 
conclude with a summary of why it is important to understand the target diseases and 
the proteins which treat them as well as the physiological conditions of the GI tract 
when designing an effective oral protein delivery system. 
 
2.1 Diabetes Mellitus 
 Diabetes is an illness in which the body cannot produce or properly use insulin.  
Specifically, diabetes mellitus refers to a group of diseases which are characterized by 
chronic hypoglycemia and abnormal metabolism due to a deficiency in the overall effect 
of insulin in the body [1].  Over 16 million people in the United States are estimated to 
have diabetes mellitus [2], many of whom are unaware they have the disease.  Diabetes 
affects people of many races and ethnicities, and even appears to have a more profound 
presence in certain ethnic groups [3].  In fact, diabetes is over 50% more common in 
African-Americans than in Americans of white or European heritage [4].   
 Globally, diabetes mellitus is estimated to affect over 150 million people [5] and 
is prevalent on virtually every continent including Europe [6], Africa [7], and Asia [8].  
Moreover, the number of diabetics is predicted to double to over 300 million worldwide 
in the next 30 years [9].  The most alarming fact is that diabetes is already the 4th-5th 
leading cause of death in developed countries and is quickly rising in developing 
countries [10].  The combination of the death toll from diabetes and the expected 
increase of diabetics to over 300 million by 2030 suggest that diabetes will become a 
worldwide epidemic in the upcoming decades. 
 There are several types of diabetes mellitus.  Type I diabetes is a disease 
characterized by the loss of insulin-secreting β cells, leading to insulin deficiency.  Type I 
diabetics generally account for 5-10% of all diabetics worldwide [11].  Type II diabetes is 
a disease referred to as “adult-onset diabetes” because it often occurs later in life as the 
body builds up a resistance to insulin.  Since the early 1990s, the number of cases of 
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type II diabetes has increased by over 60% and is still rising due to increasingly 
sedentary lifestyles [12].   
 Another condition, called pre-diabetes, is related to type II diabetes in that it is 
characterized by people with higher blood glucose levels that are at risk for type II 
diabetes but are technically not in that classification.  The number of cases of pre-
diabetes is also rising, increasing from an estimated 12 million in 1994 [13] to an 
estimated 41 million in 2006 [14].  There is another subset of diabetes mellitus which 
affects pregnant women and their children which consists of two diseases:  
pregestational diabetes mellitus (PDM) and gestational diabetes mellitus (GDM).  PDM 
and GDM occur in 0.3-0.6% and 2-9% of all pregnancies and typically have adverse 
effects on the mother and newborn child [15]. 
 Type I diabetes is often referred to as autoimmune diabetes mellitus because of 
the autoimmune attack of insulin-secreting β cells, leading to insulin deficiency.  The 
autoimmune attack is mediated by T-cells and occurs in the β cells in the pancreatic 
islets of Langerhans.  Generally, no preventative measures can be taken against type I 
diabetes.  However, some options for preservation of β cells are being investigated.  
One option is to regenerate the β cells through β cell growth factors and stem cell 
technologies [16].  Another approach is to replace the β cells with either healthy β cells, 
transplanted islets, artificial insulin-secreting cells, or an artificial pancreas [17].  The 
protection of β cells through modulation of cytokine signaling, anti-oxidative stress, and 
the increase of intracellular levels of NAD have also been investigated [18].  Apart from 
possible technologies resulting from recent research, type I diabetics are generally 
dependent on insulin therapy to maintain proper blood glucose levels.  Regular and 
controlled insulin dosage is required for the survival of type I diabetics.  Improper insulin 
dosage can result in extremely high blood glucose levels and ketoacidosis, a condition in 
which the body undergoes abnormal metabolism and releases dangerous amounts of 
ketone bodies into the bloodstream [19].  If ketoacidosis is not recognized and treated 
immediately, it can result in a coma or even death of the patient. 
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 Type II diabetes is the most common form of diabetes mellitus and generally 
develops as a result of the combination effect of an increased insulin resistance as well 
as a decrease in insulin secretion.  The exact cause of type II diabetes is unknown, but 
obesity, high carbohydrate intake, and lack of physical activity have been shown to 
increase insulin resistance in the body [20].  Many patients at risk for developing type II 
diabetes, or those with pre-diabetes, have the possibility of preventing or at least 
delaying the onset of type II diabetes by adopting healthy eating habits, being regularly 
active, and maintaining a healthy body weight [21].  Once a patient has developed type 
II diabetics, the level of insulin dependence can vary over a wide range.  Diabetics in the 
early stages of type II diabetes often do not require therapeutic insulin, but the 
transition into insulin therapy is typically inevitable due to the progressive nature of the 
disease [22].  Type II diabetics often have difficulty in determining when they should 
begin their insulin therapy.  Noncompliance of insulin-dependent diabetics, either by 
skipping needed injections or by miscalculating the amount of insulin, is a point of 
emphasis in diabetes education and can lead to serious complications if repeated over 
prolonged periods [23].  
 Pregestational diabetes mellitus (PDM) and gestational diabetes mellitus (GDM) 
are two of the less common forms of diabetes and only affect a small percentage of all 
pregnancies.  Gestational diabetes is typically characterized by an elevated blood 
glucose level in the later months of the pregnancy due to an inadequate adjustment to 
the glucose metabolism required during pregnancy [24].  Similar to type II diabetes, the 
risk factors for PDM and GDM include obesity and lack of activity [25].  In some cases, 
PDM or GDM results from patients which are unaware that they have type II diabetes 
until they enter a pregnancy.  As with type II diabetes, the risk of PDM and GDM can be 
minimized by maintaining healthy eating habits and an active lifestyle before becoming 
pregnant.  At the onset of gestational diabetes, very precise blood glucose levels must 
be maintained to prevent diabetic symptoms in the newborn.  Blood glucose levels can 
be controlled primarily through diet; if diet fails, then precise amounts of insulin therapy 
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are needed [26].  If gestational diabetes in pregnant females is not detected or is not 
properly treated, childbirth complications such as hydramnios, fetal anomalies, and 
preterm births can occur [27]. 
 Patients who feel they are at risk for diabetes may get tested in one of two ways.  
Health care providers will typically either perform a oral glucose tolerance test (OGTT) 
or a fasting plasma glucose (FPG) test [28].  These tests can be performed to determine 
if the patient is normal, pre-diabetic, or diabetic.  Patients with pre-diabetic blood 
glucose levels are said to have either impaired glucose tolerance (IGT), or impaired 
fasting glycemia (IFG) [29].  The American Diabetes Association recommends the use of 
only FPG to diagnose diabetes, while the World Health Organization recommends the 
use of OGTT for subjects with IFG [30]. 
 Fasting plasma glucose tests are performed by requiring the patient to perform 
an overnight fast, then analyzing the blood glucose level the following morning [31].  
According to the ADA, normal blood glucose level is indicated by an FPG level of less 
than 5.6 mmol/L.  Patients with FPG levels between 5.6 mmol/L and 7 mmol/L are said 
to have pre-diabetes, while those with FPG levels over 126 mg/dL are diagnosed with 
diabetes [32]. 
 Oral glucose tolerance tests are performed similar to FPG tests, but the patient is 
required to drink a glucose-rich beverage at the end of the overnight fast, and the blood 
glucose level is measured 2 hours after beverage consumption (2H-PG value).  In an 
OGTT, a normal blood glucose level is represented by a 2H-PG value less than 7.8 
mmol/L.  If the patient has a 2H-PG value between 7.8 mmol/L and 11.1 mmol/L, he or 
she is considered pre-diabetic while a 2H-PG value over 11.1 mmol/L classifies the 
patient as diabetic [33].  FPG tests are becoming the accepted standard for diagnosing 
diabetes because they are cheaper and faster to perform.  In fact, a complete FPG test is 
performed within the protocol for an OGTT analysis, making FPG tests simpler and 
quicker to perform. 
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 The most important factor for patients who have developed diabetes is glycemic 
control.  Researchers have investigated and modified insulin for use in insulin therapy 
for diabetics.  Some of the developments in insulin therapy to further diabetes 
treatment and maintain better glycemic control are discussed in the next section. 
 
2.2 Insulin and Insulin Therapies 
 The ongoing discovery of the role of insulin in diabetes has had several notable 
benchmarks over the past 125 years.  In 1889, two European physicians, von Mering and 
Minkowski, removed the pancreas from a healthy dog to determine its effect on 
biological processes.  The scientists discovered that removal of the pancreas caused the 
dog to develop diabetes.  Through further study, they concluded that the pancreas 
secreted a substance which is used for metabolism of sugar [34].  Attempts to extract 
this substance now known as insulin were mostly met with frustration due to 
degradation by digestive enzymes until 1921, when Frederick Banting was able to 
successfully isolate insulin for use in diabetic subjects [35].  The insulin extraction 
technique Banting discovered was used to extract insulin for diabetics for several 
decades without a complete understanding of the structure and function of insulin.  In 
1959, Joseph Sanger discovered the primary structure of insulin, allowing for greater 
understanding of its activity and function [36]. 
 Insulin is a hormone protein which is synthesized in the β cells of the pancreas.  
Insulin is initially produced as a large preprohormone (~11.5 kDa) and later cleaved into 
proinsulin (~9 kDa).  Proinsulin splits into two pieces, one of which is common insulin.  
Insulin (~5.8 kDa) is comprised of 51 amino acids and has a hydrodynamic radius of 20 Ǻ 
[37].  The structure of insulin consists of an A chain with 21 amino acids and a B chain 
with 30 amino acids connected by two disulfide bonds.  The structure of insulin is shown 
in Figure 2.1. 
 In healthy individuals, the blood glucose level is maintained within a narrow 
range from 3.5-7.0 mmol/L despite a wide range of fluctuations induced by exercise or 
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food intake [38].  The maintenance of blood glucose levels is achieved by the regulatory 
action of the pancreas, which controls the release of insulin and glucagon.  While insulin 
is secreted during periods of high blood glucose, glucagon is just the opposite and is 
released during periods of low blood glucose.  Glucagon is a 29 amino acid polypeptide 
(~3.5 kDa) which helps increase blood glucose level by binding to glucagon receptors on 
hepatocytes, causing the liver to release glucose into the bloodstream [39]. 
 The mechanism of insulin release in response to high blood glucose levels begins 
in the pancreas.  After food intake or variable glucose change, glucose enters the β cells 
in the pancreas via the glucose transporter GLUT2.  The glucose in the β cells cause ATP 
molecules to be formed which can cause the potassium channels to close.  Closing of the 
potassium channels depolarizes the cell, which leads to the intake of calcium through 
calcium channels.  An increased concentration of calcium within the cell allows 
previously stored insulin to be released from the β cell. 
 After insulin has been released it will reach the bloodstream via the liver.  Freely 
circulating insulin will interact with several types of cells, the majority of which are fat 
and muscle cells.  Insulin then binds with the insulin receptors on the cell surface.  The 
insulin receptor consists of two extracellular α-subuntis and two transmembrane β-
subunits joined by disulfide bonds.  Upon insulin binding, the receptor undergoes a 
rapid conformational change, resulting in activation of the tyrosine kinase domain [40].  
Activation of this domain is referred to as receptor autophosphorylation.  After 
phosphorylation of the β-subunits, the insulin receptor activates key enzymes which 
undergo a complex series of signaling using several signaling pathways which ultimately 
increase the cell permeability to glucose [41].  The increased permeability in the 
affected cells allow for increased glucose uptake, providing needed energy for the 
normal function of the cells.  Overall, improper insulin levels affect the body’s ability to 
regulate blood-glucose level, which can lead to serious complications [42]. 
 Insulin therapy is essential to maintaining an average quality of life for millions of 
insulin-dependent diabetics.  Generally, diabetics undergo several injections a day to 
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maintain their blood glucose levels.  Within their daily dosing regimen, diabetics require 
several different types of insulin.  Rapid-acting insulin yields the quickest therapeutic 
response, beginning to work 5 minutes after injection, peaking at 1 hour, and continuing 
to work for 2 to 4 hours.  Rapid-acting insulin is most often use to immediately reduce 
post-prandial blood glucose levels [43].   
 Insulin analogues which take longer to take effect are known as regular insulin, 
which takes effect 30 minutes after injection, peaks at 2 to 3 hours, and lasts for 3 to 6 
hours, and intermediate-acting insulin, which gives a response 2 to 4 hours after 
injection, peaks at 4 to 12 hours, and lasts 12 to 18 hours.  These intermediate insulin 
analogues are typically injected to maintain a constant blood glucose level through the 
day, or even in the evening before the patient sleeps [44].  The slowest therapeutic 
response but also longest lasting effect is produced by long-acting insulin, or basal 
insulin, which takes effect 6 to 10 hours after injection and usually lasts for 20 to 24 
hours.  Basal insulin is mostly injected to achieve a minimum basal level of insulin in the 
bloodstream that is intended to last for 24 hours [45].  
 Apart from injections performed by the patient several times a day, there are 
also alternative delivery devices to inject the required insulin.  Gaining prominence in 
the past decade is the use of the insulin pump.  The insulin pump eliminates the need 
for individual injections by supplying regular, accurate amounts of insulin for both basal 
dosages and bolus dosages after meals.  However, insulin pumps are often expensive 
and have several disadvantages such as an associated weight gain, importance of 
somewhat complex training, and a possibility of induced ketoacidosis if disconnected 
from pump [46].  To help alleviate some of the pain and complications which arise from 
traditional vial and syringe injections, insulin pens were developed.  Insulin pens 
increase therapeutic utility and make injections easier for diabetic patients [47].  
However, there is still an associated level of complexity from using the device as well as 
an associated pain. 
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 Insulin therapy in its most basic form consists of patients injecting themselves 
multiple times per day.  Because of this painful inconvenience that is required of all 
diabetics to maintain a high quality of life, alternative routes of administration for 
therapeutic insulin need to be investigated.  Several attempts at designing alternative 
routes of administration for insulin will be explored and discussed later in this section. 
 
2.3 Osteoporosis and Paget’s Disease 
 Protein therapy is used to treat a variety of other illnesses as well.  Specifically, 
calcitonin is used in the treatment of osteoporosis and Paget’s disease, as well as 
hypercalcemia and bone metastases [48].  Osteoporosis is a disease in which bone 
structure deteriorates and there is a resultant low bone mass.  Osteoporosis affects 10 
million Americans, and it is especially common in postmenopausal Caucasian women 
[49].  Paget’s disease of bone refers to the condition marked by excessive and abnormal 
remodeling of bone into a disorganized bone formation.  Paget’s disease affects only 3% 
of the population over 40 years old, but approximately 10% of the population over 85 
years old [50]. 
 Osteoporosis is marked by a biological imbalance of osteoclast activity, which 
removes bone tissue, and osteoblast activity, which helps to reform bone tissue.  
Specifically, osteoporosis occurs in the presence of excessive osteoclast activity, or 
increased bone resorption, resulting in reduced bone mass and increased chance of 
fracture [51].  Osteoporosis generally has a greater presence in the postmenopausal 
female generation, but it can affect men as well [52].  Risk factors for the development 
of osteoporosis include but are not limited to age, Asian or Caucasian ethnicity, 
excessive alcohol or smoking, family history of osteoporosis, lack of weight-bearing 
exercise, sedentary lifestyle, and small body frame [53]. If a patient determines they are 
at risk for osteoporosis, suggested prevention techniques include physical activity, 
increased calcium and vitamin D intake, as well as everyday fall prevention [54].  The 
diagnosis of osteoporosis is most commonly determined by the measurement of bone 
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mineral density (BMD) using dual energy X-ray absorptiometry (DXA) on the hip or 
lumbar spine region [55].  The diagnostic criteria for osteoporosis are determined based 
on the patient’s T-score, or number of standard deviations of his or her BMD from the 
standard set by the World Health Organization.  A patient is said to have normal bone 
mass if his or her T-score is greater than -1.  Someone with low bone mass and at risk for 
osteoporosis would have a T-score between -1 and -2.5.  A patient is diagnosed with 
osteoporosis if he or she has a T-score less than -2.5 [56].   
 Currently, there are no known cures for osteoporosis but the disease is typically 
treated with salmon calcitonin, a calcitonin analog that is usually more potent than 
human calcitonin [57].  Calcitonin acts as an inhibitor to the development of osteoclasts, 
or bone cells which remove bone tissue [58].  By controlling the amount of osteoclasts, 
calcitonin mitigates the rate of bone degradation in patients, thus lowering the chance 
of a fracture.  If a patient were noncompliant with his or her required calcitonin dosage, 
possibly due to the nature of injection therapy, the development of osteoclasts would 
continue unabated, resulting in bone density loss, elevated calcium levels, and a high 
chance for bone fracture [59]. 
 Paget’s disease of bone is an illness in which there is an excessive amount of 
bone deterioration and subsequent reformation.  The reformation of the affected bone 
tissue often results in an overall weaker bone structure, thus increasing the chances for 
pain, arthritis, and bone fractures.  Specifically, the cause of the illness comes from 
abnormal number, size and activity of osteoclasts at the affected bone site.  However, 
Paget’s disease largely differs from osteoporosis in that the abnormal activity of the 
osteoclasts is also mirrored by an abnormal amount of activity in the osteoblasts as well, 
or cells that create bone tissue [60].  The resultant rapid resorption and reformation of 
bone tissue is the most recognizable feature of Paget’s disease.  The exact cause of 
Paget’s disease, however, is somewhat more uncertain.  Several have suggested that the 
abnormal osteoclast function stems from the presence of paramyxoviruses present in 
the nuclei of the affected osteoclasts, while others suggest the presence of the viruses 
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are merely a reflection of the abnormal activity rather than a cause [61].  There appear 
to be no risk factors for Paget’s disease related to one’s lifestyle, but family history of 
the disease has been stated as a factor for increased risk of developing the disease [62].  
If a patient is at risk for Paget’s disease, there is no known method for prevention of 
development of the disease, but regular physical activity for strengthening bone 
structure could alleviate some of the future symptoms.  There are no known cures for 
Paget’s disease, but it can typically be treated with salmon calcitonin and 
biphosphonates [63].  Calcitonin and biphosphonates inhibit osteoclast activity and 
significantly decrease the rate of bone resorption and reformation that is characteristic 
of Paget’s disease, thus decreasing pain felt by the patient and increasing overall quality 
of life [64].  Due to the nature of calcitonin injection therapy, many patients have to 
choose to live with the pain associated with Paget’s disease or to live with the pain and 
inconvenience inherent to daily injection therapy. 
 Calcitonin is a major therapeutic protein for the treatment of diseases related to 
bone structure.  Calcitonin acts as an osteoclast inhibitor, thus reducing bone resorption 
and strengthening bone structure.  While effective in treating osteoporosis and Paget’s 
disease of bone, calcitonin is also used to treat other afflictions resulting from increased 
bone resorption such as hypercalcemia or bone metastases.  The next section will 
discuss calcitonin therapy in greater detail, including the structure and biological 
function of calcitonin within the body. 
   
2.4 Calcitonin Therapy 
 The discovery and development of calcitonin as a therapeutic protein has 
occurred much more recently than some other therapeutic proteins, such as insulin, but 
still has undergone many changes in the past 40 years for treating bone diseases.  
Calcitonin was largely discovered in the early 1960s, when Copp noted that a hormone 
from the parathyroids regulated the “tone” of calcium in body fluids.  He named the 
protein calcitonin [65].  The ability of calcitonin to lower the calcium levels in the body 
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were quickly determined to be due to osteoclast inhibition.  Knowing that osteoporosis 
occurred because of increased osteoclast activity, calcitonin was researched as a 
therapeutic for osteoporosis by the late 1970s.  After many years of FDA testing, the 
first injectable calcitonin, called Calcimar, was approved for treatment of osteoporosis 
[65]. 
 Calcitonin is a hormone polypeptide which is produced in the thyroid cells of 
humans.  The final form of calcitonin is achieved after the proteolytic cleavage of a large 
α calcitonin gene.  If the α calcitonin gene is cleaved at the 4th exon of 6, the protein 
calcitonin will result [66].  Calcitonin (~3.4 kDa) is comprised of 32 amino acids with a 
cyclical end connected by a disulfide linkage.  The structure of calcitonin can be seen in 
Figure 2.2. 
 Calcitonin formation generally occurs in the thyroidal C cells through 
alternatively splicing of the α calcitonin gene.  The resulting product of the alternative 
gene splice is α-calcitonin gene-related peptide (α-CGRP).  The α-CGRP is mainly a 
neuropeptide, but it has been found outside of the nervous system [67].  Calcitonin is 
generally formed in the body in response to a hypercalcemic stimulus [68].  After its 
formation, the primary function of calcitonin is to decrease calcium levels in the body, 
mostly through osteoclast inhibition.  In addition to its primary function, calcitonin also 
provides some secondary functions as well.  Calcitonin has been shown to have 
analgesic effects, inhibit postprandial calcium intake, and reduce gastric acid secretion 
as well as intestinal motility.  Many of these effects are thought to occur through 
calcitonin interaction with receptors in the central nervous system [69]. 
 The mechanism of osteoclast inhibition by calcitonin is initiated by a ligand-
receptor interaction.  The calcitonin receptor belongs to the class II family of the 7-
trans-membrane G-protein-coupled receptors and is expressed on osteoclasts [70].  
Moreover, the calcitonin receptor is the primary characteristic used to differentiate 
osteoclasts from other cell types such as macrophages and phagocytic cells [71].  Upon 
calcitonin binding to the calcitonin receptor, the osteoclasts undergo a conformational 
  19 
change, reducing their activity and bone resorption ability.  Reduced bone resorption 
leads to lower serum calcium levels and stronger bone structure in patients with 
osteoporosis. 
 Calcitonin therapy in treating osteoporosis and Paget’s disease typically consists 
of patients injecting themselves daily with salmon calcitonin.  Human and salmon 
calcitonin only share 16 of 32 amino acids, but the only sequence required for activity is 
an 8 amino acid sequence near the N-terminal disulfide bridge.  Salmon calcitonin is up 
to forty times more potent than human calcitonin due to a highly flexible α-helical 
peptide structure which allows for optimal binding with the calcitonin receptor [72]. 
 Many patients have improved their quality of life by undergoing treatment with 
salmon calcitonin injections.  However, these injections are still painful and may 
eventually lead to noncompliance with chronic use.  Noncompliance in calcitonin 
therapy may very often lead to an increased risk of fracture and weaker bone structure.  
Because of the nature of injection therapy, alternative routes of administration for 
calcitonin need to be investigated.  The next section will cover attempts at alternatives 
to injection therapy for therapeutic proteins such as insulin and calcitonin. 
 
2.5 Alternative Routes for Protein Delivery 
 Currently, diabetic patients must inject themselves several times a day with 
insulin to maintain their blood glucose levels.  Daily injection therapy often leads to 
noncompliance, thus lowering the overall efficacy of the treatment.  Alternative routes 
of administration for insulin which are non-invasive and convenient are being 
investigated.  The development of such a system would mean an increase if efficacy and 
quality of life for diabetic patients worldwide.  In this section, several alternative 
systems will be discussed.  The systems will be categorized by their route of delivery and 
will include pulmonary, transdermal, nasal, buccal, ocular, rectal, and vaginal delivery 
systems. 
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2.5.1 Pulmonary Delivery 
Recently, there have been many attempts to use pulmonary delivery, or delivery 
through the lungs, to administer therapeutic proteins [73].  Delivery through the lungs 
offers many advantages such as a very thin (0.1-0.5 μm) alveolar epithelium and a large 
surface area (~75 m2) for absorption.  Also, pulmonary delivery allows for avoidance of 
first pass hepatic metabolism [74].  However, within pulmonary delivery also exists 
many barriers to effective absorption including delivery device inefficiency and rapid 
clearance of the drug from the lungs through enzymatic degradation, mucociliary 
clearance, and phagocytosis [75].  Despite these challenges, there have been several 
moderately successful therapeutic protein pulmonary delivery systems. 
Several pulmonary delivery systems have been designed specifically for insulin, 
many of which have actually made it into FDA testing.  Some of these systems include 
AERx Insulin Diabetes Management System (AERx iDMS) (Aradigm/Novo Nordisk), AIR 
system (Alkermes/Eli Lilly), Technosphere (MannKind Corporation), and Kos Inhaled 
Insulin (Kos Pharmaceuticals) [76].  However, probably the furthest progressed and 
most notable formulation of inhalable insulin to enter the marketplace is Exubera 
(Nektar/Pfizer/Sanofi-Aventis).  The Exubera delivery system consists of rapid-acting dry 
powder human insulin packaged in blister packaging for stability and delivered through 
use of an inhaler device which has a holding chamber from which the patient inhales the 
insulin.  Exubera is intended to be used for post-prandial blood glucose maintenance 
due to its relatively quick peak insulin concentrations occurring after 49 minutes [77].  
However, the size and complexity of the Exubera delivery device reduced its 
convenience.  Also, patients were still required to inject themselves with basal insulin 
everyday as well as undergo periodic lung tests to ensure proper lung function.  These 
disadvantages of Exubera limited the market success and subsequently caused Pfizer to 
abandon the sale of the device.  In a similar situation, Novo Nordisk also abandoned 
their inhalable insulin device, AERx iDMS [78].  Development of other inhalable insulin 
products like MannKind’s Technosphere continue in an effort to learn from the mistakes 
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of the market predecessors, but inherent disadvantages to pulmonary insulin delivery 
such as delivery device inefficiency and unreliable dosing present challenges that must 
be addressed. 
Although less publicized relative to inhalable insulin, researchers are 
investigating the possibility of pulmonary calcitonin delivery.  Patton et al. used 
intratracheal administration to deliver salmon and human calcitonin  to rats and were 
able to achieve 17% absolute bioavailability in both cases [79].  Also, using a different 
dry powder salmon calcitonin formulation, Deftos et al. were able to administer inhaled 
calcitonin with 66% of the bioactivity and 28% relative bioavailability to calcitonin 
injections [80].  In both cases, the inhalable calcitonin formulations benefited from the 
inherent advantages of pulmonary delivery (higher bioavailabilities than alternative 
routes, reduced side effects) but still must overcome complexities of the delivery device 
and unreliable dosing regimens to become a viable mainstream option. 
Pulmonary delivery devices for the administration of therapeutic proteins have 
probably achieved more success than most of the other types of delivery devices as 
evident by the push of new inhalable insulin products into the pharmaceutical 
marketplace.  The moderate success can most likely be attributed to the high 
bioavailability values achievable through pulmonary delivery.  However, further 
research is needed to overcome the existing challenges with pulmonary delivery 
mentioned in this section. 
 
2.5.2 Transdermal Delivery 
In recent years, researchers have also focused on administering therapeutic 
proteins using transdermal delivery, or delivery through the skin [81].  The major 
advantages of transdermal delivery are simplicity of design and ease of administration.  
Most formulations would only require the patient to apply a small patch to his or her 
skin or to apply a topical cream.  Transdermal systems would be extremely non-invasive 
and painless.  However, most transdermal delivery systems suffer from poor transport 
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into the bloodstream due to the stratum corneum, a protective layer which lines the 
skin.  Effective delivery of large molecules such as therapeutic proteins across the skin 
requires disruption or a bypass of the stratum corneum.  Common methods to 
circumvent this barrier include iontophoresis, electroporation, ultrasound, and high 
velocity powder penetration [82].  Iontophoresis involves applying a small electrical 
current to the skin to allow protein delivery, although the maximum amount delivered is 
often less than one milligram and the method can suffer from protein size limitations 
[83].  Electroporation is the method by which brief high energy bursts are used to 
disrupt the skin and allow for protein transport.  Ultrasound has also been used to 
increase protein transport by disrupting the stratum corneum by cavitation.  Another 
method to increase transport is to use high velocity powders driven by helium at 
supersonic speeds [82].  Using these methods, several researchers have designed 
transdermal delivery systems which show promise for future transdermal delivery 
research. 
Many scientists have investigated the possibility of insulin delivery through a 
transdermal route of administration.  Smith et al. used ultrasound-mediated 
transdermal delivery to deliver insulin across the stratum corneum and were able to 
achieve a sevenfold increase in insulin transport relative to a passive transmission 
control [84].  However, a sevenfold increase in transmission of insulin naturally across 
the skin still results in a low bioavailability and limits the use of the research as a 
potential delivery device, even though it does promise potential for possible inclusion of 
the technique in the design of future devices.  Also, using electroporation as a 
transdermal delivery enhancer, Sen et al. [85] showed that lipids, specifically 1,2-
dimyristoyl-3-phosphatidylserine (DMPS), present during electroporation can increase 
insulin transport by a factor of twenty.  However, lipid enhanced electroporation 
generally can only increase transport of molecules up to 10 kDa in size, limiting its 
application for larger therapeutic proteins.  In both transdermal insulin delivery systems, 
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the devices suffer from low bioavailability due to the effective protection of the stratum 
corneum. 
In addition to transdermal insulin delivery systems, researchers have also 
investigated the possibility of transdermal salmon calcitonin delivery.  Nakamura et al. 
designed a transdermal delivery system for salmon calcitonin using pulse depolarization-
iontophoresis.  Iontophoresis generally has a protein size limitation of around 11 kDa, 
but because salmon calcitonin is relatively small (~3.4 kDa), it is a suitable candidate for 
delivery through iontophoresis.  Nakamura et al. [86] showed an increase in calcitonin 
for an increase of current up to 0.5 mA and also achieved an absolute bioavailability of 
~35% [86].  While transdermal delivery of salmon calcitonin is somewhat effective 
through iontophoresis, many proteins are excluded from iontophoresis as a transport 
enhancer due to their large size. 
 Transdermal delivery systems for the administration of therapeutic proteins 
have gained increasing interest over the past several years.  The increased desire for the 
appearance of one of these systems in the marketplace most likely results from the high 
degree of non-invasiveness associated with transdermal delivery systems as well as the 
ease of administration.  However, before suitable transdermal delivery systems can be 
sold to the general public, researchers must continue to search for ways in which 
protein transport can be increased across the stratum corneum as well as ways to 
eliminate the protein size limitations typically inherent to transdermal delivery. 
  
2.5.3 Nasal Delivery 
In addition to pulmonary and transdermal delivery, researchers have also 
investigated administration of therapeutic proteins through the nasal route, or delivery 
through the nasal cavity [87].  Nasal drug delivery offers many advantages such as a 
large surface area for absorption, a thin nasal epithelium allowing for increased 
absorption, and an avoidance of first pass metabolism [88].  Most nasal delivery devices 
consist of a inhaler to be administered through the nostril of the patient.  An effective 
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nasal delivery device would have the advantages of being non-invasive to the patient 
and relatively easy to administer.  In many ways, nasal delivery devices benefit from the 
same advantages as pulmonary delivery devices with the major difference being the site 
of absorption.  However, as with pulmonary devices, there are also associated 
disadvantages for nasal delivery systems.  Administration through the nasal route can be 
affected by barriers to permeability such as enzymes in the nasal cavity or nasal mucosa, 
mucociliary clearance or ciliary beating.  Also, nasal delivery is often limited by molecule 
size, excluding the majority of proteins from being delivered efficiently [89].  Despite 
these challenges, several attempts have been made to design an effective nasal delivery 
system for the administration of therapeutic proteins. 
In an effort to decrease the invasiveness of insulin therapy, researchers have 
begun investigating the possibility of using nasal delivery to administer therapeutic 
insulin.  Dondeti et al. administered an insulin spray formulation to diabetic rabbits to 
observe its hypoglycemic effect.  The insulin spray formulations were combined with 
bioadhesive polymers and permeation enhancers to increase the overall bioavailability.  
In the most successful of the formulations (insulin, microcrystal cellulose, and sodium 
taurocholate), the absolute bioavailability was found to be 8.36% [90].  While a 
significant increase from insulin administered with no additives, the achieved 
bioavailability is still considerably lower than bioavailability levels expected to warrant 
the formation of a marketplace product for insulin.  The decrease in bioavailability of 
insulin administered through the nasal route in this research is most likely due to the 
barriers to permeability such as enzymes and mucociliary clearance. 
In relation to insulin(~5.8 kDa), salmon calcitonin (~3.4 kDa) is significantly 
smaller in size, making it a more likely candidate for effective delivery through the nasal 
cavity.  In fact, the ability of calcitonin to be delivered nasally was recognized by Sandoz 
Pharmaceuticals, who introduced Miacalcin in 1995.  Miacalcin is a nasal spray 
formulation for calcitonin which has been shown to reduce postmenopausal bone loss 
as well as reduce the incidence of vertebral fracture by 60% [91].  However, the 
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bioavailability was shown to vary greatly among patients, fluctuating from 0.3% to 
30.6% with an average bioavailability of 3% relative to injections.  The significant 
variability most likely increases the difficulty of calculating proper dosages, leading to 
inefficient clinical use and wasted therapeutic calcitonin.  Despite these drawbacks, 
nasal delivery of calcitonin shows promise for alleviating the inconvenience of daily 
injections for patients with bone disorders. 
Nasal delivery systems for the administration of therapeutic proteins have 
gained considerable attention over the past decade and will continue to grow in interest.  
The potential benefits of a non-invasive, simple administration nasal delivery device 
have led researchers to try and overcome some of the barriers of nasal delivery such as 
barriers to permeation and drug size limitations.  Because of the size limitation, many 
therapeutic proteins may not make suitable candidates for nasal delivery.  However, the 
smaller proteins such as calcitonin represent the subcategory of therapeutic proteins 
most suitable for nasal delivery and should be investigated further. 
 
2.5.4 Buccal Delivery 
Recently, there has also been increased emphasis on administering therapeutic 
proteins using buccal delivery, or delivery through the mucosa of the mouth [92].  Some 
of the associated benefits of buccal delivery are direct access to systemic circulation 
allowing a bypass of first pass metabolism, low enzymatic activity, ease of 
administration, and an ability to easily include permeation enhancers or enzyme 
inhibitors in the formulation [93].  However, buccal delivery also presents many 
challenges or barriers which must be overcome.  The buccal membrane typically offers a 
smaller area for absorption (170 cm2) as well as having a low associated permeability.  
Also, the continuous secretion of saliva also presents challenges such as dilution of the 
drug, loss of drug or dosage form through swallowing, and even a danger of choking on 
the delivery system [94].  Several researchers have attempted to overcome these 
challenges and to design an effective buccal delivery system for therapeutic proteins. 
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Because of its prevalence in patients worldwide, insulin has become a target for 
the design of an effective buccal delivery system.  Portero et al. [95] designed a novel 
system to attempt to overcome many of the challenges of buccal delivery of insulin.  The 
system consists of a mucoadhesive chitosan layer containing insulin and an 
impermeable protective layer composed of ethylcellulose.  This device design allows for 
unidirectional insulin release, preventing significant loss of the drug due to saliva 
scavenging.  While this design helps to alleviate the problems arising from saliva 
production, it still does not address the challenge of small area for absorption or low 
permeability.  Alternative research has suggested the use of permeation enhancers and 
enzyme inhibitors to increase insulin absorption in the oral cavity [96].  A successful and 
effective buccal insulin delivery system would most likely require a combinatorial 
approach, utilizing the concept of mucoadhesiveness and unidirectional drug flow as 
well as increase permeability and stability. 
Buccal delivery of calcitonin has not been investigating nearly to the extent that 
many other proteins have been investigated.  Buccal calcitonin delivery systems still 
must overcome the same challenges of low absorption area, low permeability, and 
saliva production.  However, the size of calcitonin is considerably less than that of 
insulin and many other proteins, most likely increasing its ability to diffuse through the 
mucosa lining the oral cavity.  While not receiving widespread attention in the research 
field, the possibility of buccal calcitonin delivery has been investigated [97].  Further 
investigation is needed to determine if calcitonin administration using buccal delivery is 
a viable alternative to injection therapy. 
 Buccal delivery systems for the delivery of therapeutic proteins have been 
gaining increasing attention from the scientific community.  While not as publicized as 
other alternative routes such as transdermal delivery or pulmonary delivery, buccal 
delivery offers many unique advantages for protein delivery including avoidance of first 
pass metabolism, low enzymatic activity, simple administration, and an ability to easily 
introduce permeation enhancers or enzyme inhibitors into the formulation.  However, 
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researchers must formulate approaches which can overcome natural barriers to protein 
absorption such as low permeability and saliva production. 
 
2.5.5 Other Routes for Protein Delivery 
Apart from the aforementioned alternative routes for delivery, there are also 
several less publicized routes of delivery also being investigated.  One alternative route 
which is being investigated is ocular delivery, or delivery through the eye [98].  However, 
due to the effective defensive mechanism in the eye, transport into the bloodstream 
and bioavailability are typically low for ocular delivery.  Intravaginal delivery has also 
received some consideration [99], but the patient discomfort and obvious gender 
limitations prevent the possibility of its widespread use.  Rectal delivery has also been 
investigated [100], but reduced surface area for absorption and wide variability in 
patient acceptability limits the potential for rectal delivery of proteins.  One final 
alternative route for protein delivery is oral delivery.  The oral route of administration 
for therapeutic proteins remains the most attractive route of drug delivery for 
investigation, despite several inherent challenges [101].  Since oral protein delivery is 
the focus of this thesis, the benefits and challenges as well as possible strategies to 
overcome those barriers will be discussed in greater detail in the following section. 
 
2.6 Oral Protein Delivery 
 Among the routes of administration as alternatives to injection therapy, oral 
delivery remains the preferred route of administration by most patients.  Oral delivery 
of proteins is beneficial due to its low cost, ease of administration, and high patient 
compliance.  Therapeutic proteins administered in a pill or capsule form would greatly 
improve the quality of life of patients who require the medicine if the oral delivery form 
could either partially or completely remove their injection therapy regimen.  However, 
designing an effective oral protein delivery system requires overcoming several barriers 
inherent to the oral route of administration.   
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 Due to the sensitive nature of most therapeutic proteins, they are typically 
degraded in the stomach after being administered orally, allowing only a minute fraction 
to reach the site of absorption in the small intestine.  The degradation occurs due to the 
harsh environment of the gastric environment, including low pH and an abundance of 
digestive enzymes which are intended to break down proteins for food and energy.  Also, 
intestinal motility presents a challenge in that it shortens the absorption window for the 
protein to absorb in the small intestine.  The reduced residence time of any intact 
protein in the small intestine further reduces the chance for protein absorption into the 
bloodstream.  Finally, the epithelial cell layer lining the microvilli in the small intestine 
also presents a final barrier to protein absorption.  Epithelial cells form a tight 
monolayer which is designed to prevent introduction of toxins and foreign bodies into 
the bloodstream.  Absorption of a large therapeutic protein would require a disruption 
of the cell monolayer or enhanced transport of the protein.  Researchers have designed 
many different systems to overcome these challenges and to create an effective oral 
delivery system for therapeutic proteins. 
 Over the past several years, many methods have been employed to overcome 
the barriers inherent to oral protein delivery.  Approaches to increase bioavailability of 
the protein include the use of permeation enhancers to increase epithelial transport 
[102], protease inhibitors to reduce protein degradation [103], enteric coatings for 
protection in the harsh environment of the stomach [104], encapsulation of the protein 
in polymer microparticles for protection and increased residence time at the site of 
absorption [105], and combinatorial approaches as well [106].  Several of these 
approaches are discussed in greater detail in later sections.   
 In order to design a more effective oral protein delivery system, it is necessary 
first to understand the conditions surrounding the oral route of administration including 
the influence and effect the surrounding environment has on the administered dosage 
form.  Specifically, it is important to understand the physiology of the gastrointestinal 
(GI) tract for oral delivery systems.  The physiology of the GI tract, including the 
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physiology of the stomach, small intestine, and epithelial cell layer, are discussed in 
detail in the following section. 
 
2.6.1 Physiology of the GI Tract 
 The gastrointestinal (GI) tract, or alimentary canal, is the system of organs which 
comprise the digestive system in animals.  The primary functions of the digestive system 
are digestion of food to extract energy and essential nutrients and excretion of the 
remaining waste.  When medication is administered orally, the medicine is subjected to 
the same processes the digestive system uses to break down food.  It is important when 
designing oral drug delivery formulations to consider the physiological barriers and 
challenges that will arise throughout the transit of the GI tract. 
  The GI tract consists of many different organs which perform several individual 
functions.  Within the GI tract, the stomach and small intestine are the primary organs 
affecting the design of an oral protein delivery system. A schematic of the GI tract is 
shown in Figure 2.3.  Most therapeutic proteins are dangerously susceptible to 
degradation by proteolytic enzymes in the GI tract, especially in the stomach.  After the 
protein passes the stomach, it enters the small intestine.  There is still a risk of 
proteolytic degradation in the small intestine, albeit reduced in comparison to the 
stomach.   
  The most formidable barrier in the small intestine is the difficult absorption and 
transport of the protein into the bloodstream.  The high molecular weight of most 
proteins and the tight junctions of the epithelial cell layer make protein transport across 
the epithelium nearly impossible.  Therapeutic proteins such as insulin which have been 
administered orally in their native form have been shown to have a bioavailability, or 
portion of the total drug which reaches the bloodstream, as low as <0.1% [107].  An in-
depth understanding of the anatomy and physiology of the stomach and small intestine 
is essential to circumventing such barriers for an oral delivery system. 
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2.6.1.1 Anatomy and Physiology of the Stomach 
 The stomach is divided into four major regions: the cardia, the fundus, the body 
(or corpus), and the pylorus (or antrum).  The cardia is the upper region of the stomach 
where the contents of the esophagus are emptied into the stomach.  The fundus is the 
region formed by the upper curvature of the stomach.  The fundus and the body, the 
central region of the stomach, harbor the acid-secreting glands within the stomach 
[108].  The pylorus is located at the bottom of the stomach and facilitates the emptying 
of the contents of the stomach into the small intestine.  A schematic of the stomach is 
shown in Figure 2.4. In order for the required nutrients to be absorbed into the 
bloodstream, the stomach must first break down the large proteins into peptides that 
can be further digested in the small intestine.   
  Proteins in the stomach are typically broken down by digestive enzymes called 
proteases.  Pepsinogen, an abundant protease in the stomach, is secreted by the gastric 
chief cells lining the stomach lumen.  Pepsinogen is an inactive enzyme, but it is readily 
converted to the active protease pepsin in the presence of the hydrochloric acid found 
in the stomach [109].  Pepsin and other digestive enzymes such as trypsin are largely 
responsible for the major degradation that proteins endure within the stomach. 
  The stomach presents a major challenge to oral protein delivery in the 
preservation of the activity of the ingested protein.  Efforts to overcome this challenge 
have included the introduction of protease inhibitors and protective encapsulation of 
the protein.  Upon administration of the protease inhibitor aprotinin with the 
therapeutic protein insulin (in bile acid), insulin absorption was amplified approximately 
30 times relative to the administration of insulin alone [110].  However, the resultant 
bioavailability of the formulation was still somewhat low (~0.75%).   
  Researchers have also been focusing on the idea of protective encapsulation for 
the protein.  The protective matrices are designed to prevent the diffusion of external 
digestive enzymes into the system, thus protecting the protein on its transit through the 
stomach.  The inherent difficulty in designing a protective encapsulation for protein 
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delivery is that it must limit diffusion in the stomach but it must also promote diffusion 
in the small intestine.  In an attempt to achieve the required dual function of the 
delivery system, degradable microspheres have been proposed as protein carriers [111].  
An alternate design strategy is to utilize a physiological difference between the stomach 
and the small intestine as an external trigger for the switch between the protection and 
release functions.  A significant physiological difference exists between the pH of the 
stomach (pH~2) and the small intestine (pH~7), prompting the need for a pH-sensitive 
carrier system.  The introduction of intelligent, pH-responsive hydrogels as protein 
carriers has shown tremendous possibility for the systems and the research remains one 
of the most promising prospects for oral protein delivery [112]. 
 
2.6.1.2 Physiology of the Small Intestine 
 The small intestine is divided into three sections: the duodenum, the jejunum, 
and the ileum.  Ingested food empties from the stomach into the duodenum, the upper 
region of the small intestine.  The duodenum is approximately 0.26 m in length and is 
responsible for the majority of the digestion that occurs in the small intestine.  The 
duodenum empties its contents into the jejunum, the middle portion of the small 
intestine.  The jejunum is approximately 2.5 m long and empties into the ileum, the 
lower part of the small intestine.  The ileum is approximately 3.5 m long and serves to 
absorb any products of digestion that were note absorbed by the jejunum.  In order to 
increase absorption of necessary nutrients, the small intestine contains many surface 
features to maximize the possible surface area for nutrient uptake.  The small intestine 
contains circular folds throughout called valvulae conniventes that increase the surface 
area by a factor of 3.   
  Lining the intestinal wall are finger-like projections called villi, which effectively 
increase the surface area of the small intestine by a factor of 10.  The intestinal villi have 
additional finger-like projections called microvilli, which increase the surface area by a 
factor of 20.  The valvulae conniventes, villi, and microvilli effectively increase the 
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overall surface area by a factor of 600 compared to that of a hollow cylinder of the same 
dimensions [113].  The large surface area of the small intestine, comparable to the area 
of a tennis court, provides an ideal environment for absorption. 
  The physiology of the small intestine presents multiple unique challenges for oral 
protein delivery.  Digestive enzymes are still present in the small intestine but are 
mostly contained in the duodenum.  Another challenge in oral protein delivery is 
intestinal motility.  Intestinal motility refers to flow through the lumen of the small 
intestine and the muscles and motions of the wall which regulate the flow.  Proteins 
administered free of any encapsulation or protective coating are generally affected by 
intestinal motility significantly less due to the possibility immediate absorption of the 
protein.  However, proteins administered without a protective encapsulation are much 
less likely to survive the transit to the small intestine [105].   
  Encapsulated proteins have an associated diffusion time for release from the 
carrier system.  The protein diffusion time combined with the narrow absorption 
window of low solubility, low permeability proteins form a major challenge for effective 
oral protein delivery.  Increasing the residence time of the protective carriers in the 
small intestine is essential for allowing time for the protein to diffuse and maximizing 
the protein absorption window [114].  Mucoadhesive materials are often used in 
designing polymeric carriers in an attempt to increase residence time by contact with 
the intestinal mucosa [115].  Mucoadhesive drug delivery systems also allow for site 
specific targeting within the brush border region of the small intestine.  Further work 
has shown that the addition of polymeric tethers to the pH-sensitive carrier systems can 
further promote mucoadhesion and enhance the complexation/decomplexation effect 
of the carrier [116].  The combination of the protection abilities of carrier systems with 
the system modifications to increase residence time is proving to be substantial 
progress towards the goal of designing an effective oral protein delivery system. 
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2.6.1.3 Epithelial Cell Layer and Transport Pathways 
 When nutrients are absorbed during the process of digestion, they must pass 
through the epithelial cell layer lining the small intestine in order to reach the 
bloodstream.  The same barrier exists for therapeutics intended for absorption into the 
bloodstream.  An administered therapeutic can be absorbed either through the 
paracellular or transcellular transport pathways.  Paracellular refers to transport of the 
molecule between the cells, while transcellular refers to transport through the cell itself.  
A diagram demonstrating the different mechanisms of absorption is shown in Figure 2.5.  
Paracellular transport of large molecules is typically limited by the tight junctions 
between the epithelial cells.  Under normal conditions, the tight junctions will only 
permit the transport of molecules with radii <11 Ǻ [117].  However, research is being 
performed to formulate strategies by which the normal paracellular transport can be 
enhanced to allow absorption of large therapeutic proteins [118].   
 A common strategy for enhancing paracellular transport is the use of permeation 
enhancers.  Ethylenediamine-tetraacetic acid (EDTA) can act as a permeation enhancer 
by binding to extracellular Ca2+, thus lowering the intracellular Ca2+, an important 
molecule in regulating the tight junctions [119].  Though permeation enhancers increase 
overall absorption of large proteins, they achieve the increase in permeability by 
disrupting the cell monolayer in a manner non-specific to the protein, thus allowing 
possible toxins and biological pathogens to enter the bloodstream [120].  Paracellular 
transport remains a viable option for the transport of large molecules such as proteins.  
However, the feasibility of an oral delivery system which utilizes paracellular transport 
hinges on a design in which the tight junctions are opened reversibly and without 
permanent damage as well as in a manner specific to the therapeutic protein. 
  There are four types of transcellular transport:  passive diffusion, carrier-
mediated transcytosis, receptor-mediated transcytosis, and efflux transport.  Utilizing 
transcellular transport in a design strategy for oral protein delivery has the inherent 
advantage that the tight junctions will not be opened, greatly decreasing the risk of 
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viruses or toxins entering the bloodstream.  However, transport of a large protein across 
the cell is very difficult under normal conditions.   
  The simplest type of transcellular transport, passive diffusion, is simple diffusion 
of a molecule from one side of the cell monolayer to the other side and is typically only 
possible for small molecules such as carbon dioxide and oxygen [121].   
  Another type of transcellular transport, efflux transport, typically does not result 
in transcytosis of the molecule, rendering it useless for most oral delivery applications.   
  Carrier-mediated transcytosis and receptor-mediated transcytosis involve the 
molecule interacting with the lipid bilayer and reversibly binding to either a carrier 
molecule or a specific receptor.  The complex is then transported to the inside of the cell.  
In carrier-mediated transport, the molecule-carrier complex dissociates after 
transporting the molecule inside the cell, allowing the molecule to drift to the other side 
and engage in a similar carrier-mediated process to exit the cell [121].  However, in 
receptor-mediated transcytosis, a specific molecule binds to a specific receptor on the 
cell surface due to its high affinity for the receptor.  The molecule-receptor complex is 
then transported into the cell and remains intact until it dissociates on the opposite side 
of the cell.   
  Receptor-mediated transport is a naturally occurring process typically used to 
transport essential nutrients into the body but recently has gained interest as a design 
strategy for oral drug delivery [122].  Strategies include conjugating the drug of choice 
to a targeting ligand which is recognized by a specific receptor and transported across 
the cell.  Receptor-mediated protein delivery systems benefit from specificity achieved 
due to the high affinity of the receptor molecule for only the ligand molecule, ensuring 
no toxins enter the bloodstream.  The specific uptake of therapeutic proteins could also 
lead to a significant increase in bioavailability.  Having a thorough understanding of the 
physiology of the stomach, small intestine, and epithelial cell layer allows for 
employment of several specific strategies in design of an oral delivery system.  The 
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following section details the background knowledge necessary to understand the 
specific approaches taken within this research to design oral protein delivery systems. 
 
2.6.2 Strategies for Enhancing Oral Delivery 
The strategies employed in this work to enhance oral delivery of proteins can be 
classified into two categories.  The first category of strategies explored consists of 
carrier entities.  This strategy does not modify the protein itself, but instead 
incorporates it into a system which can protect it in the stomach, target the site of 
absorption, and facilitate release of the therapeutic protein for subsequent absorption.  
In contrast, the second category of strategies consists of drug modification.  
Fundamentally different from carrier strategies, drug modification strategies consist of 
modifying the therapeutic protein itself to change its mechanics and properties.  
Specifically, these strategies typically consist of covalent conjugation of another 
molecule to the protein of interest in such a way as to preserve medicinal activity but 
also enhancing transport properties.  In this work, drug modification is used to increase 
transport across the epithelial cell layer in the small intestine.  The following sections 
detail necessary background information concerning incorporation of carriers and drug 
modification for improved oral protein delivery. 
 
2.6.2.1 Hydrogels and Carriers 
 The sensitivity and delicate nature of most therapeutic proteins have led many 
researchers to investigate the possibility of encapsulating proteins to be delivered orally 
[123].  These novel carrier systems are designed to protect the protein within the 
environment of the stomach, and also to release the protein to be absorbed within the 
small intestine.  One of the more promising options for protein carrier systems are 
hydrogel carriers [98, 124, 125].  A hydrogel carrier is comprised of a three-dimensional 
hydrophilic polymer network which will typically swell and imbibe water under certain 
specific conditions.  The swelling is considered an “intelligent” response to the stimulus 
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generated by the specific conditions.  Hydrogel systems can be designed such that in the 
swollen state, large molecules such as proteins are free to diffuse in and out of the 
system.  However, these same systems can be forced to collapse using a specific 
stimulus, thus entrapping any proteins present within the polymer network.  Entrapped 
proteins will remain within the polymer network as long as the carrier is collapsed, 
preventing any diffusion inward of enzymes or other substances which could degrade 
the protein.  Hydrogels possess tremendous potential for oral protein delivery in that a 
protein can be protected in the stomach while in the collapsed state and then 
subsequently released for absorption in the small intestine by the swelling response of 
the system. 
 Hydrogels are crosslinked, water-insoluble polymeric carriers capable of 
exhibiting a stimuli-sensitive swelling response.  Swelling behavior can be triggered in 
response to changes in factors such as temperature, pH, electric field, light, and even 
the presence of specific molecules [126].  For oral delivery applications, swelling of the 
hydrogel carrier is desired near the site of absorption in the small intestine.  One of the 
most notable differences between the stomach (pH ~ 2) and the small intestine (pH ~ 7) 
is the pH of surrounding environment.  For this reason, many oral protein delivery 
systems are designed around the use of pH-sensitive hydrogels [105].   
 Hydrogels are generally divided into four categories:  neutral, ampholytic, 
anionic, and cationic [127].  Most pH-sensitive hydrogels are typically either classified as 
anionic or cationic hydrogels depending on the nature of their ionizable pendant groups.  
Cationic hydrogels contain pendant groups which become protonated at a pH below the 
pKa of the ionizable groups.  The protonation results in local positive charges 
throughout the network, causing the system to swell as a result of electrostatic 
repulsion.  At a pH above the pKa of the ionizable groups, cationic hydrogels will remain 
collapsed due to interpolymer hydrogen bonding.  Anionic hydrogels exhibit an opposite 
response to environmental pH compared with cationic hydrogels.  Anionic hydrogels 
contain pendant groups which become deprotonated at a pH above the pKa of the 
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ionizable groups.  The deprotonated pendant groups results in local negative charges 
throughout the polymer system, causing an overall swelling response.  At a pH below 
the pKa of the ionizable groups, anionic hydrogels will remain collapsed due to 
interpolymer hydrogen bonding.  For oral protein delivery applications, the hydrogel 
carrier needs to protect the protein in the stomach (remain collapsed) and release the 
protein for absorption in the small intestine (become swollen).  Based on the design 
requirements, the pH-sensitive hydrogels investigated in this thesis will be anionic. 
 The primary hydrogel system under investigation in this thesis is comprised of a 
poly(methacrylic acid) polymer backbone grafted with poly(ethylene glycol) tethers 
(P(MAA-g-EG)).  However, other hydrogel systems such as poly(methacrylic acid) 
polymerized with the copolymer N-vinyl pyrrolidone (P(MAA-co-NVP)) will also be 
investigated.  The primary materials used in synthesizing P(MAA-g-EG) are methacrylic 
acid (MAA) and poly(ethylene glycol) monomethyl ether monomethacrylate (PEGMA).  
In acidic conditions, MAA and PEG form interpolymer complexes due to hydrogen 
bonding, forming physical crosslinks within the system and forcing the polymer into a 
collapsed state.  A schematic showing the interaction of the MAA and PEG polymer 
chains in the collapsed and swollen states is presented in Figure 2.6.  The P(MAA-g-EG) 
hydrogels are crosslinked by poly(ethylene glycol) dimethacrylate (PEGDMA), which can 
have an effect on the mesh size and release characteristics of the system by altering the 
length of the crosslinker and the crosslinking ratio.  The polymer hydrogels are 
synthesized by UV initiated free radical polymerization using the UV initiator Irgacure 
184TM.  The structures of the materials used in the synthesis of P(MAA-g-EG) hydrogels 
can be seen in Figure 2.7. 
 P(MAA-g-EG) microparticles have been shown to possess desirable 
characteristics for oral delivery such as the ability to protect proteins such as insulin 
within the stomach and also the ability to increase residence time through 
mucoadhesion within the small intestine.  Encapsulation of insulin within P(MAA-g-EG) 
microparticles has been shown to preserve over 80% of the loaded insulin after being 
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treated for one hour in gastric fluid.  In contrast, only 20% of free insulin remained 
intact after the same treatment with gastric fluid [128].  The addition of PEG tethers to a 
poly(acrylic acid) (PAA) system design was shown to increase the mucoadhesive capacity 
of the microparticles, generating a work of adhesion of approximately 130 x 10-3 mJ, or 
five times that of a pure PAA system.  P(MAA-g-EG) microparticles have proven to be a 
viable means for delivering insulin to the bloodstream, achieving a 12.8% bioavailability 
relative to subcutaneous injection [129].  The implementation of P(MAA-g-EG) hydrogel 
microparticles as an oral delivery system for proteins has shown significant promise 
through scientific results and the system remains a viable option for further research 
and optimization.  However, the system design needs to be modified to address such 
concerns as the intestinal transport of the protein in an effort to increase overall 
bioavailability, thus leading to a more economical and viable alternative to injections of 
therapeutic proteins. 
 
2.6.2.2 Drug Modification 
 One of the major challenges of oral protein delivery is transport across the 
epithelium of the small intestine.  To increase intestinal transport, researchers have 
investigated the possibility of drug modification by conjugation to a transporter 
molecule, often proteins or polypeptides, which can utilize specific membrane transport 
mechanisms [130].  One transporter protein being investigated for its possible use in 
oral delivery systems is transferrin, a glycoprotein used by the body for iron transport 
into the bloodstream.  Transferrin (~80 kDa) is a single chain protein naturally occurring 
in the human body which has the ability to bind to two iron ions per transferrin 
molecule.  Transferrin bound with two iron ions (holo-transferrin) has a greater affinity 
for the transferrin-receptor than transferrin bound with one iron ion (mono-transferrin) 
or no iron ions (apo-transferrin)  [131].  Transferrin-receptors are expressed on many 
types of cells in the human body, including intestinal epithelial cells.  The transferrin-
receptor is a homodimer comprised of two identical subunit monomers of 
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approximately 90 kDa each [122].  When iron bound transferrin binds to the transferrin-
receptor on the apical side of the cell layer, the complex can undergo either endocytosis, 
which is transport into the cell, or transcytosis, which is transport to the basolateral side 
of the cell layer [132].  Due to its ability to serve as a transporter targeting ligand for 
specific cellular uptake as well as its ability to resist trypsin and chymotrypsinogen 
degradation [121], transferrin remains an attractive option for circumventing the limited 
transport of the epithelium for drug delivery applications. 
   Aside from transferrin, another receptor-mediated transport system being 
considered for its potential applications to oral protein delivery is the vitamin B12 system 
[133].  Researchers have investigated the use of the vitamin B12 transport mechanism 
for oral delivery of insulin using dextran nanoparticles [134] and for uptake of 
erythropoietin in cellular models [135].  Vitamin B12 (~1.36 kDa) is used by the body 
primarily for the formation of red blood cells and regulation of the nervous system.   
  The vitamin B12 transport mechanism involves a number of transport proteins.  
Vitamin B12 is initially released when food substances are digested in the stomach.  The 
vitamin B12 binds to the transport protein haptocorrin, a binding protein secreted in 
saliva.  The vitamin B12-haptocorrin complex travels through the stomach and into the 
duodenum, where the haptocorrin is degraded by trypsin and chymotrypsin.  Vitamin 
B12 then binds to the transport protein intrinsic factor, which is produced in the parietal 
cells of the stomach.  The vitamin B12-intrinsic factor complex travels into the small 
intestine until it reaches the ileum, where the complex will bind to specific intrinsic 
factor receptors on the intestinal epithelium.  The receptor-transporter-vitamin complex 
undergoes receptor-mediated endocytosis and enters the cell.  Within the cell, the 
vitamin B12 is released from intrinsic factor and binds to another transport protein, 
transcobalamin II.  The transcobalamin II-vitamin B12 complex completes the 
transcytosis and is released into blood circulation [136].   
  Due to the involvement of multiple transport proteins in the vitamin B12 
transport mechanism, strategies for drug delivery using vitamin B12 would most likely 
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require drug conjugation to the vitamin itself and not the transport protein.  Within this 
thesis, there will be no attempt to synthesize an actual protein-B12 conjugate due to 
prohibitive cost of the transport protein intrinsic factor.  However, the possibility of 
forming B12 conjugates is explored.  The ability of intrinsic factor to act as a targeting 
ligand for the uptake of vitamin B12-protein conjugates combined with the ability of the 
conjugate complexes to be effectively transcytosed merits the investigation of the 
vitamin B12 transport mechanism as a viable solution to increase epithelial protein 
transport. 
 
2.7 Conclusions 
 Due to the nature of injection therapy, doctors, patients, and the medical 
community have been waiting for a suitable alternative for the administration of 
therapeutic proteins.  Scientists have attempted to design systems using many 
alternative routes of administration such as pulmonary, transdermal, nasal, buccal, and 
oral delivery.  Because of its high patient acceptability and ease of administration, many 
researchers have investigated the possibility of designing effective oral protein delivery 
systems.  To address challenges inherent to oral delivery such as protein degradation 
and poor transport, oral protein formulations include the use of strategies such as 
permeation enhancers, protease inhibitors, protein encapsulation, and drug 
modification.  While several of these strategies have been met with moderate success, 
the optimal approach to maximize bioavailability of administered proteins most likely 
consists of a combination of design strategies as well as an optimization of the systems 
employed within the formulation. 
  41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glu
Arg
GlyProLysThr PhePheTyrThr
GlyPhe Val Asn Gln His Leu Cys
Gly Ser His Leu
Val Glu Ala Leu Tyr Leu Val Cys
Gly Ile Val Glu Gln Cys
Cys
Thr Ser
Ile
Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys AsnS S
S
S
S
S
A chain = 21 amino acids
B chain = 30 amino acids
Figure 2.1  Basic structure of insulin. 
 
Insulin contains a total of 51 amino acids comprised of two separate chains connected 
by disulfide linkages.  The A-chain contains 21 amino acids while the B-chain contains 30 
amino acids.  The molecular weight of insulin is approximately 5,728 Da. 
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Figure 2.2  Basic structure of calcitonin. 
 
Calcitonin contains a total of 32 amino acids in a single long chain.  The molecular weight of 
insulin is approximately 3,418 Da. 
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Figure 2.3  Schematic of the human digestive system. 
 
Image shows the stomach as well as the three sections of the small intestine: the 
duodenum, the jejunum, and the ileum. 
(Illustration copyright 2001 by Nucleus Communications, Inc.  Adapted from original image) 
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Cardia
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Body
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To Small Intestine
From Esophagus
Figure 2.4  Diagram of the human stomach. 
 
Images shows the location within the stomach of its 4 major regions: the cardia, fundus,  
body, and the pylorus. 
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Figure 2.5  Cellular mechanisms of absorption in the small intestine. 
 
Schematic of (A) paracellular transport and (B) transcellular transport.  Specific types of 
transcellular transport include (B1) passive diffusion, (B2) carrier-mediated transcytosis, 
(B3) receptor-mediated transcytosis, and (B4) efflux transport.  
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Figure 2.6  Schematic showing interpolymer hydrogen bonding and electrostatic 
repulsion which cause swelling/deswelling response of polymer. 
 
Chains of P(MAA-g-EG) exhibiting (a) hydrogen bonding at a low pH, allowing for a 
collapsed, complexed system, and (b) electrostatic repulsion from local negative 
charges, forcing the system to swell.  
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Figure 2.7  Structures of components comprising P(MAA-g-EG) systems. 
 
P(MAA-g-EG) polymer systems are comprised of (a) methacrylic acid (MAA), which 
forms the polymer backbone, (b) poly(ethylene glycol) monomethyl ether 
monomethacrylate (PEGMA), which grafts a PEG polymer of chosen molecular weight as 
a tether, (c) poly(ethylene glycol) dimethacrylate (PEGDMA), which serves as a 
crosslinker to form a polymer network, and (d) Irgacure 184TM, a UV initiator used to 
start the polymerization reaction. 
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CHAPTER 3 
OBJECTIVES 
  
 The advantages of oral delivery for administration of therapeutic proteins are 
well known to the pharmaceutical industry.  Advantages such as the low cost, ease of 
administration, and increased patient compliance of oral protein delivery make the 
development of a successful oral protein delivery formulation a highly sought after goal 
for the industry.  Orally delivered proteins could greatly increase the efficacy of 
treatment regimens for patients worldwide, significantly improving overall health.  
However, oral protein delivery presents many challenges which, until recently, were 
though to be insurmountable.  Over recent years, scientists have made significant 
advances in overcoming natural barriers to oral protein delivery such as protein 
degradation, narrow absorption window, and low epithelial transport. 
 One strategy to overcome some of the barriers of oral protein delivery has been 
investigated in this laboratory and involves incorporation of the protein in complexation 
hydrogel carriers.  Hydrogel carriers used as delivery systems benefit from their ability 
to protect the protein in the harsh environment of the stomach as well as increase 
residence time at the site of absorption by using mucoadhesive materials and polymer 
tethers.  Another strategy to increase overall efficacy of oral protein delivery 
formulations is the modification of the therapeutic protein itself by conjugation to a 
transporter ligand which can utilize the natural transcellular transport pathways.  As 
mentioned in Chapter 2, a combinatorial approach utilizing hydrogel carriers and drug 
modification may result in significantly increased bioavailability relative to other oral 
formulations. 
 The overall goal of this research was to synthesize protein-transporter 
bioconjugates to be incorporated into complexation hydrogels and to optimize the 
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hydrogel carriers as to achieve the greatest potential for high bioavailability in the 
bloodstream.  The specific aims of this research are as follows: 
 
(1) Optimization of synthesis parameters of the poly(methacrylic acid)-based 
microparticles with specific emphasis on crosslinker, monomer to solvent 
ratio, particle size and incorporated comonomer for maximal protection 
and release of bioconjugates. 
 
(2) Formulation and characterization of conjugation reactions of therapeutic 
proteins to transporter molecules using heterobifunctional crosslinkers. 
 
(3) Investigation into the in vitro properties of the insulin-transferrin 
conjugate, specifically its ability to be loaded and released from several 
hydrogel formulations. 
 
(4) Evaluation of the interactions between synthesized calcitonin-transferrin 
conjugate with the hydrogel polymer carrier formulations including 
loading and release characteristics. 
 
(5) Evaluation of the effect of synthesized conjugates and polymer carriers 
on bioavailability and bioactivity using in vitro cell culture models and in 
vivo animal models. 
 
Within this body of work, each specific aim was covered in separate chapters.  
Specific Aim #1 was addressed and investigated in Chapter 4.  The conjugation reactions 
described by Specific Aim #2 were covered in Chapter 5.  As described in Specific Aim #3, 
the synthesized insulin-transferrin conjugate was investigated as a potential entity to be 
loaded and released in Chapter 6.  Chapter 7 contains the studies mentioned in Specific 
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Aim #4, which are investigations into the polymer-conjugate interactions existing 
between the calcitonin-transferrin conjugate and the polymer carrier via loading and 
release studies.  Finally, Specific Aim #5 was addressed in Chapter 8 by investigation into 
cellular studies and animal studies using synthesized conjugates.  With each specific aim 
addressed in previous chapters, Chapter 9 provides general conclusions encompassing 
the entire body of research. 
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CHAPTER 4 
SYNTHESIS AND CHARACTERIZATION OF METHACRYLIC ACID BASED HYDROGELS AS 
CARRIERS FOR NOVEL PROTEIN-TRANSPORTER BIOCONJUGATES 
 
 
4.1 Introduction 
Generally, bioavailability of orally administered therapeutic proteins is 
significantly lowered due to degradation in the stomach.  Any protein administered 
orally must endure the low pH environment as well as the multitude of digestive 
enzymes present in the stomach.  The average pH of the stomach is approximately 2.0, 
creating an environment which can readily damage or denature therapeutic proteins 
and render them inactive [1].  Also, digestive enzymes such as pepsin and trypsin will 
attack administered proteins and cleave them into smaller peptide fragments to 
facilitate uptake for energy within the small intestine.  Bioavailability of orally delivered 
proteins can also be reduced by lack of residence time at the site of absorption and poor 
epithelial transport.  Any design strategy intended to increase bioavailability of orally 
administered proteins must include ways to protect from degradation, increase 
residence time at the site of absorption, and increase epithelial transport. 
 Many researchers have designed methods to overcome these barriers to oral 
protein delivery.  Much research has focused on the inclusion of protease inhibitors into 
the oral dosage formulation.  Protease inhibitors would effectively inhibit the activity of 
proteolytic enzymes, preventing them from attacking administered therapeutic proteins, 
thereby preserving the bioactivity of the dosage form.  For example, Ziv et al. [2] 
demonstrated that upon administration of the protease inhibitor aprotinin with the 
therapeutic protein insulin (in bile acid), insulin absorption was amplified approximately 
30 times relative to the administration of insulin alone.  However, the resultant 
bioavailability of the formulation was still very low (~0.75%). 
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 An alternative strategy to increase bioavailability of administered proteins is the 
use of permeation enhancers, which focus on increasing epithelial transport across the 
cell monolayer.  Permeation enhancers are administered with the dosage form to 
disrupt or in some way modify the cell monolayer, specifically the tight junctions of the 
monolayer.   
 The tight junctions between the cells are composed of the transmembrane 
proteins occludin and claudin, and cytoplasmic plaque proteins zonula occludens (ZO)-1, 
ZO-2, ZO-3, cingulin, and 7H6 [3].  These proteins are of a dynamic nature, responding 
and altering their function based on changes in the extracellular environment.  Most 
permeation enhancers operate by altering the extracellular environment in such as way 
as it forces the transmembrane proteins to relax or loosen the tight junctions between 
the cells.  For example, ethylenediamine-tetraacetic acid (EDTA) can act as a permeation 
enhancer by binding to extracellular Ca2+, thus lowering the extracellular Ca2+ 
concentration and consequently lowering the intracellular Ca2+ concentration due to 
passive diffusion.  Because of the importance of calcium to the transmembrane 
proteins’ regulating of the tight junctions, the tight junctions are loosened in the 
presence of EDTA and transport across them is increased [4].   
 While protease inhibitors and permeation enhancers each present a possible 
solution to different individual barriers of oral protein delivery, design strategies utilizing 
methods to address all the oral protein delivery barriers are more desirable and 
represent greater potential to achieve high bioavailability of the protein in the 
bloodstream.   
 One method which at least partially addresses all of the oral protein delivery 
barriers is the incorporation of the protein into hydrogel carriers.  A hydrogel carrier is a 
three-dimensional hydrophilic polymer network which will typically swell and imbibe 
water under certain specific conditions.  The swelling is considered an “intelligent” 
response to the stimulus generated by the specific conditions.  Swelling behavior can be 
triggered in response to changes in factors such as temperature, pH, electric field, light, 
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and even the presence of specific molecules [5].  Also, hydrogel systems can be tailored 
such that in the swollen state, large molecules such as proteins are free to diffuse in and 
out of the system.  However, these same systems can be forced to collapse using a 
specific stimulus, thus entrapping any proteins present within the polymer network.  
Entrapped proteins will remain within the polymer network as long as the carrier is 
collapsed, preventing any diffusion inward of enzymes or other substances which could 
degrade the protein.  Because of the ability of hydrogel carriers to protect encapsulated 
proteins in the harsh environment of the stomach, they effectively address the protein 
degradation barrier to oral protein delivery. 
 For oral delivery applications, swelling of the hydrogel carrier is desired near the 
site of absorption in the small intestine.  One of the most notable differences between 
the stomach (pH ~ 2) and the small intestine (pH ~ 7) is the pH of the surrounding 
environment.  For this reason, many oral protein delivery systems are based on pH-
sensitive hydrogels [6].  
 Hydrogels are generally divided into four categories:  neutral, anionic, cationic, 
and ampholytic [7].  Most pH-sensitive hydrogels are typically either classified as anionic 
or cationic hydrogels depending on the nature of their ionizable pendant groups.  
Cationic hydrogels contain pendant groups which become protonated at a pH below the 
pKa of the ionizable groups.  The protonation results in local positive charges 
throughout the network, causing the system to swell as a result of electrostatic 
repulsion.  At a pH above the pKa of the ionizable groups, cationic hydrogels will remain 
collapsed due to interpolymer hydrogen bonding.  Anionic hydrogels exhibit an opposite 
response to environmental pH compared with cationic hydrogels.  Anionic hydrogels 
contain pendant groups which become deprotonated at a pH above the pKa of the 
ionizable groups.  The deprotonated pendant groups results in local negative charges 
throughout the polymer system, causing an overall swelling response.  At a pH below 
the pKa of the ionizable groups, anionic hydrogels will remain collapsed due to 
interpolymer hydrogen bonding.  For oral protein delivery applications, the hydrogel 
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carrier needs to protect the protein in the stomach (remain collapsed) and release the 
protein for absorption in the small intestine (become swollen).  Based on the design 
requirements, the pH-sensitive hydrogels investigated in this thesis will be anionic. 
 In addition to their ability to protect proteins, hydrogels can be constructed 
using mucoadhesive materials which can bind to the mucosa lining the small intestine.  
This binding increases residence time next to the wall of the small intestine, allowing 
more time for diffusion of the protein out of the system as well as time for increased 
absorption.  The addition of polymer tethers which can penetrate the mucosa and act as 
anchors to mucoadhesive polymers combine for an even further increased residence 
time and increased chance for absorption.  In addition to increased residence time, 
certain hydrogels can also somewhat increase epithelial transport due to their ability to 
bind to extracellular calcium.  Similar to permeation enhancers, the depleted levels of 
extracellular calcium cause a relaxation of the tight junctions, increasing paracellular 
transport.  However, calcium binding will only occur with anionic hydrogel carriers due 
to the negative charges spread throughout the system.  Ca2+ ions have a positive charge, 
causing attraction to the negatively charged hydrogel carrier.  Hydrogels possess 
tremendous potential for oral protein delivery in that protein degradation is minimized 
due to the collapsing of the system, residence time at the site of absorption is increased 
from the use of mucoadhesive polymers and polymer tethers, and epithelial transport is 
increased due to the calcium binding of the system in the swollen state. 
 Over the past few decades, scientists have become increasingly aware of the 
potential of hydrogels as carriers for the oral delivery of therapeutic proteins [8-10].  
The major interest in hydrogels began as early as 1960 with the work of Wichterle and 
Lim [11] on crosslinked HEMA hydrogels.  The work of Wichterle and Lim showed the 
biocompatibility of hydrogels as well as their hydrophilic nature, gaining the interest of 
biomaterials researchers worldwide.  Later, in 1980, Lim and Sun [12] created a system 
for cell encapsulation using calcium alginate microcapsules.  A few years later, Yannas et 
al. [13] utilized collagen and shark cartilage in a hydrogel network to use as artificial 
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burn dressings.  In the late 1980’s to early 1990’s, hydrogels were beginning to be 
considered for the delivery of therapeutic proteins [14].  However, it was not until 
recently that a system designed using hydrogels was able to achieve a significant 
increase in bioavailability relative to subcutaneous injection [15]. 
 Within our laboratory, significant research has been performed to further the 
understanding of hydrogels for use in oral protein delivery.  In 1991, Brannon-Peppas 
and Peppas [16] investigated the kinetics of the response of ionic hydrogels to changes 
in environmental pH and ionic strength.  Also, Khare et al. [17] determined the degree of 
swelling of the hydrogel that occurs due to changes in pH and ionic strength.  An 
understanding of the kinetics and degree of the swelling reaction of specific ionic 
hydrogels to changes in environmental pH and ionic strength is essential to 
advancement towards designing an effective oral protein delivery system.  In 1995, am 
Ende et al. [18] detailed the factors which affect protein release from ionic hydrogels.  
Also, Bell and Peppas [19] described diffusion characteristics of water, solute, and 
proteins within the hydrogel network.  After understanding the swelling characteristics 
of the ionic hydrogels, it is necessary to investigate the diffusion of entities within the 
network as well as factors affecting protein release to fully understand the 
characteristics of a hydrogel system for therapeutic proteins. 
 After performing fundamental research related to the kinetics and factors of 
swelling, diffusion modeling, and factors affecting protein release, research in our 
laboratory focused on obtaining in vitro results to determine the effectiveness of the 
delivery system as well as system optimization to provide the highest potential for 
increased bioavailability.  In recent years, our hydrogel systems have exhibited 
properties which show strong potential for overcoming many of the known barriers for 
oral protein delivery.  For example, Yamagata et al. [20] demonstrated the potential of 
the hydrogel carriers to protect proteins by encapsulating insulin within P(MAA-g-EG) 
microparticles and achieving preservation of over 80% of the loaded insulin after being 
treated for one hour in gastric fluid.  In contrast, only 20% of free insulin remained 
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intact after the same treatment with gastric fluid.  Also, increased residence time at the 
site of absorption has been achieved by the addition of polymers which are known to be 
mucoadhesive [21] and through the implementation of polymer tethers.  Serra et al. 
[22] showed that the addition of PEG tethers to a poly(acrylic acid) (PAA) hydrogel 
system increased the mucoadhesive capacity of the microparticles, generating a work of 
adhesion of approximately 130 x 10-3 mJ, or five times that of a pure PAA system.  
Finally, Morishita et al. [15] demonstrated the overall effectiveness and potential of the 
hydrogel system by performing in vivo studies in which insulin was administered in 
P(MAA-g-EG) carriers to diabetic rats, resulting in a bioavailability of 12.8%, a significant 
increase over insulin administered alone.  Currently, our research continues to search 
for novel ways to improve efficacy and bioavailability of proteins administered in 
hydrogel carriers.  Currently researched design strategies include drug conjugation, 
particle conjugation, inclusion of sensors, and improved materials. 
 The hydrogels synthesized and investigated in this thesis are based on a 
poly(methacrylic acid) (P(MAA)) backbone.  The primary polymer hydrogel being 
investigated is a polymer comprised of poly(methacrylic acid) with grafted poly(ethylene 
glycol) (PEG) tethers (henceforth denoted as P(MAA-g-EG)).  The components which 
comprise P(MAA-g-EG) are shown in Figure 4.1.   
 Another polymer formulation being investigated as well is a comonomer 
comprised of poly(methacrylic acid) and N-vinyl pyrrolidone (NVP) (henceforth denoted 
as P(MAA-co-NVP)).  The components which comprise P(MAA-co-NVP) are shown in 
Figure 4.2.   
 P(MAA-g-EG) and P(MAA-co-NVP) are anionic hydrogels which means that the 
system will be complexed at a lower pH and swollen at a higher pH.  The MAA groups 
have a pKa of around 4.9, allowing for complexation at a significantly lower pH than 4.9 
and swelling at a significantly higher pH than 4.9.  As P(MAA-g-EG) enters the stomach 
(pH ~ 2), hydrogen bonding is occurring between hydrogens in the MAA groups and 
etheric oxygens in the PEG crosslinkers or grafted tethers.  For P(MAA-co-NVP), the 
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hydrogen bonding exists between the hydrogen in the MAA group and the oxygen in the 
NVP pendant group.  However, as the formulations pass into the small intestine (pH ~ 7), 
the MAA pendant groups become deprotonated and gain a local negative charges.  The 
negatives charges accumulate throughout the system and cause static repulsion, 
swelling the hydrogel.  A schematic showing P(MAA-g-EG) at the molecular level in both 
low and neutral pH is shown in Figure 4.3.  A schematic showing molecular interactions 
for P(MAA-co-NVP) at low and neutral pH is shown in Figure 4.4. 
 In addition to their abilities to swell, P(MAA-g-EG) and P(MAA-co-NVP) are both 
constructed with a methacrylic acid, a mucoadhesive polymer.  The mucoadhesive 
capacity of MAA allows for a binding interaction between the polymer carrier and the 
mucosa lining the small intestine.  The binding creates a longer residence time for the 
carrier at the specific site of absorption, allowing for greater time for diffusion and a 
higher probability for absorption.  In addition to its mucoadhesive capacity, P(MAA-g-
EG) also benefits from its design structure of having grafted tethers.  The grafted PEG 
tethers are thought to penetrate within the mucus and generate an “anchor” effect, 
thus creating a stronger interaction between the hydrogel carrier and the mucosa.  The 
increased binding should further increase residence time and also increase the potential 
for higher bioavailability.  The hypothesized interactions of P(MAA-g-EG) and P(MAA-co-
NVP) with the mucosa layer are shown in Figure 4.5. 
 Anionic hydrogels such as P(MAA-g-EG) and P(MAA-co-NVP) are also known to 
act as permeation enhancers for increasing epithelial transport.  As mentioned earlier, 
the MAA groups become deprotonated in the neutral pH of the small intestine, creating 
local negative charges.  Because of these negative charges, the hydrogel carriers are 
able to bind positively-charged calcium, or Ca2+, from the extracellular domain.  Binding 
extracellular calcium lowers the calcium concentration outside the cell, creating 
diffusion of intracellular calcium outside the cell.  Intracellular calcium has been shown 
to be important in regulating tight junctions, and a significant decrease in intracellular 
calcium will loosen the tight junctions and increase transport of large molecules such as 
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proteins [4].  A diagram demonstrating the calcium binding ability of the hydrogel 
systems is shown in Figure 4.6. 
 In addition to the general properties of the hydrogel design, the carriers can be 
specifically modified to optimize the loading and release of specific therapeutics.  
Therapeutic proteins or modified protein formulations can vary in size, structure, 
surface charges, isoelectric point, or a myriad of other properties which can affect its 
interaction with the hydrogel carrier.  Through manipulation of synthesis parameters, 
one can change the properties of the resultant formulation.  In this thesis, the synthesis 
parameters for P(MAA-g-EG) were altered to obtain optimal loading and release of 
synthesized bioconjugates.  The synthesis parameters investigated include crosslinker 
length, monomer-to-solvent ratio, particle size, and replacement of the PEG graft 
comonomer with a NVP comonomer. 
 Crosslinks in a hydrogel polymer network are small connecting polymer chains 
which connect the longer polymer backbones.  In theory, longer crosslinker chains 
create more distance between connected polymer backbones.  While longer crosslinker 
chains may not generate distance in the collapsed state because of coiling and 
compression due to hydrogen bonding.  However, in the swollen state, the polymer 
strands are trying to spread apart due to local negative charges throughout the system.  
As the polymer backbone increasingly expands, the presence of a longer crosslinker will 
allow greater separation within the polymer network.  The increased expansion of the 
network will translate to an increased average mesh size for the network.  Larger mesh 
size upon swelling allows for increased and quicker diffusion of the therapeutic out of 
the system, giving better overall release.  A diagram showing the relationship of 
crosslinker length and mesh size is shown in Figure 4.7. 
 Another way to increase the effective mesh size of hydrogel carriers is to alter 
the monomer-to-solvent ratio.  The relationship between amounts of monomer and 
solvent in a polymer formulation is crucial to developing a polymer carrier.  If the 
amount of monomer or solvent is too high relative to the other, it is typically difficult to 
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synthesize a workable polymer.  However, if the monomer-to-solvent ratio is within a 
certain range, then the polymer can easily be synthesized.  Within the workable range, 
the monomer-to-solvent ratio can be altered to modify the polymer properties.  
Generally, a lower monomer-to-solvent ratio results in creating a polymer carrier with 
increased effective mesh size and thus increased diffusion of therapeutic.  The inclusion 
of more solvent in the system introduces more solvent molecules around which the 
backbones will polymerize, thus creating a more open and porous network.  As the 
network becomes more porous, the therapeutic protein inside will release quicker and 
to a higher overall degree. 
 The effect of manipulation of the particle size is different than the effects of 
modification of crosslinker length or monomer-to-solvent ratio.  Rather than increase 
the mesh size of the polymer, changing the particle size affects the diffusion path length 
of the therapeutic protein.  In theory, creating smaller particles means the therapeutic 
proteins have a quicker route for release, and therefore should exit the carrier faster.  
Also, during loading the proteins cannot penetrate as deeply, allowing a greater overall 
release in a given time for the smaller particle system.  In addition to quicker diffusion, 
smaller particles also have an increased ability to penetrate deeper into the mucosa, 
thus release their protein closer to the site of absorption.  In fact, Morishita et al. 
showed a significantly quicker release, increased mucoadhesive capacity, and increased 
absorption into the bloodstream using small particles (<43 µm) relative to larger 
particles (180-230 µm) [15].  A diagram showing the diffusion path length and mucosa 
interaction of two differently sized particles is shown in Figure 4.8. 
 Optimization of P(MAA-g-EG) for the loading and release of synthesized 
bioconjugates consists of opening up the system and increasing mesh size to effectively 
release the larger bioconjugates.  However, the mesh size cannot be increased too much 
or the therapeutic protein will diffuse out in the collapsed state in the stomach.  If an 
attempt to modify synthesis parameters such as to generate stronger complexation and 
greater protection in the stomach, the replacement of PEG tethers with NVP was 
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investigated.  Due to strong intermolecular affinity between the chains, the MAA/NVP 
interaction is stronger and allows for greater complexation relative to MAA/PEG 
systems [23].  P(MAA-co-NVP) is thought to protect encapsulated proteins in the 
stomach better than P(MAA-g-EG) which could lead to have more intact, bioactive 
protein for release in the small intestine. 
 The objective of this section of the thesis is to synthesize and characterize 
several different polymer formulations with the ultimate goal of creating the optimal 
carrier for ideal loading and release of synthesized bioconjugates.  In an effort to create 
four variables for optimization, synthesis parameters such as crosslinker length, 
monomer-to-solvent ratio, particle size, and comonomer were modified within the 
synthesized polymers.  The systems were then characterized to observe any differences 
between the systems other than loading and release characteristics.  The synthesis and 
characterization of all polymer formulations used in this thesis will be covered in this 
chapter. 
 
4.2 Materials and Methods 
4.2.1 Polymer Microparticle Formation by UV Polymerization 
P(MAA-g-EG) and P(MAA-co-NVP) were prepared using a free radical UV 
polymerization in solution.  P(MAA-g-EG) was prepared by mixing MAA (Sigma-Aldrich 
Inc., St. Louis, MO) with poly(ethylene glycol) monomethyl ether monomethacrylate 
with a approximate molecular weight of 1000 (PEGMA1000, Polysciences Inc., 
Warrington, PA) in a 1:1 molar ratio of MAA:EG.  P(MAA-co-NVP) was prepared by 
mixing MAA with NVP (Sigma-Aldrich Inc., St. Louis, MO) in a 1:1 molar ratio of 
MAA:NVP.  Crosslinkers were then added into the monomer mixtures consisting of 
MAA/EG or MAA/NVP.  The crosslinkers used within this study were tetraethylene glycol 
dimethacrylate (TEGDMA, Sigma-Aldrich Inc., St. Louis, MO) and poly(ethylene glycol) 
dimethacrylate with an approximately molecular weight of 1000 (PEGDMA1000, 
Polysciences Inc., Warrington, PA).  The amount of crosslinker added to each monomer 
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mixture was equal to 1 mol% of the total amount of monomer (MAA/EG or MAA/NVP).  
In order to eventually initiate the polymerization, the photoinitiator 1-
hydroxycyclohexyl phenyl ketone (Irgacure 184, Sigma-Aldrich Inc., St. Louis, MO) was 
added to the polymerization mixture in the amount of 1 wt% of the total monomer 
added (MAA/EG or MAA/NVP).  A solvent mixture consisting of 50:50 by weight 
deionized water (Milli-Q Plus system, Millipore) and ethanol (AAPER Alcohol, Shelbyville, 
KY) was added to the polymer mixture in the amounts of either 50:50, 60:40, or 67:33 
by weight polymer mixture to solvent mixture.  The presence of the solvent solution is 
essential to prevent autopolymerization as well as to produce a workable thin polymer 
film. 
To ensure all components dissolved and went into a homogenous solution, the 
polymer mixture was sonicated for 15 minutes.  After sonication, nitrogen was bubbled 
through the polymer solution within a nitrogen environment to eliminate oxygen.  
Oxygen is a free radical scavenger and significant oxygen levels could prematurely end 
the polymerization process.  After removal of oxygen by nitrogen purging, the polymer 
mixture was poured between two glass slides (153 x 153 x 3 mm) separated by a Teflon 
spacer (0.7 mm) while still in a nitrogen environment.  The glass slide apparatus 
containing the polymer solution spread into a thin film was then placed under a UV light 
source while still in a nitrogen environment.  The solution was allowed to polymerize 
under the light source within an intensity range of 16-17 mW/cm2 for 30 minutes.  After 
the polymerization was completed, the polymer gels were removed from the nitrogen 
environment, separated from the glass slides, and placed in deionized water.  The 
polymer films were washed in the deionized water for 7 days to remove excess 
monomer and contaminants.  After washing was completed, the polymers were dried in 
a vacuum oven at approximately 30° C for 2 days. 
After completely drying the polymer films, they were removed from the vacuum 
oven and crushed into microparticles using a mortar and pestle.  The crushed 
microparticles were then sieved into appropriate size ranges of either less than 75 
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microns, 90-150 microns, or 150-212 microns.  The crushed and sieved microparticles 
were then stored in a vial within a desiccator to prevent moisture entering until further 
use.  A schematic of the polymerization process is shown in Figure 4.9. 
 
4.2.2 Polymer Microparticle Characterization by Scanning Electron Microscopy 
Characterization of size, morphology, and surface texture of the polymer 
formulations was performed using a field emission scanning electron microscope (FE-
SEM, LEO 1530, Oberkochen, Germany).  The polymer formulations examined included 
P(MAA-g-EG) and P(MAA-co-NVP), all three particle size ranges (less than 75 microns, 
90-150 microns, and 150-212 microns), the two extremes of monomer-to-solvent ratios 
(50:50 and 67:33 monomer-to-solvent ratio), and the TEGDMA and PEGDMA1000 
crosslinked systems.  The microparticles were dried in a vacuum oven prior to analysis 
to reduce any moisture present.  The microparticles were applied to conductive carbon 
tape and mounted on an aluminum SEM stage.  The particles were then coated with 
gold for 20 seconds using a sputter-coater (Model 3, Pelco, Redding, CA) in an argon 
environment.  The gold-coated particles were placed in the SEM, which was operated 
between 2 kV and 10 kV.  All images were taken from magnifications ranging from 50X 
to 1000X. 
 
4.3 Results and Discussion 
4.3.1 Polymer Microparticle Formation by UV Polymerization 
Optimization of the hydrogel carriers for encapsulation of synthesized 
bioconjugates required the synthesis of several polymer formulations.  Within these 
polymer formulations, several synthesis parameters were individually varied to 
determine their effect on the loading and release characteristics of the system.  As a 
result of the analysis, an optimized hydrogel carrier could be designed.  The altered 
synthesis parameters include crosslinker length, monomer-to-solvent ratio, particle size, 
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and comonomer used.  A table of all successfully synthesized polymer formulations is 
presented in Table 4.1. 
As evident from Table 4.1, two polymer formulations were synthesized while 
varying crosslinker length.  One formulation was crosslinked with TEGDMA (4 ethylene 
glycol repeat units) and the other with PEGDMA1000 (~23 ethylene glycol repeat units).  
The length of the crosslinker has a direct effect on mesh size and overall openness of 
the polymer network.  Consequently, polymer formulations containing TEGDMA 
crosslinker will be tighter and able to protect the conjugate better in the stomach due to 
a tighter collapsed state.  However, polymer formulations containing PEGDMA1000 
crosslinker will allow more diffusion of the protein in both the collapsed and swollen 
state.  While minimal diffusion is desired in the collapsed state, an effective hydrogel 
carrier requires that the swollen state promotes maximal diffusion as to have a quick 
and total release.  The trade-off between these characteristics is investigated in later 
chapters.  The synthesis of a polymer film using the crosslinker poly(ethylene glycol) 
diacrylate with a molecular weight of 4000 (PEGDA4000) was attempted but was not 
successful because the longer crosslinker created a polymer which was not rigid enough 
to undergo thin film washing and drying.  This problem may be possible to prevent with 
a different type of polymerization such as solution polymerization but for the purpose of 
analyzing the effect of crosslinker length, the two crosslinkers used were sufficient. 
Three polymer formulations were synthesized with variation with respect to the 
monomer-to-solvent ratio.  The three monomer-to-solvent ratios used in the 
polymerizations were 50:50, 60:40, and 67:33 monomer-to-solvent ratios.  The 
monomer-to-solvent ratio is known to have an effect on the porosity of the system, the 
mesh size, and the relative space within the polymer network.  The polymer formulation 
with a 67:33 monomer-to-solvent ratio forms a tighter network which limits diffusion, 
making it ideal for protecting the loaded bioconjugate in the stomach.  However, while 
diffusion is limited in the systems with more monomers, diffusion is increased in the 
systems with relatively more solvent, such as the 50:50 monomer-to-solvent system.  
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The increased capacity for diffusion would be ideal for obtaining a quicker and greater 
total release than the other systems.  The balance between the two effects of altering 
monomer-to-solvent ratio is investigated in later chapters.  Synthesis of polymer films 
with 40:60 and 33:67 monomer-to-solvent ratios were attempted but were not 
successful using the thin film method.  Excess solvent separates the monomer and 
crosslinker molecules to the degree that a complete polymer network cannot be formed, 
resulting in a loose polymer gel.  However, the effect of monomer-to-solvent ratio can 
clearly be observed by testing the three formulations synthesized in this work. 
As seen in Table 4.1, three polymer formulations were synthesized while varying 
the particle size of the microparticles.  Microparticles were synthesized within the size 
ranges of less than 75 microns, 90-150 microns, and 150-212 microns.  The particle size 
does not have an effect on the general internal characteristics of the polymer network, 
but instead on the overall dynamics of loading and release.  The larger microparticles, 
such as those in the 150-212 micron size range, have a longer diffusion path length for 
any object diffusing in or out of the system.  This has advantages and drawbacks in that 
it is more difficult for digestive enzymes and gastric acid to reach the protein, preserving 
its stability, but it is also more difficult for the protein to diffuse out of the system in the 
small intestine, leading to slower release and decreased amounts released.  Conversely, 
smaller particles, such as those that are less than 75 microns, have shorter diffusion 
path lengths which may present a danger in the stomach but will lead to better release 
in the small intestine as well as a release closer to the site of absorption due their ability 
to penetrate further into the mucosa.  The effect of particle size on loading and release 
is investigated in later chapters.  Particles in a size range above 212 microns were not 
synthesized due to the diminished probability of larger microparticles being effective 
protein delivery devices.  Particles in a size range significantly less than 75 microns were 
not synthesized due to the inability to reach such small sizes using a mortar and pestle.  
Smaller particles could be formed through the use of different polymerization 
techniques or possibly a different crushing method. 
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In addition to altering synthesis parameters, the polymer structure was also 
altered by creating two formulations, P(MAA-g-EG) and P(MAA-co-NVP).  The 
introduction of NVP as a replacement comonomer to PEG is thought to result in a more 
stable system with a higher capacity to complex and form stronger hydrogen bonds.  
The stronger interaction would provide better protection for the loaded bioconjugate, 
thus preserving its activity and increasing the chance for higher efficacy.  However, the 
increased interaction would have minimal effect on the swelling response of the 
hydrogel.  Also, replacing PEG tethers with NVP also results with a loss of the ability of 
the PEG tethers to penetrate the mucosa, generating an increased residence time at the 
site of absorption.  The effect of P(MAA-g-EG) and P(MAA-co-NVP) on the loading and 
release of synthesized bioconjugates is explored in later chapters. 
 An effective oral delivery hydrogel carrier must be able to perform a dual 
function:  protection of the protein in the stomach and release in the small intestine.  
Because one of these functions depends on limiting diffusion and the other on 
promoting diffusion, systems must be designed very carefully to utilize both attributes.  
Because the protection and release characteristics are so inherently different, it is 
extremely difficult to determine the optimal system for incorporation of a specific 
protein or conjugate without experimental investigation.  Experiments testing the 
loading and release characteristics of all the specific systems are required to maintain 
the correct balance between protection and release and are performed in Chapter 6 and 
Chapter 7. 
 
4.3.2 Polymer Microparticle Characterization by Scanning Electron Microscopy 
To analyze and characterize the synthesized polymer formulations, several 
different formulations of microparticles were examined using a scanning electron 
microscope (SEM).  Analysis of the microparticles by SEM yielded information regarding 
size, morphology, and surface texture which can be used to better understand the 
differences between the formulations and their effects on the efficiency of the drug 
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delivery system.  Polymer formulations including TEGDMA and PEGDMA crosslinker 
polymers, the highest and lowest monomer-to-solvent ratios, all three particle size 
ranges, and P(MAA-g-EG) and P(MAA-co-NVP) were analyzed through SEM. 
The first polymer formulation characterized by SEM was that of P(MAA-g-EG) 
with a 50:50 monomer-to-solvent ratio, crosslinked by PEGDMA1000, and sized less 
than 75 microns.  The SEM micrograph of this formulation is shown as Figure 4.10.  As 
can be seen in Figure 4.10, the observed sizes of the microparticles generally measure 
around 75 microns or less.  The particles are not spherical or any other regular shape 
but instead are randomly shaped with long, flat edges.  The formation of the edges is 
most likely a result from shear inherent to crushing by mortar and pestle.  This particular 
formulation shows very little surface features and instead shows a very smooth outer 
surface.  The interesting data from the SEM image for this formulation is the wide 
variation in particle sizes all the way down to less than 10 microns.  Because the 
particles were crushed with no lower limit on size, smaller particles can develop.  
Microparticles that are significantly smaller will most likely have different loading and 
release characteristics, but within this formulation the characteristics are used to 
describe an average particle size. 
Another polymer formulation characterized by SEM was the polymer 
formulation of P(MAA-g-EG) with a 50:50 monomer-to-solvent ratio, crosslinked by 
PEGDMA1000, and sized between 90-150 microns.  The SEM image of this polymer 
formulation is shown as Figure 4.11.  Within Figure 4.11, it can be observed that the 
measurable size of the microparticles generally fall within the 90-150 microns size range.  
Similar to the previous formulation, the shape of the microparticles are not regular but 
instead random with flat edges.  Relative to the previous formulation, the polymer 
microparticles in Figure 4.11 appear to exhibit different surface features.  Specifically, 
the surface appears to be rougher with more imperfections than the smooth 
formulation of less than 75 microns.  The change in surface texture may be attributed to 
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sample to sample variation, or possibly variation within the method of crushing by 
mortar and pestle. 
The polymer formulation of P(MAA-g-EG) with a 50:50 monomer-to-solvent ratio, 
crosslinked by PEGDMA1000, and sized between 150-212 microns was also 
characterized by SEM.  The SEM image of this formulation is shown as Figure 4.12.  As 
seen in Figure 4.12, the visual sizes of the microparticles in the image closely represent 
the specified range of 150-212 microns.  As with all other polymer formulations, the 
shape is not regular or spherical but instead is random with long, flat edges.  The surface 
features of this polymer formulation are somewhere between the smoothness of the 
less than 75 microns formulation and the roughness of the 90-150 microns formulation.  
The variations in surface texture between the three formulations with different particle 
size ranges are mostly insignificant and can be attributed to variation between samples.  
Changing only the synthesis parameter of particle size should not have an observed 
effect in the surface of a microparticle other than artificial effects which arise from the 
processing (crushing, sieving, etc.) of the microparticles. 
To determine the effect of monomer-to-solvent ratio and crosslinker length, a 
polymer formulation of P(MAA-g-EG) with a 67:33 monomer-to-solvent ratio crosslinked 
with TEGDMA and size below 75 microns was characterized by SEM.  The SEM 
micrograph of this formulation is shown as Figure 4.13.  The sizes of the particles are 
consistent with their specified size of less than 75 microns.  Also, because shape was not 
controlled in the synthesis, the microparticles are mostly random with flat edges.  The 
surface of this polymer formulation appears very smooth, most likely due to the 
network being tighter with features that are more difficult to observe at the specified 
magnification. 
The last polymer formulation characterized by SEM consisted of P(MAA-co-NVP) 
with a 50:50 monomer-to-solvent ratio, crosslinked with PEGDMA1000, and sized below 
75 microns.  The obtained SEM image is shown as Figure 4.14.  The visible sizes of the 
microparticles in Figure 4.14 appear to accurately represent the size range of less than 
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75 microns.  As with all polymer formulations in this thesis, the shape is mostly random 
with curved edges.  The surface texture of the microparticles has more distinct regions 
and features than many of the other formulations. 
To determine the effect of each synthesis parameter on the characteristics of the 
microparticle, it is necessary to compare the SEM micrographs of the polymer 
formulations.  The first synthesis parameter investigated through SEM characterization 
is the particle size range.  A composite image showing the three size range formulations 
is shown as Figure 4.15.  In Figure 4.15, one can clearly see the difference in size among 
the three formulations.  Differences in size are very easy to observe but the micrographs 
also confirm the accuracy of the method of crushing and sieving into a specific particle 
size range.  Apart from particle size, the three formulations appear to have similar shape 
and similar surface textures, although differences can be observed when comparing 
individual particles. 
After size characterization of the particles, the effect of the tightness of the 
polymer network on the microparticles was investigated by comparing SEM micrographs.  
A formulation with a tighter network containing TEGDMA crosslinker and a 67:33 
monomer-to-solvent ratio was compared against a looser network containing 
PEGDMA1000 crosslinker and a 50:50 monomer-to-solvent ratio.  The comparison of the 
SEM images is shown as Figure 4.16.  While the sizes and shapes of the microparticles 
appear to be congruent between the two images, slight differences can be observed 
between the surface features.  The tighter-networked polymer (TEGDMA crosslinked 
and 67:33 monomer-to-solvent ratio) appears to consists of smoother surfaces with 
fewer distinguishable surface features than the looser-networked polymer 
(PEGDMA1000 crosslinked and 50:50 monomer-to-solvent ratio).  The increase in 
surface features in the looser polymer formulation may be a result of the more open 
network allowing for extrusions and movement of the polymer segments while the 
tighter network may constrict movement of the polymer during crushing thus limiting 
surface features.  However, it is difficult to definitively declare a difference in the two 
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surfaces.  Significantly further magnification could possibly allow visualization of the 
differences in network rigidity, but the degree of magnification required to observe the 
polymer mesh is beyond the capabilities of the scanning electron microscope. 
The effect of the replacement of the PEG tether comonomer with the NVP 
comonomer on the polymer microparticles was also investigated by comparing SEM 
images of P(MAA-g-EG) and P(MAA-co-NVP).  The comparison of the SEM images of the 
two formulations is presented as Figure 4.17.   As specified by their individual synthesis 
parameters, the size and random shape of the two formulations are mostly consistent.  
However, upon further analysis it is possible to see differences between the structures 
and surfaces of P(MAA-g-EG) and P(MAA-co-NVP).  The P(MAA-g-EG) formulation differs 
in its structure in that the particles formed contain flat, smooth faces while the P(MAA-
co-NVP) particles are more globular, having very few flat sides or edges.  The difference 
in structure can most likely be attributed to the reaction of each to the shear force 
applied from crushing using a mortar and pestle.  P(MAA-g-EG) microparticles may 
fracture and create straight breaks throughout the face while P(MAA-co-NVP) reacts 
more like a powder and simply splits apart randomly without following a specific 
fracture line.  Also, P(MAA-co-NVP) differs in that it has generally more surface 
roughness and surface features than do the smooth surfaces of the P(MAA-g-EG) 
microparticles.  Characterization of the differences in the surfaces and the overall 
structures of P(MAA-g-EG) and P(MAA-co-NVP) is vital to understanding the different 
mechanical properties and particle characteristics which will ultimately affect loading 
and release properties of the system. 
 
4.4 Conclusions 
Several polymer formulations including P(MAA-g-EG) and P(MAA-co-NVP) of 
different crosslinker lengths, monomer-to-solvent ratios, and particle sizes were 
successfully synthesized.  The majority of the formulations were analyzed and 
characterized by scanning electron microscopy to elucidate the size variations, 
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morphology, and surface features of each system.  Based on the characterizations, 
insight can be gained on the visual changes rigidity and tightness of the polymer 
network can create between systems as well as insight into mechanical properties which 
will ultimately affect the performance of the polymer carriers.  The variations created 
through polymer synthesis in this chapter and characterized by SEM also in this chapter 
will provided the basis for selecting an optimal polymer carrier for effective delivery of 
protein bioconjugates. 
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Parameter Successfully Synthesized 
Solvent/monomer ratio 50/50 40/60 33/67 
Particle size <75 microns 90-150 microns 150-212 microns 
Crosslinker length 4 repeat units ~23 repeat units 
Presence of Copolymer P(MAA-g-EG) P(MAA-co-NVP) 
 
Table 4.1 Synthesis parameters used in successfully prepared polymer films. 
 
Synthesized polymers differ in crosslinker lengths, particle sizes, solvent to monomer 
ratios, and comonomer used. 
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Figure 4.1  Structures of components comprising P(MAA-g-EG) systems. 
 
P(MAA-g-EG) polymer systems are comprised of (a) methacrylic acid (MAA), which 
forms the polymer backbone, (b) poly(ethylene glycol) monomethyl ether 
monomethacrylate (PEGMA), which grafts a PEG polymer of chosen molecular weight as 
a tether, (c) poly(ethylene glycol) dimethacrylate (PEGDMA), which serves as a 
crosslinker to form a polymer network, and (d) Irgacure 184TM, a UV initiator used to 
start the polymerization reaction. 
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Figure 4.2  Structures of components comprising P(MAA-co-NVP) systems. 
 
P(MAA-co-NVP) polymer systems are comprised of (a) methacrylic acid (MAA), which 
forms the polymer backbone, (b) n-vinyl pyrrolidone (NVP), a comonomer added to 
increase interpolymer complexation, (c) poly(ethylene glycol) dimethacrylate 
(PEGDMA), which serves as a crosslinker to form a polymer network, and (d) Irgacure 
184TM, a UV initiator used to start the polymerization reaction. 
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Figure 4.3  Schematic showing interpolymer hydrogen bonding and electrostatic 
repulsion which cause swelling/deswelling response of P(MAA-g-EG). 
 
Chains of P(MAA-g-EG) exhibiting (a) hydrogen bonding at a low pH, allowing for a 
collapsed, complexed system, and (b) electrostatic repulsion from local negative 
charges, forcing the system to swell at neutral pH.  
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Figure 4.4  Schematic showing interpolymer hydrogen bonding and electrostatic 
repulsion which cause swelling/deswelling response of P(MAA-co-NVP). 
 
Chains of P(MAA-co-NVP) exhibiting (a) hydrogen bonding at a low pH, allowing for a 
collapsed, complexed system, and (b) electrostatic repulsion from local negative 
charges, forcing the system to swell at neutral pH.  
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Figure 4.5  Illustration showing mucosa interactions of polymer formulations 
 
Polymer formulation of (a) P(MAA-co-NVP) binds to the mucosa from use of 
mucoadhesive materials.  Polymer formulation of (b) P(MAA-g-EG) binds to the mucosa 
from the use of mucoadhesive material and also has PEG tethers which penetrate the 
mucosa, creating a stronger interaction with the mucosa layer. 
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Figure 4.6  Illustration of permeation enhancement ability of anionic hydrogels 
through calcium binding 
 
Epithelial transport is increased by the presence of the hydrogels in a 3-step manner: (1)  
Negative charges throughout the network cause positively-charged calcium to bind to 
the polymer.  (2) Depletion of extracellular calcium causes intracellular calcium to 
diffuse out of epithelial cells.  (3)  Loss of intracellular calcium results in a loosening of 
tight junctions, allowing transport of larger molecules across the cell layer. 
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Figure 4.7  Schematic showing effect of crosslinker length on mesh size of the 
polymer network 
 
Mesh size, ξ, is measured (1) from one crosslink to the next crosslink.  If examining a 
specific crosslink (2), one can see the crosslinker is a small polymer chain that connects 
the two larger strands.  If the polymer chain is short (a), the longer polymer strands are 
very close to each other and minimal length is added to the mesh size.  However, if the 
polymer chain is longer (b), it further separates the polymer strands and increases the 
mesh size proportionately. 
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Figure 4.8  Schematic showing magnitude of diffusion path length based on 
particle size 
 
Diffusion path length, a, is dependent upon particle size.  In a smaller particle (1), the 
diffusion path length (a1) is short, allowing for quick release.  In a larger particle (2), the 
diffusion path length (a2) is increased, thus taking longer for an encapsulated protein to 
diffuse out from the center of the particle. 
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Figure 4.9  Method of UV polymerization for thin film polymers 
 
The UV polymerization process contains several steps: (1) mix components in desired 
monomer-to-solvent ratio, (2) sonicate solution, (3) purge with nitrogen to remove 
oxygen, (4) pour between glass slides, (5) UV polymerize for 30 mins, and (6) wash film 
for 7 days and crush to desired particle size. 
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Figure 4.10 SEM micrograph of P(MAA-g-EG) with a size <75 microns 
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Figure 4.11 SEM micrograph of P(MAA-g-EG) with a size 90-150 microns 
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Figure 4.12 SEM micrograph of P(MAA-g-EG) with a size 150-212 microns 
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Figure 4.13 SEM micrograph of P(MAA-g-EG) with 67:33 monomer-to-solvent ratio 
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Figure 4.14 SEM micrograph of P(MAA-co-NVP) 
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Figure 4.15 SEM micrograph comparison of P(MAA-g-EG) with particle sizes of (a) 
less than 75 microns, (b) 90-150 microns, and (c) 150-212 microns 
 
Comparison of three particle size ranges demonstrates differences in visual size of the 
average P(MAA-g-EG) microparticles. 
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Figure 4.16 SEM micrograph comparison of P(MAA-g-EG) with (a) PEGDMA1000 
crosslinker and 50:50 monomer-to-solvent ration and (b) TEGDMA crosslinker and 
67:33 monomer-to-solvent ratio 
 
Comparison shows the effect of crosslinker length and monomer-to-solvent ratio on 
surface texture and surface features. 
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 Figure 4.17 SEM micrograph comparison of (a) P(MAA-g-EG) and (b) P(MAA-co-NVP) 
 
Comparison of micrographs show different surface features and surface textures between 
P(MAA-g-EG) and P(MAA-co-NVP). 
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CHAPTER 5 
SYNTHESIS AND CHARACTERIZATION OF PROTEIN-TRANSPORTER CONJUGATES FOR 
ORAL DELIVERY USING COMPLEXATION HYDROGELS 
 
 
5.1 Introduction 
Bioavailability of orally administered therapeutic proteins depends on several 
factors such as protein degradation and residence time at the site of absorption.  
However, the factor which most directly affects absorption into the bloodstream is 
transport across the epithelial cell layer.  Protection of the protein ensures that more 
protein reaches the site of absorption and increasing residence time in the small 
intestine ensures more time for absorption.  However, the epithelial cell layer is 
designed to absorb only required nutrients such as vitamins and minerals and to expel 
unrecognized or unwanted entities such as toxins or viruses.   
Under normal conditions, the tight junctions will only permit the transport of 
molecules with radii <11 Ǻ [1].  Because of its ability to limit transport of large molecules, 
an unmodified epithelial cell layer will still significantly decrease potential bioavailability 
by inhibiting transport of most therapeutic proteins, even if 100% of the protein 
survives the transit through the GI tract and has an extended residence time in the small 
intestine.  To design an effective oral protein delivery formulation, epithelial transport 
must be significantly increased. 
In earlier chapters, the use of hydrogels was suggested as a possible delivery 
mechanism to increase bioavailability of administered proteins.  Hydrogels have been 
proven to effectively protect the protein [2] as well as increase residence time in the 
small intestine [3], but are less adept at promoting epithelial transport.  Specifically, 
anionic hydrogels can act as permeation enhancers by binding positively-charged 
extracellular calcium.  The depletion of extracellular calcium causes calcium within the 
cells to also be depleted due to diffusion.  The levels of intracellular calcium play a 
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significant role in the maintenance of the tight junctions between the cells, and a 
decrease in calcium levels will loosen the tight junctions [4].  While this effect has been 
shown to increase transport of therapeutic proteins across the epithelial cell layer, the 
increase is not significant enough to achieve a high bioavailability.  To design a highly 
effective oral protein delivery system, design strategies must be employed which 
increase epithelial transport even further beyond the effect achieved using only 
hydrogels. 
In recent years, many design strategies have been implemented by researchers 
to increase epithelial transport and ultimately raise bioavailability of orally administered 
proteins.  One strategy employed by several scientists is encapsulation of the 
therapeutic protein in nanoparticle carriers to improve transport [5].  Because of their 
size, nanoparticle carriers are thought to be uptaken more readily by epithelial cells 
than any microparticle formulation, increasing the chance of transcytosis of the protein.   
Another set of strategies involve modification of the protein to improve 
transport characteristics.  Hinds et al. [6] investigated the effect of poly(ethylene glycol) 
(PEG) conjugation to insulin, a common therapeutic protein.  The presence of a grafted 
PEG chain significantly reduced the tendency of the insulin to agglomerate.  Also, the 
conjugated PEG-insulin entity exhibited reduced immunogenicity, allergenicity, and 
antigenicity.  The addition of PEG to insulin also increased the circulation time of the 
conjugate relative to unmodified insulin after subcutaneous injection.  While many of 
these properties are desirable, there is no significant effect on the epithelial transport 
properties resulting from PEG conjugation.  
 A large portion of the design strategies to improve epithelial transport focuses 
on protein transport through the tight junctions which exist between the cells within the 
monolayer.  In other words, the protein can absorbed through the paracellular route, or 
route between the cells.  System designs based on large molecule absorption through 
the paracellular route contain an inherent disadvantage.  Based on the regulation 
mechanism of the tight junctions, proteins are known to transport poorly across 
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unmodified epithelial cell layers, requiring the tight junctions be disrupted or loosened 
to promote absorption.  However, the tight junctions between the cells control the 
influx of outside entities into the bloodstream and are a natural barrier to toxins or 
viruses entering the bloodstream.  Monolayer disruption may result in increased protein 
absorption, but the trade-off is a decreased capacity for the cell monolayer to inhibit 
absorption of other undesirable entities.  Even if the loosening of the tight junctions is 
quick and reversible, the underlying fact is that the monolayer is disrupted in a manner 
that is non-specific to the administered protein, creating a possibly safety concern from 
entering viruses or toxins. 
 An alternative to protein absorption through the paracellular route is to absorb the 
protein through the cell itself, utilizing the transcellular route for absorption.  There are 
many ways in which a molecule can undergo transcellular transport.  The simplest type 
of transcellular transport is passive diffusion, or diffusion through a cell based on a 
concentration gradient.  This type of transport requires no real response from the cell, 
but is typically limited to very small molecules such as carbon dioxide and oxygen.   
  Another type of transcellular transport is efflux transport in which a molecule is 
brought into the cell, some action is often performed, and then the molecule is expelled 
on the same side.  However, efflux transport does not result in transcytosis, limiting its 
useful potential for protein absorption into the bloodstream.  There are two more types 
of transcellular transport, both of which involve more complex cell interactions:  carrier-
mediated transport and receptor-mediated transcytosis.  Both processes involve the 
molecule interacting with the lipid bilayer and reversibly binding to either a carrier 
molecule or a specific receptor.   
  In carrier-mediated transport, the molecule-carrier complex dissociates after 
transporting the molecule inside the cell, allowing the molecule to drift to the other side 
and engage in a similar carrier-mediated process to exit the cell [7].  However, in 
receptor-mediated transcytosis, a specific molecule binds to a specific receptor on the 
cell surface due to its high affinity for the receptor.  The molecule-receptor complex is 
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then transported into the cell and remains intact until it dissociates on the opposite side 
of the cell.  Both processes often involve the uptake of very large molecules which are 
similar in size to therapeutic proteins, demonstrating the potential for the utilization of 
both transport pathways for protein delivery. 
  The transcellular mechanism of absorption receiving the most consideration for 
use in protein delivery systems is receptor-mediated transcytosis.  Receptor-mediated 
transcytosis benefits from several advantages.  Because the protein is being transported 
through the cells, the tight junctions are left mostly unaffected and are not disrupted.  
Keeping the tight junctions unmodified and functioning is essential to ensuring the 
lowest probability of toxins entering.  Perhaps the most important advantage is the 
specificity with which the protein is being transported.  If transport occurs only by a 
specific receptor-ligand interaction, then the protein is being transcytosed in a manner 
specific to only the protein and nearly all chance of toxins entering is eliminated.  Also, 
because of the specific targeting associated with receptor-mediated transcytosis, the 
overall transport and bioavailability of the administered protein is likely to increase 
relative to paracellular mechanisms of absorption. 
  To utilize receptor-mediated transcytotic pathways, scientists have attempted to 
form reversible covalent bonds between therapeutic proteins and transporter molecules 
[8].  The chosen transporter molecule acts as a ligand for a specific receptor which is 
expressed on human epithelial cells.  Assuming the ligand-receptor affinity is unaffected 
by the conjugation reaction, the resulting transport is specific to the bioconjugate of 
interest.  Xia et al. [9] developed an insulin conjugate by binding it to transferrin and 
observed the hypoglycemic effect after administration to rats.  Also, Russell-Jones [10] 
demonstrated that erythropoietin can be conjugated to vitamin B12 and absorbed 
through the vitamin B12 uptake system.  Both systems attempted to improve epithelial 
transport of the respective therapeutic protein, but neither facilitated the delivery of 
the bioconjugate to the site of absorption by use of carrier or any other means. 
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  Within this thesis, the proposed strategy to increase epithelial transport was to 
utilize receptor-mediated endocytosis by conjugating therapeutic proteins of interest to 
transferrin.  Transferrin (~80 kDa) is a single chain protein naturally occurring in the 
human body which has the ability to bind to two iron ions per transferrin molecule.  
Transferrin bound with two iron ions (holo-transferrin) has a greater affinity for the 
transferrin-receptor than transferrin bound with one iron ion (mono-transferrin) or no 
iron ions (apo-transferrin)  [11].  Transferrin-receptors are expressed on many types of 
cells in the human body, including intestinal epithelial cells.  The transferrin-receptor is a 
homodimer comprised of two identical subunit monomers of approximately 90 kDa 
each  [9].  When iron bound transferrin binds to the transferrin-receptor on the apical 
side of the cell layer, the complex can undergo either endocytosis (i.e. transport into the 
cell), or transcytosis (i.e. transport to the basolateral side of the cell layer)  [12].  Due to 
its ability to serve as a transporter targeting ligand for specific cellular uptake as well as 
its ability to resist trypsin and chymotrypsinogen degradation [13], transferrin remains 
an attractive option for circumventing the limited transport of the epithelium for drug 
delivery applications. 
 This work focuses on forming insulin-transferrin bioconjugates as well as 
calcitonin-transferrin bioconjugates.  The potential advantages of forming these 
bioconjugates include further protection from degradation by digestive enzymes, 
increased epithelial transport, and specific targeting of the bioconjugates.  Moreover, 
the incorporation of synthesized bioconjugates in complexation hydrogel carriers 
increase the probability of stable, intact conjugates reaching the site of absorption.  
However, forming bioactive conjugates which effectively transport into the bloodstream 
requires overcoming several challenges.  The most important challenge in synthesizing 
bioconjugates is to form an entity which still retains the bioactivity of both the protein 
and the transporter ligand.  Both bioactivities are essential because lack of protein 
activity results in inefficient treatment of the disease and lack of transporter activity 
leads to minimal to no transport into the bloodstream.  Also, it is important to examine 
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whether the conjugate is only being endocytosed, or if it is eventually transcytosed into 
the bloodstream. 
 In this chapter, the conjugation reactions to synthesize insulin-transferrin 
conjugates and calcitonin-transferrin conjugates are discussed.  In both cases, the 
proteins were conjugated by the protein conjugation method first proposed by Carlsson 
et al [14].  The protein conjugation scheme involves conjugation of the two proteins by 
the protein crosslinker N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP).  SPDP is a 
heterobifunctional crosslinker which can react with a primary amine group and a 
sulfohydryl group on two separate proteins.  The heterobifunctionality ensures minimal 
formation of homoconjugates, or conjugates consisting of the same protein.  Instead, it 
promotes synthesis of heteroconjugates, or conjugates consisting of one of each protein.  
The final result is a bioconjugate which connects both proteins with disulfide linkages.  
The newly formed disulfide linkages can be broken to separate the proteins under 
certain conditions such as incubation in blood plasma [15]. 
 The purpose of synthesizing protein-transporter conjugates is to effectively 
increase epithelial transport.  While similar strategies have been employed by several 
researchers, they have been met with limited success as oral delivery systems due to 
lack of consideration for other barriers to oral delivery such as degradation in the 
stomach and intestinal motility.  However, utilizing a combinatorial approach of 
synthesizing protein-transporter conjugates and loading them inside complexation 
hydrogel carriers presents the ideal opportunity to obtain acceptable overall 
bioavailability values.  The combination of the known abilities of the hydrogel carriers to 
protect from degradation in the stomach as well as create adhesion near the site of 
absorption with the increased epithelial transport of using the specific targeting 
characteristics of protein-transporter conjugates merits the investigation and 
optimization of the oral protein delivery system explored in this thesis. 
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5.2 Materials and Methods 
5.2.1 Synthesis of Insulin-Transferrin Conjugates 
The method for protein conjugation outlined in this section was originally 
developed by Carlsson et al [14].  The protein conjugation method was first utilized for 
the conjugation of insulin to transferrin by Shah and Shen [9].  The conjugation scheme 
consists of using N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) as a protein 
crosslinker to conjugate insulin (Ins) to transferrin (Tf) to form insulin-transferrin (Ins-Tf) 
heteroconjugates.  The structure of SPDP is shown as Figure 5.1.  The final form of the 
conjugate is comprised of insulin molecules bound to a transferrin molecule by disulfide 
linkages. 
 
Step I:  Insulin modification by DMMA:  The n-terminals of the insulin chains were 
effectively “blocked” by reaction of insulin with dimethylmaleic anhydride (DMMA, 
Fluka/Sigma Aldrich Inc., St. Louis, MO), excluding possible reactive sites for SPDP.  Step 
I of the conjugation reaction is illustrated in Figure 5.2.  To begin Step I of the 
conjugation reaction, a sample of 25 mg of bovine insulin (Sigma Aldrich Inc., St. Louis, 
MO) was added to an acidic solution consisting of 3 mL PBS buffer solution (pH 6.9, 
Fisher Scientific, Fair Lawn, NJ) and 1.5 mL 1 N HCl (Fisher Scientific, Fair Lawn, NJ).  
After the insulin had completely dissolved in the acidic solution, 1.5 mL 1 N NaOH 
(Fisher Scientific, Fair Lawn, NJ) was added to bring the solution back to pH 6.9.  A 
sample of 3.5 mg of DMMA was then added to the solution of dissolved insulin and 
allowed to react under constant stirring for 0.5 h.   
 During the reaction period, the pH was monitored using a micro-pH meter (IQ 
Scientific Instruments, San Diego, CA) and was maintained within the pH range of 6.8-
6.9 by adding small volumes of a 1 M Na2CO3 (Fisher Scientific, Fair Lawn, NJ) solution.  
After the reaction finished within 0.5 h, the process of adding 3.5 mg DMMA and 
maintaining the pH of the solution was repeated two more times.  At the end of the final 
reaction period, the resultant solution was transferred to dialysis tubing (MWCO 3,500, 
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Spectrum Laboratories Inc., Rancho Dominguez, CA) and dialyzed against PBS buffer (pH 
6.9) for approximately 24 hours.  Dialysis is performed on the product to remove trace 
contaminants as well as unreacted DMMA. 
 
Step II:  PDP Addition to Insulin:  After dialysis of the product, insulin-DMMA was 
reacted with SPDP (Pierce Biotechnology Inc., Rockford, IL) to add disulfide bonds to the 
remaining unblocked primary amine at B29-Lysine.  The newly introduced disulfide bond 
serves as the conjugation site for the later addition of transferrin.  Step II of the 
conjugation reaction is illustrated in Figure 5.3.  The insulin-DMMA product formed 
from Step I was removed from dialysis and cooled to 4°C and placed under constant 
stirring in an Erlenmeyer flask.  The pH of the insulin solution was then raised to 9.0 by 
adding small volumes of 1 M Na2CO3.  Before its addition to the reaction mixture, 6.0 mg 
of SPDP was dissolved in 150 µL of dimethyl formamide (DMF, Fisher Scientific, Fair 
Lawn, NJ).  Upon dissolving, the SPDP solution was added in its entirety to the insulin-
DMMA solution.  The combined solution was allowed to react for 2 hours under 
constant temperature and stirring.  The pH of the solution was maintained within the pH 
range of 8.8-9.0 for the duration of the reaction using a micro-pH meter.  Upon 
completion of the reaction time period, the insulin-PDP product was transferred to 
dialysis tubing (MWCO 3,500) and allowed to dialyze at 4°C for 24 hours.  Dialysis of 
insulin-PDP ensures the removal of trace contaminants as well as excess SPDP reagent. 
                   
Step III:  Transferrin modification by SPDP:  In addition to the insulin modification 
reactions, transferrin was also reacted with SPDP to form PDP groups on the 
transferring molecule.  After forming PDP groups, the newly formed Tf-PDP was reduced 
by reaction with dithiothreitol (DTT, Sigma Aldrich Inc., St. Louis, MO).  Step III of the 
conjugation reaction is illustrated in Figure 5.4.  To begin Step III of the conjugation 
reaction, a sample of 120 mg of human holo-transferrin (Tf, Sigma Aldrich Inc., St. Louis, 
MO) was added to a solution consisting of PBS buffer (pH 7.0).  Before its addition to the 
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reaction mixture, 8.0 mg of SPDP was dissolved in 100 µL DMF.  The SPDP/DMF solution 
was added to the transferrin solution and allowed to react for 2 hours under constant 
stirring and at approximately 4°C.  After the completion of the reaction period, the 
product solution was removed and placed in dialysis tubing (MWCO 12,000-14,000, 
Spectrum Laboratories Inc., Rancho Dominguez, CA) in a solution of PBS buffer (pH 8.0).  
The Tf-PDP product was dialyzed overnight to remove any unreacted SPDP.   
 After formation of PDP groups on transferrin, the modified protein must be 
reduced to alter the PDP groups and to form sulfohydryl groups.  To reduce Tf-PDP, a 
solution consisting of 1 M DTT in H2O was first prepared.  After 24 hours of dialysis, the 
Tf-PDP solution was reduced using the prepared 1 M DTT solution.  The solutions were 
combined and allowed to react for 1 h.  The newly formed product was a solution of 
transferrin with attached sulfohydryl groups (Tf-SH) and was allowed to dialyze for 24 h 
to remove unreacted DTT. 
  
Step IV:  Combination of modified proteins:  Upon completion of Step III, the Tf-SH 
product was purified by elution from D-Salt Dextran Desalting Columns (10 mL, Pierce 
Biotechnology Inc., Rockford, IL).  To achieve a high level of purity, four columns were 
connected in series.  During elution from the columns, small 1 mL fractions were 
obtained using a fractional collector (CF-1, Spectrum Chromatography, Rancho 
Dominguez, CA).  A PBS buffer solution (pH 8.0, 3mM EDTA) was used to elute the 
modified protein from the columns.  Each fraction was analyzed using UV spectroscopy 
and the fractions having relatively higher absorbances at a wavelength of 280 nm 
indicating higher protein concentration and were collected for further use.  The 
presence of EDTA in the PBS solution used to elute the columns is necessary to prevent 
any metal-catalyzed oxidation of free sulfohydryl groups into disulfide bonds, thereby 
reducing the possibility of forming any crosslinked transferrin complexes. 
 Step IV of the conjugation reaction consists of combining the two modified 
proteins to form a final conjugate product.  Step IV of the reaction is illustrated in Figure 
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5.5.  To initiate the final step in the conjugation reaction, the product solutions of Ins-
PDP and Tf-SH were combined into one Erlenmeyer flask.  The reaction is allowed to 
proceed under constant stirring.  The reaction progress can be monitored by first taking 
small samples of the reaction mixture at any desired time point of the reaction period.  
Each sample can be analyzed by UV spectroscopy to determine its absorbance.  
 When Ins-PDP reacts with Tf-SH, the chromophore 2-pyridinethione is released.  
The concentration of 2-pyridinethione can be determined by measuring the absorbance 
of the reaction mixture at 343 nm. The concentration of 2-pyridinethione can be 
compared to the concentration of transferrin in the solution to determine how many 
average insulin molecules are attaching to each transferrin molecule.  It is desirable to 
limit the number of insulin molecules per transferrin molecule to prevent the conjugate 
from being too large.  The reaction can be stopped at any point by the addition of n-
ethylmaleimide (NEM, ACROS Organics, Geel, Belgium), which reacts with free thiol 
groups [16] and prevents further crosslinking.  Typically, the reaction was stopped by 
addition of NEM after a period of 90 minutes to prevent bulkiness of the conjugate 
product.  After the reaction had been halted, the product was transferred to dialysis 
tubing (MWCO 12,000-14,000) and allowed to dialyze for 48 hours to remove unreacted 
reagents.  To determine the concentration of the conjugate solution, the product was 
analyzed using HPLC (Waters Corporation, Milford, MA).  After analysis, the conjugate 
solution was refrigerated until further use. 
 
5.2.2 Synthesis of Calcitonin-Transferrin Conjugates 
The protein conjugation method explored in this section was originally 
developed by Carlsson et al [14].  The conjugation scheme for the formation of 
calcitonin-transferrin bioconjugates is similar to the reaction scheme employed to make 
insulin-transferrin conjugates by Shah and Shen [8] as well as Kavimandan et al [17].  
The conjugation scheme consists of using the protein crosslinker SPDP to conjugate 
calcitonin (Calc) to transferrin (Tf) to form calcitonin-transferrin (Calc-Tf) 
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heteroconjugates.  The final product of the reaction is a conjugate molecule consisting 
of calcitonin molecules conjugated to a transferring molecule by disulfide linkages. 
 
Step I:  Calcitonin modification by SPDP:  The primary amines on calcitonin were reacted 
with SPDP to provide disulfide linkages for subsequent protein conjugation.  Step I of 
the calcitonin-transferrin conjugation reaction is illustrated in Figure 5.6.  To begin Step I 
of the conjugation reaction, a sample of 25 mg of salmon calcitonin (EMD Biosciences 
Inc., Darmstadt, Germany) was added to a solution consisting of 5% by volume acetic 
acid (Fisher Scientific, Fair Lawn, NJ) in 6 mL of PBS buffer (pH 8.0) and allowed to 
dissolve.  The presence of acetic acid in the initial solution is necessary to facilitate the 
dissolution of calcitonin.  After calcitonin had successfully been dissolved, a reagent 
solution consisting of 6 mg SPDP in 150 µL DMF was prepared.  The SPDP/DMF solution 
is added to the calcitonin solution and allowed to react for 2 hours under constant 
stirring and at 4°C.  At the end of the final reaction period, the Calc-PDP solution was 
transferred to dialysis tubing (Spectrum Laboratories Inc., Rancho Dominguez, CA) and 
dialyzed against PBS buffer (pH 8.0) for approximately 24 hours.  Dialysis is performed 
on the product to remove trace contaminants as well as unreacted SPDP. 
 
Step II:  PDP Addition to Transferrin:  Transferrin is modified by the addition of PDP 
groups to later allow for conjugation to calcitonin.  The newly introduced PDP group is 
reduced in a later step to allow for reaction with modified Calc-PDP.  Step II of the 
calcitonin-transferrin conjugation reaction is illustrated in Figure 5.7.  To begin the 
modification of transferrin, a sample of 125 mg of transferrin is added to a PBS buffer 
solution (pH 6.9).  Before its addition to the reaction mixture, 6.0 mg of SPDP was 
dissolved in 150 µL of DMF.  Upon dissolving, the SPDP solution was added in its entirety 
to the transferrin solution.  The combined solution was allowed to react for 2 hours 
under constant stirring and at 4°C.  After the reaction was complete, the transferrin-PDP 
product was transferred to dialysis tubing (MWCO 12,000-14,000) and allowed to 
  114 
dialyze at 4°C for 24 hours.  Dialysis of transferrin-PDP ensures the removal of trace 
contaminants as well as excess SPDP reagent. 
 
Step III:  Reduction of Transferrin-PDP by DTT:  After forming PDP groups, modified 
transferrin (Tf-PDP) was reduced by reaction with DTT.  Reduction of Tf-PDP by DTT 
allows the replacing of PDP groups with sulfohydryl groups (-SH) to form another 
modified transferrin molecule (Tf-SH).  Step III of the calcitonin-transferrin conjugation 
reaction is illustrated in Figure 5.8.  To reduce Tf-PDP, a solution consisting of 1 M DTT in 
H2O was first prepared.  After 24 hours of dialysis, the Tf-PDP solution was reduced 
using the prepared 1 M DTT solution.  The 1 M DTT solution was added to the Tf-PDP 
solution and allowed to react for 1 hour under constant stirring.  The newly formed 
product was a solution of transferrin with attached sulfohydryl groups (Tf-SH) and was 
placed in dialysis tubing (MWCO 12,000-14,000) for 24 h to remove unreacted DTT. 
 
Step IV:  Combination of modified proteins:  Upon completion of Step III, the Tf-SH 
product was purified by elution from D-Salt Dextran Desalting Columns.  To achieve a 
high level of purity, four columns were connected in series.  During elution from the 
columns, small 1 mL fractions were obtained using a fractional collector.  A PBS buffer 
solution (pH 8.0, 3mM EDTA) was used to elute the modified protein from the columns.  
Each fraction was analyzed using UV spectroscopy and the fractions having relatively 
higher absorbances at a wavelength of 280 nm indicating higher protein concentration 
and were collected for further use.  The presence of EDTA in the PBS solution used to 
elute the columns is necessary to prevent any metal-catalyzed oxidation of free 
sulfohydryl groups into disulfide bonds, thereby reducing the possibility of forming any 
crosslinked transferrin complexes. 
 Step IV of the calcitonin-transferrin conjugation reaction consists of combining 
modified calcitonin (Calc-PDP) with modified transferrin (Tf-SH) to form a final conjugate.  
Step IV of the reaction is illustrated in Figure 5.9.  The final step of the calcitonin-
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transferrin conjugation reaction is initiated by combining both product solutions (Calc-
PDP and Tf-SH) into one Erlenmeyer flask.  The reaction is then allowed to proceed 
under constant stirring.  The reaction progress can be monitored by first taking small 
samples of the reaction mixture at any desired time point of the reaction period.  Each 
sample can be analyzed by UV spectroscopy to determine its absorbance.  When Calc-
PDP reacts with Tf-SH, the chromophore 2-pyridinethione is released.  The 
concentration of 2-pyridinethione can be determined by measuring the absorbance of 
the reaction mixture at 343 nm. The concentration of 2-pyridinethione can be compared 
to the concentration of transferrin in the solution to determine how many average 
calcitonin molecules are attaching to each transferrin molecule.  It is desirable to limit 
the number of calcitonin molecules per transferrin molecule to prevent the conjugate 
from being too large.  The reaction can be stopped at any time by the addition of NEM 
which will prevent any further crosslinking.  Generally, the reaction was stopped by 
addition of NEM after a period of 90 minutes to prevent bulkiness of the calcitonin-
transferrin product.  At the completion of the reaction period, the product was 
transferred to dialysis tubing (MWCO 12,000-14,000) and allowed to dialyze for 48 
hours to remove unreacted reagents.  To determine the concentration of the calcitonin-
transferrin conjugate solution, the product was analyzed using HPLC.  The final 
conjugate solution was refrigerated until further use. 
 
5.2.3 Analysis of Protein-Transporter Conjugates 
Throughout the steps of the conjugation reactions, intermediates as well as the 
final conjugate products were characterized to gain insight into the nature of the 
crosslinking bonds as well as to verify the synthesis of a confirmed protein-transporter 
conjugate.  Characterization methods include UV spectroscopic analysis of 
intermediates to determine nature of modified proteins and analysis by HPLC to verify 
synthesis of the final product. 
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Conjugate Analysis using UV Spectroscopy:  As an analysis of Step II of the conjugation 
reaction, it is possible to use UV spectroscopy to determine the average number of PDP 
groups that are bound to each insulin molecule (PDP:Insulin ratio).  Upon reduction of 
Ins-PDP with DTT, there is a release of 2-pyridinethione, a chromophore whose 
concentration can be measured by analyzing absorbance of the solution at a wavelength 
of 343 nm (A343).  To analyze the Ins-PDP solution, a small volume of approximately 40 
µL was obtained and subsequently reduced with 25mM DTT.  After reduction of the 
sample, the absorbance was measured using a microplate reader (Synergy HT, Bio-Tech 
Instruments, Winooski, VT) at a wavelength of 280 nm (A280) to determine protein 
concentration and at a wavelength of 343 nm (A343) to obtain chromophore 
concentration. Molar extinction coefficients of 8.08 x 103 M-1cm-1 at 343 nm (ε343,TP) and 
5.10 x 103 M-1cm-1 at 280 nm (ε280,TP) were used for the calculations for the 
chromophore [14, 18]. Insulin concentration was determined by measuring the 
absorbance at 280 nm (A280). The molar extinction coefficient used for proteins was 5.8 
x 103 M-1cm-1 at 280 nm (ε280,INS).  The sample of 40 µl reduced Ins-PDP solution was 
diluted to 700 µl and the absorbance was measured in triplicates at 343 nm and 280 nm.  
The PDP:Insulin ratio was calculated using Equation 1 shown below: 
 
 
 
 Similar to the UV spectroscopic analysis after Step II, Step III can be analyzed by 
determining the average number of PDP groups attached to each transferrin molecule 
(PDP:Tf ratio).  As with insulin, reduction of transferrin with DTT releases 2-
pyridinethione, a chromophore whose concentration can be measured by analyzing 
absorbance of the solution.  After completion of Step III, a small volume of 40 µL was 
extracted from the already reduced Tf-PDP solution, now denoted as Tf-SH.  The small 
sample was diluted to 700 µL and the absorbance was measured in triplicates at 
wavelengths of 280 nm and 343 nm using a microplate reader.  The PDP:Tf ratio was 
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calculated using Equation 1 from the previous section.  The molar extinction coefficients 
for the chromophore were the same as those used to find the PDP:Insulin ratio, but the 
molar extinction coefficient used for transferrin was 93.0 x 103 M-1cm-1 (ε280,TF).   
 
HPLC Analysis of Protein-Transporter Conjugates:  High Performance Liquid 
Chromatography (HPLC) was used to verify production of both insulin-transferrin and 
calcitonin-transferrin conjugates as well as for quantification of reaction yield and final 
concentration of conjugate solutions.  The HPLC equipment used consists of a Waters 
2695 Separation Module (Waters Corporation, Milford, MA) attached to a Waters 2487 
Dual λ Absorbance Detector (Waters Corporation, Milford, MA).  Characterization is 
performed using a reverse-phase analytical HPLC method designed to elute a wide 
range of proteins within a specified time period.  The method includes the use of water 
(HPLC Grade, Fisher Scientific, Fair Lawn, NJ) with 0.1% by volume trifluoroacetic acid 
(TFA, ACROS Organics, Geel, Belgium) as Solvent A and acetonitrile (Optima, Fisher 
Scientific, Fair Lawn, NJ) with 0.08% by volume TFA as Solvent B.  During the separation 
process, the mobile phase begins at a composition of 70% Solvent A and 30% Solvent B.  
The mobile phase changes composition using a gradient to 40% Solvent A and 60% 
Solvent B within 6 minutes.  The mobile phase composition is then returned to initial 
conditions of 70% Solvent A and 30% Solvent B for the next sample to be analyzed.  The 
mobile phase was introduced at a constant flow rate of 0.6 mL/min.  All separations are 
performed using a Symmetry300TM C4 column (particle size 5 µm, 3.9 mm I.D. x 150 mm 
length, Waters Corporation, Milford, MA) held at a constant temperature of 40°C.  After 
separation of proteins, absorbance of the solution was detected at a wavelength of 220 
nm.  All instrument and processing methods were controlled and specified using the 
Empower software. 
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5.3 Results and Discussion 
5.3.1 Synthesis of Insulin-Transferrin Conjugates 
By using the conjugation scheme outlined by Carlsson et al. [14], insulin was 
conjugated to transferrin by disulfide linkages from use of the protein crosslinker SPDP.  
SPDP is classified as a heterobifunctional crosslinker because of its ability to react with 
two different types of functional groups.  As can be seen in Figure 5.1, SPDP can react 
with amine groups near the region of the n-hydroxysuccinimide (NHS) ester.  After 
reaction occurs by nucleophilic attack from the nitrogen to the carbonyl group, the 
amine group is modified and now contains a reactive 2-pyridyldithio group.  The free 2-
pyridyldithio group provides the other half of the reactivity of SPDP and is reactive with 
sulfohydryl groups.  By using SPDP, it is possible to crosslink a protein with primary 
amine groups with a different protein which contains sulfohydryl groups.  The 
heterobifunctional properties of SPDP ensure the formation of heteroconjugates, or 
conjugates consisting of two different proteins.  At the same time, using SPDP to form 
protein conjugates also excludes formation of homoconjugates, or conjugates consisting 
of multiple molecules of the same protein, due to SPDP not having two amine reactive 
sites or two sulfohydryl reactive sites. 
The result of binding two proteins using SPDP is conjugation by disulfide linkages.  
The prospect of protein conjugation by disulfide linkages is especially relevant 
considering the inherent instability and tendency of disulfide bonds to cleave within 
blood plasma [19].  Due to the instability of disulfide bonds in blood plasma, the 
conjugated proteins may be cleaved once they reach systemic circulation, thus releasing 
free insulin [8, 20, 21].  In fact, Xia et al. [15] showed that free insulin is released after 
only 5 minutes of incubation of insulin-transferrin conjugates in rat liver slices.  Also, 
free insulin was detected in the rat serum up to 4 hours after insulin-transferrin 
conjugates were orally administered. 
Step I of the insulin-transferrin conjugation reaction involves the “blocking” of 
two primary amine groups of insulin by reaction with DMMA.  Insulin has three primary 
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amine moieties which are reactive with DMMA.  The three primary amine groups are 
located at A1-Glycine (A1-Gly), B1-Phenylalanine (B1-Phe), and B29-Lysine (B29-Lys).  
The same three primary amine moieties are also reactive with the protein crosslinker 
SPDP.  However, the amine groups can only react with SPDP or with DMMA at a pH 
which will make the amine group deprotonated and able to act as a nucleophile.  The 
NH2 group, acting as a nucleophile, can react with the electron-deficient carbon atom in 
the succinimidyl group of SPDP or the carbon atom in either carbonyl group of DMMA.  
The nucleophilic attack of DMMA is shown in Figure 5.2 and the attack of SPDP is shown 
in Figure 5.3.  However, Lindsay and Shall [22] reported that conjugation of a large 
molecule to the A1-Glycine residue of insulin can significantly reduce its bioactivity.  Due 
to the specificity requirement of the conjugation site, a method had to be devised to 
selectively conjugate transferrin to insulin at either the B1-Phenylalanine site or the 
B29-Lysine site while inhibiting reaction at the A1-Glycine site.  The chosen strategy to 
overcome this barrier is to first conjugate a small molecule, such as DMMA, to the 
primary amine at A1-Glycine to prevent subsequent reaction with SPDP.  However, a 
factor had to be found which controlled the reactivities of the possible conjugation sites 
such that all three possible conjugation sites are not blocked by DMMA.  A major factor 
differentiating the conjugation sites is the pKa of the primary amine groups.  A1-Glycine 
and B1-Phenylalanine, which are n-terminal residues, have a pKa of 7.5-8.0 while the 
primary amine at B29-Lysine has a pKa around 10.5 [23].  Thus, control of the reaction 
pH can be used to selectively react either the two n-terminal primary amines or only the 
primary amine at B29-Lysine.  The structure of insulin along with labeling of its possible 
conjugation sites for DMMA and SPDP is presented as Figure 5.10.  The pH of Step I of 
the conjugation reaction is maintained between pH 6.8-6.9, ensuring a significant 
portion of the n-terminal primary amines are deprotonated and can react with DMMA, 
thus preventing subsequent reaction with SPDP.  However, the reaction pH is 
significantly below the pKa of the primary amine residue at B29-Lysine, ensuring that 
there will be little to no reaction at that site. 
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After successfully blocking the n-terminal primary amine residues of insulin, Step 
II involves raising the reaction pH and reacting the remaining primary amine located at 
B29-Lysine with SPDP.  At the completion of Step I of the insulin-transferrin conjugation 
reaction, insulin had been modified by conjugating DMMA molecules to A1-Glycine and 
B1-Phenylalanine (Insulin-DMMA).  With the n-terminal primary amines effectively 
“blocked”, the pH of the solution was raised to 9.0 to allow a significant number of the 
amines at B29-Lysine to become deprotonated and able to react.  The reaction pH was 
maintained within the range of 8.8-9.0 during the addition and reaction of SPDP to 
Insulin-DMMA.  SPDP will react with any primary amine which has not previously been 
conjugated to DMMA, forming another modified insulin intermediate (Insulin-PDP).  The 
PDP groups on insulin still possess free 2-pyridyldithio groups, which are reactive to 
sulfohydryl groups.  The other half of the bioconjugate, transferrin, will be modified to 
contain sulfohydryl groups. 
Step III of the insulin-transferrin conjugation reaction involves modification of 
transferrin, a second protein implemented to improve insulin transport.  The objective 
in Step III is to modify transferrin in such a way as to add sulfohydryl groups (-SH), 
making it reactive to Insulin-PDP.  Sulfohydryl groups were added by the addition and 
subsequent reduction of SPDP, the same protein crosslinker used in previous steps.  Due 
mostly to the size of insulin (5.8 kDa) relative to transferrin (80 kDa), conjugation at any 
primary amine would most likely not hinder bioactivity.  Since there is no need to 
perform site-specific conjugation, the pH is not controlled as SPDP is added to 
transferrin.  At the conclusion of the reaction, a modified transferrin is formed which 
contains PDP groups (Transferrin-PDP), similar to Insulin-PDP formed at the conclusion 
of Step II.  To reduce Transferrin-PDP, the reducing agent DTT is added to cleave the 
disulfide bonds and create sulfohydryl groups.  DTT is added to the solution at a 
concentration low enough to prevent cleavage of the internal disulfide bonds of the 
transferrin molecule.  After reduction with DTT, Transferrin-SH is formed and is now 
reactive with PDP-modified proteins. 
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Step IV of the insulin-transferrin conjugation reaction is the final step and 
involves combination of both modified proteins in an effort to form a single conjugate.  
For the final reaction, approximately two moles of Insulin-PDP were added for every one 
mole of Transferrin-SH.  During the reaction, the release of 2-pyridinethione relative to 
transferrin was monitored to prevent the addition of too many insulin molecules to each 
transferrin molecule.  Typically, the reaction was stopped by the addition of NEM within 
90 minutes to reduce bulkiness of the conjugate.  If the conjugate were to become too 
large, the transport properties would be greatly affected and diffusion within the 
polymer network could be greatly reduced, thus adversely affecting loading and release 
characteristics.  Also, Shah and Shen [8] showed that insulin-transferrin conjugates with 
too many insulin molecules attached could not be effectively transported across a Caco-
2 cell monolayer using a transcellular mechanism.  The final product of Step IV of the 
conjugation reaction is a newly formed insulin-transferrin conjugate with on average 2 
insulin molecules attached to each transferrin molecule. 
 
5.3.2 Synthesis of Calcitonin-Transferrin Conjugates 
Calcitonin was conjugated to transferrin to form active bioconjugates using the 
protein crosslinker SPDP and the conjugation scheme first outlined by Carlsson et al [14].  
SPDP is a useful crosslinker for forming hetero conjugates because of its 
heterobifunctional characteristics, which means it can react with two different types of 
functional groups.  As demonstrated in Figure 5.1, the region of the n-hydroxy 
succinimide (NHS) ester of SPDP can react with primary amine groups.  This reaction 
occurs by nucleophilic attack from the amine nitrogen to the carbonyl group and the 
result is a modified amine group which now contains a reactive 2-pyridyldithio group.  
The free 2-pyridyldithio group provides the other half of the reactivity of SPDP and is 
reactive with sulfohydryl groups.  By using SPDP, it is possible to crosslink a protein with 
primary amine groups with a different protein which contains sulfohydryl groups.  This 
characteristic of SPDP ensures the formation of heteroconjugates, or conjugates 
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consisting of two different proteins.  At the same time, because SPDP does not have two 
amine reactive sites or two sulfohydryl reactive sites, the use of SPDP excludes 
formation of homoconjugates, or conjugates consisting of multiple molecules of the 
same protein.   
The result of binding two proteins using SPDP is conjugation by disulfide linkages.  
The method of protein conjugation by disulfide linkages is especially useful considering 
tendency of disulfide bonds to cleave within blood plasma [19].  Due to the instability of 
disulfide bonds in blood plasma, the conjugated proteins may be cleaved once they 
reach systemic circulation, thus releasing free calcitonin [8, 20, 21].   
Step I of the calcitonin-transferrin conjugation reaction involves the reaction of 
calcitonin with SPDP to form a modified protein with PDP groups attached (Calcitonin-
PDP).  In contrast to the insulin-transferrin conjugation reaction, the initial step of 
blocking reactive amines relating to protein activity with DMMA was not taken for this 
conjugation reaction.  There is no known adverse effect to the activity of calcitonin due 
to large molecule conjugation at any specific site.  Therefore, conjugation of transferrin 
to calcitonin does not have to be site-specific and SPDP can react freely with any 
primary amine group on calcitonin.  Thus there is no need for rigid control of reaction 
pH, allowing the majority of the amine groups to react with SPDP.  The intermediate 
product from Step I is Calcitonin-PDP. 
Step II of the calcitonin-transferrin conjugation reaction involves initial 
modification of transferrin, a transporter protein intended to improve calcitonin 
transport.  Step II is very similar to Step I in that SPDP is used to add PDP groups to 
modify a protein.  However, Step II involves modifying transferrin which will later be 
reacted with modified Calcitonin-PDP.  Due mostly to the size of calcitonin (3.4 kDa) 
relative to transferrin (80 kDa), conjugation at any primary amine would most likely not 
hinder bioactivity or reduce affinity for the transferrin receptor.  Since there is no need 
to perform site-specific conjugation, the pH is not controlled as SPDP is added to 
transferrin.  At the conclusion of the reaction, a modified transferrin is formed which 
  123 
contains PDP groups (Transferrin-PDP), similar to Calcitonin-PDP formed at the 
conclusion of Step I. 
Step III of the calcitonin-transferrin conjugation reaction involves the reduction 
of Transferrin-PDP to form a modified transferrin with sulfohydryl groups (Transferrin-
SH).  The newly modified Transferrin-SH is reactive with the free 2-pyridyldithio groups 
on Calcitonin-PDP.  Sulfohydryl groups can be formed by the reduction of already 
existing PDP groups on the transferrin molecule.  To reduce Transferrin-PDP, the 
reducing agent DTT is added to cleave the disulfide bonds and create sulfohydryl groups.  
DTT is added to the solution at a concentration low enough to prevent cleavage of the 
internal disulfide bonds of the transferrin molecule.  After reduction with DTT, 
Transferrin-SH is formed and is now reactive with PDP-modified proteins. 
Step IV of the calcitonin-transferrin conjugation reaction is the final step and 
involves combination of both modified proteins in an effort to form a single conjugate.  
For the final reaction, approximately two moles of Calcitonin-PDP were added for every 
one mole of Transferrin-SH.  During the reaction, the release of 2-pyridinethione relative 
to transferrin was monitored to prevent the addition of too many calcitonin molecules 
to each transferrin molecule.  The reaction was typically stopped by the addition of NEM 
within 90 minutes to reduce bulkiness of the conjugate and to minimize complex 
aggregation.  If the conjugate were to become too large, the transport properties would 
be greatly affected and diffusion within the polymer network could be greatly reduced, 
thus adversely affecting loading and release characteristics.  The final product of Step IV 
of the conjugation reaction is a newly formed calcitonin-transferrin conjugate with on 
average 2 calcitonin molecules attached to each transferrin molecule. 
 
5.3.3 Analysis of Protein Transporter Conjugates 
At the completion as well as during the insulin-transferrin and calcitonin-
transferrin conjugation reactions, specific analyses were performed to quantify the 
amount of conjugate produced as well as verify the combination of the two proteins.  
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After addition of SPDP to each protein, PDP:Protein ratios were calculated using 
Equation 1.  Also, at the completion of each conjugation reaction, the final product was 
analyzed using HPLC to verify the conjugation process as well as to quantify the absolute 
yield of the reaction. 
 
PDP Modification Analysis by UV Spectroscopy:  The addition of SPDP to insulin in Step II 
of the insulin-transferrin conjugation reaction as well as the addition of SPDP to 
transferrin in Step III of the insulin-transferrin conjugation reaction and Step II of the 
calcitonin-transferrin conjugation reaction was analyzed using UV spectroscopy.  After 
addition of SPDP to the respective proteins, a small aliquot of the product was reduced 
with 25 mM DTT to release the chromophore 2-pyridinethione.  The DTT was introduced 
to the solution at a concentration low enough to only break the disulfide bonds on the 
PDP groups and not cleave the internal disulfide bonds which may exist within the 
protein structure.  The absorbance of each solution was measured at 280 nm and 343 
nm and the PDP:Protein ratio was calculated using Equation 1 and same molar 
extinction coefficients given previously.  The PDP:Insulin ratio determined after Step II of 
the insulin-transferrin conjugation reaction was found to be 1.09.  Under ideal 
conditions, the primary amines located at A1-Glycine and B1-Phenylalanine would be 
blocked by DMMA, leaving only one possible conjugation site for SPDP at B29-Lysine 
and giving an ideal PDP:Insulin ratio of 1.00.  An experimental PDP:Insulin ratio of 1.09:1 
means that Step I and Step II were carried out properly, with only a small portion of 
insulin molecules having more than one PDP group.  The experimental PDP:Transferrin 
ratio for both conjugation reactions was found to be approximately 7.5:1.  Assuming all 
PDP groups on transferrin are reduced to sulfohydryl groups, the existence of over 
seven possible conjugation sites provides opportunity for insulin molecules to 
successfully bind to transferrin.  In comparison to insulin, the amount of PDP groups on 
calcitonin is less important due to the lack of requirements for site-specific conjugation.  
Therefore, the PDP:Calcitonin ratio was not determined. 
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Insulin-Transferrin Conjugate Verification Analysis by HPLC:  Synthesized insulin-
transferrin conjugates were examined by HPLC after purification and dilution.  The 
verification of a successful conjugation reaction is indicated by a significant shift from 
the typical transferrin HPLC peak.  The HPLC chromatogram for the insulin-transferrin 
conjugate is shown as Figure 5.11.  As evident in the chromatogram, the HPLC analysis 
of the insulin-transferrin conjugate shows a peak that elutes a full minute later than the 
unmodified transferrin peak.  The shift in elution time indicates a significant structure 
modification as to strengthen the interaction with the separations column, forcing it to 
elute later.  Also, the shift can also indicate an increase in size, causing the conjugate to 
elute later from the column than unmodified transferrin.  Simple modification of 
transferrin by adding PDP groups or reducing them to –SH groups does not result in any 
noticeable shift.  Only after the addition of insulin to the transferrin molecules is such a 
shift observed.  While the HPLC analysis does not specifically determine the number of 
insulin molecules attached to each transferrin molecule, it does confirm the 
combination of insulin and transferrin molecules into a single conjugate. 
 
Calcitonin-Transferrin Conjugate Verification Analysis by HPLC:  HPLC analysis was used 
to verify the synthesis of calcitonin-transferrin conjugates after their purification and 
necessary dilution.  Similar to the insulin-transferrin conjugation reaction, the 
verification of a successful conjugation reaction should be indicated by a significant shift 
from the typical transferrin HPLC peak.  The HPLC chromatogram for the calcitonin-
transferrin conjugate is shown as Figure 5.12.  The chromatogram shows a shift of over 
one minute from unmodified transferrin to the calcitonin-transferrin conjugate.  Such a 
significant shift in elution time of the conjugate relative to transferrin means that the 
transferrin is undergoing a significant change to its size and structure.  As the transferrin 
molecule grows in size from the addition of calcitonin molecules and the surface 
properties change as well, the interaction of the conjugate with the column will change 
and cause it to elute later.  In fact, the unmodified transferrin peak shown may also be 
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partially attributed to unreacted Transferrin-PDP or Transferrin-SH.  This means that 
modification of large proteins such as transferrin with small groups such as PDP groups 
or –SH groups will not noticeably change the elution peak.  Therefore, the significant 
shift in elution time confirms the addition of another large molecule such as insulin to 
transferrin to form a single conjugate. 
  
Conjugation Reaction Yield Quantification by HPLC:  The final products from both 
conjugation reactions were analyzed by HPLC to verify the reaction was successful.  The 
same analysis can also be used to quantify the amount of conjugate synthesized in each 
reaction.  By determining the concentration of the sample using HPLC, the amount of 
conjugate can be back-calculated and compared to the initial amounts of reagents used 
to determine a reaction yield.  The reaction yields for both conjugation reactions are 
shown as Figure 5.13.  The insulin-transferrin conjugation reaction achieved the higher 
overall yield of the two reactions.  Since the protein reactivities with SPDP are fairly 
similar and the transferrin portion of the reaction is the same, the difference can most 
readily be attributed to the differences in solubility.  Neither insulin nor calcitonin will 
dissolve in neutral PBS buffer.  Insulin dissolution requires the addition of acid to lower 
the pH and dissolving calcitonin requires making the solution 5% acetic acid.  Based on 
the overall yields, one can observe that insulin most likely dissolves more readily than 
calcitonin using the protocols outlined earlier in this chapter.  However, both overall 
reaction yields are relatively high, indicating a significant amount of conjugate is being 
produced.  Due to the high expense of the proteins involved, a significant yield is 
important and necessary to designing a practical and useful protein-transporter 
conjugate for therapeutic applications. 
 
5.4 Conclusions 
Protein-transporter conjugates consisting of therapeutic proteins bound to 
transporter proteins were designed and investigated.  Insulin-transferrin and calcitonin-
  127 
transferrin conjugates were synthesized using the protein crosslinker SPDP and the 
bound proteins are connected by disulfide linkages.  Each conjugation reaction was 
analyzed using UV spectroscopy, HPLC for conjugate verification, and HPLC for 
quantification of overall reaction yield.  Based on the analyses, it was shown that intact 
conjugates were indeed synthesized in a controlled, repeatable manner which gave   
significant reaction yields.  The conjugates synthesized and investigated in this chapter 
will provide a greater specificity for drug uptake as well as provide potential for 
increased transport.  The conjugates will be incorporated into the polymer hydrogel 
carriers explored in Chapter 4 and the in vitro loading and release characteristics will be 
examined along with the hydrogel systems optimized in the following chapters. 
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Figure 5.1  Structure and reactive sites of succinimidyl 3-(2-pyridyldithio) 
propionate (SPDP).  
 
SPDP is a cleavable heterobifunctional crosslinker for conjugating proteins. Contains an 
amine-reactive N-hydroxysuccinimide (NHS) ester, and sulfohydryl reactive pyridyldithio 
groups.  
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Figure 5.2  Step I of insulin-transferrin conjugation reaction 
 
In this step, the primary n-terminal amines of insulin are “blocked” with DMMA to 
prevent transporter conjugation.  Reaction carried out at pH of 6.8-6.9 to ensure n-
terminal amines are deprotonated and will react while the amine group at B29-Lysine is 
protonated and unreactive. 
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Figure 5.3  Step II of insulin-transferrin conjugation reaction 
 
In this step, the remaining primary amine at the B29-Lysine position is reacted with the 
crosslinker SPDP.  Reaction carried out at pH of 8.8-9.0 to ensure the primary amine at 
B29-Lysine is deprotonated and will react. 
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Figure 5.4  Step III of insulin-transferrin conjugation reaction 
 
In this step, the primary amines of transferrin are reacted with SPDP to form Tf-PDP.  
Transferrin-PDP is reduced with DTT to form sulfohydryl groups on the modified 
transferrin. 
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Figure 5.5  Step IV of insulin-transferrin conjugation reaction 
 
In this step, the modified transferrin and modified insulin are combined to form an 
insulin-transferrin conjugate bound by cleavable disulfide linkages. 
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Figure 5.6  Step I of calcitonin-transferrin conjugation reaction 
 
In this step, the primary amines of calcitonin are reacted with SPDP to form Calc-PDP.   
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Figure 5.7  Step II of calcitonin-transferrin conjugation reaction 
 
In this step, the primary amines of transferrin are reacted with SPDP to form Tf-PDP.   
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Figure 5.8  Step III of calcitonin-transferrin conjugation reaction 
 
In this step, transferrin-PDP is reduced with DTT to form sulfohydryl groups on the 
modified transferrin (Tf-SH). 
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Figure 5.9  Step IV of calcitonin-transferrin conjugation reaction 
In this step, the modified transferrin and modified calcitonin are combined to form a 
calcitonin-transferrin conjugate bound by cleavable disulfide linkages. 
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Figure 5.10 Structure and conjugation reactivity of insulin. 
 
Insulin contains two chains of amino acids connected by disulfide linkages.  A1-Glycine, 
B1-Phenylalanine, and B29-Lysine are possible conjugation sites if using the 
heterobifunctional crosslinker SPDP.  B29-Lysine has a significantly different pKa than 
A1-Glycine and B1-Phenylalanine, allowing for the possibility of site-specific conjugation. 
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Figure 5.11 HPLC chromatogram showing elution times for insulin, transferrin, and 
the insulin-transferrin conjugate. 
 
The chromatogram was the result of an HPLC analysis following the final step of the 
insulin-transferrin conjugation reaction. 
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Figure 5.12 HPLC chromatogram showing elution times for calcitonin, transferrin, 
and the calcitonin-transferrin conjugate. 
 
The chromatogram was the result of an HPLC analysis of the final product following the 
final step of the calcitonin-transferrin conjugation reaction. 
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Figure 5.13 Average reaction yields for both the insulin-transferrin conjugation 
reaction and the calcitonin-transferrin conjugation reaction. 
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CHAPTER 6 
LOADING AND RELEASE CHARACTERISTICS OF INSULIN-TRANSFERRIN CONJUGATES 
FROM COMPLEXATION HYDROGELS 
 
 
6.1 Introduction 
Before administration to human or animal subjects, newly synthesized drugs and 
polymer systems for oral delivery must first be combined and tested in the laboratory to 
determine the interactions and how they relate to overall efficacy.  Specifically, the 
protein of interest can be loaded into the hydrogel carrier using laboratory procedures 
and subsequently released in conditions which are designed to mimic physiological 
conditions.   
The simulated conditions used in release studies can mimic important stages of 
the transit through the GI tract such as the periods spent in the stomach or small 
intestine.  The results from these loading and release studies are valuable to 
understanding the effect that the hydrogel carrier has on the encapsulated protein as 
well as obtaining insight on how to improve the system to achieve optimal efficacy.   
After selecting an optimal system design for the loading and release of the 
specific protein, the formulation can be then tested using cell culture models to 
determine interaction with the cell monolayer.  While synthesis of polymer carriers and 
protein bioconjugates is based on theoretical predictions, loading and release studies on 
these entities provide initial insight into properties relating to actual performance of the 
delivery system. 
In the previous chapter, insulin was bound to transferrin to create a protein-
transporter conjugate designed to improve specificity of uptake as well as overall 
transport.  The major advantage of the addition of the transferrin molecule to the 
therapeutic insulin protein is utilized during the interaction of the protein with the 
epithelial cell monolayer lining the small intestine.  However, in terms of loading the 
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conjugate into the polymer carrier, transit through the GI tract, and eventually release 
in the small intestine, the formation of a conjugate has little strategic utility.  In fact, 
relative to unmodified insulin, the use of a much larger conjugate molecule can possibly 
hinder diffusion, thus adversely affecting loading and release characteristics.  Loading 
and release studies on the insulin-transferrin conjugate are explored in this chapter to 
determine the existence of a possible detrimental effect of the conjugate on system 
characteristics as well as to alter the polymer carrier in such a way as to minimize this 
effect and to maximize potential bioavailability. 
The process of loading refers to the incorporation of the conjugate into or onto 
the polymer component to form a single system.  In general, there are many different 
ways in which a molecule can be loaded into the system.  In some systems, drugs are 
often covalently bound to polymers to better take advantage of improved properties 
such as improved transport and better stealth characteristics [1-3].  In systems with a 
larger polymer component, such as a carrier, the conjugate could still be covalently 
bound but is often times loaded into the polymer using diffusion.  However, once inside, 
it is extremely limited diffusion which keeps the conjugate molecule contained within 
the carrier [4-6].  Because the diffusion characteristics of the conjugate within the 
polymer network can be significantly changed using pH-responsive hydrogel carriers, the 
loading performed in this chapter is based on diffusion and occurs through equilibrium 
partitioning. 
Release of the encapsulated therapeutic could also happen in a number of 
different ways.  Typically, release is simply the reverse process of the loading 
mechanism.  In the case of covalently bound therapeutic drugs, the bond is typically 
broken by the presence of certain conditions or molecules and the drug can be released 
freely.  In the case of systems in which the drug was loaded using diffusion, the release 
typically occurs in one of two ways.  The mechanism of release can be initiated from a 
contraction of the polymer carrier, resulting in a burst release of loaded therapeutics [7-
10].  The mechanism of release can also be triggered from an expansion of the polymer 
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system, increasing diffusion in and out of the system and allowing the therapeutic entity 
to diffuse out.  In this chapter, release of insulin-transferrin conjugates is triggered by an 
expansion of the hydrogel carrier and subsequent increase in diffusive properties of the 
conjugate. 
The loading and release characteristics of insulin-transferrin conjugates in 
complexation hydrogels are affected by a number of factors inherent to the system 
design.  A primary concern in designing a system to have desirable loading and release 
properties is selecting materials while understanding that possible interactions may 
occur between the polymer and the conjugate.  For example, a common interaction 
which has a profound effect on loading and release is the surface charge interaction of 
both the polymer and the conjugate.  The forces which occur due to opposite charge 
attraction or like charge repulsion will have a significant effect on the rate at which the 
conjugate loads and releases as well as how much is loaded and released.  Also 
important in selecting materials for use is the hydrophilicity of both materials.  Because 
loading and release is performed in solution, the respective hydrophilicities of both the 
polymer and conjugate play a significant role in whether the conjugate can load into the 
polymer properly. 
Another set of factors can influence the diffusion coefficient of the insulin-
transferrin conjugate into and out of the polymer network, greatly affecting loading and 
release.  A major factor affecting diffusion within the system is the mesh size of the 
polymer network.  The mesh size refers to the average space between crosslinks of the 
polymer network, or how much space there is for the conjugate to diffuse.  The mesh 
size of the polymer is a direct function of the materials used and synthesis parameters 
of the polymer formation and can be easily controlled.   
Another factor affecting diffusion is the size of the conjugate molecule itself.  
The larger the molecule, the more difficult it is for it to diffuse through a given mesh size.  
While the size of the insulin-transferrin conjugate is mostly limited by the choice of 
therapeutic and transporter proteins, it can be somewhat controlled by limiting the 
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number of insulin molecules that attach to each transferrin molecule.  The insulin to 
transferrin ratio can be easily controlled by using specific protocol during the conjugate 
synthesis. 
The factors which affect loading and release of a system can be controlled by 
selecting the correct design specifications.  For example, the diffusion within the system 
can be controlled by selecting a number of specifications.  Diffusion of the insulin-
transferrin conjugate within the system can be increased by increasing the effective 
mesh size of the polymer network.  By increasing the length of the crosslinker, the mesh 
size can also be increased, leading to better overall release.  Also, by lowering the 
monomer-to-solvent ratio during polymerization, the system becomes more porous and 
open, leading to better overall release.  Diffusion can also be increased by limiting the 
size of the synthesized conjugate.  To limit the size of the conjugate, the conjugation 
reaction can be stopped before the complex becomes too bulky.  Crosslinker length, 
monomer-to-solvent ratio, and conjugate size are all controllable synthesis parameters 
which can be manipulated to achieve optimal diffusivity of the conjugate within the 
system. 
Apart from factors affecting diffusion within the system, other controllable 
parameters can also affect loading and release.  Selection of the proper particle size has 
an effect on diffusion as well.  However, particle size does not affect the rate at which 
the conjugate diffuses, but rather the diffusion path length necessary for the conjugate 
to be released.  Smaller particle sizes translate to a shorter, less tortuous path to release, 
leading to a quicker release and a better overall release in a specified time [11].  
Interactions between the conjugate and polymer network can also have an effect on 
loading and release and can be controlled by the selection of materials.   
In this chapter, insulin-transferrin conjugates were tested with both P(MAA-g-
EG) and P(MAA-co-NVP) polymer networks to determine which system has more 
desirable interactions with the conjugate molecule.  In fact, P(MAA-co-NVP) polymers 
are thought to have a stronger interpolymer complexation [12] but it is relatively 
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unknown if they will have a desirable interaction with insulin-transferrin conjugates.  
Particle size and selected materials are two controllable synthesis parameters which 
have an effect on overall loading and release but are not related to changing the 
diffusivity of the insulin-transferrin conjugate. 
The objectives of the studies performed in this chapter are related to 
determining performance of the insulin-transferrin conjugate with the hydrogel carriers 
already synthesized with respect to loading and release and also optimizing the system 
based on the results.  Because the polymer networks are usually used for smaller 
proteins such as insulin, they must first be tested on much larger molecules to 
determine if loading and release is feasible.  After testing a large molecule and 
appropriately adjusting synthesis protocol, insulin-transferrin conjugates will be loaded 
and released from a variety of polymer networks to examine performance and efficiency 
as well as to determine which synthesis parameters lead to an optimal system.  At the 
conclusion of the studies in this chapter, the goal is to find a polymer network which can 
successfully load insulin-transferrin conjugates and can also quickly release a large 
portion of the loaded conjugate in conditions simulating the small intestine.  The ideal 
polymer for use with the insulin-transferrin conjugate will consist of specially selected 
materials and will be a precise combination of a number of synthesis parameters based 
on loading and release experiments performed in this chapter. 
 
6.2 Materials and Methods 
6.2.1 Polymer Microparticle Formation by UV Polymerization 
P(MAA-g-EG) and P(MAA-co-NVP) were prepared using a free radical UV 
polymerization in solution.  P(MAA-g-EG) was prepared by mixing MAA (Sigma-Aldrich 
Inc., St. Louis, MO) with poly(ethylene glycol) monomethyl ether monomethacrylate 
with a approximate molecular weight of 1000 (PEGMA1000, Polysciences Inc., 
Warrington, PA) in a 1:1 molar ratio of MAA:EG.  P(MAA-co-NVP) was prepared by 
mixing MAA with NVP (Sigma-Aldrich Inc., St. Louis, MO) in a 1:1 molar ratio of 
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MAA:NVP.  Crosslinkers were then added into the monomer mixtures consisting of 
MAA/EG or MAA/NVP.  The crosslinkers used within this study were tetraethylene glycol 
dimethacrylate (TEGDMA, Sigma-Aldrich Inc., St. Louis, MO) and poly(ethylene glycol) 
dimethacrylate with an approximately molecular weight of 1000 (PEGDMA1000, 
Polysciences Inc., Warrington, PA).  The amount of crosslinker added to each monomer 
mixture was equal to 1 mol% of the total amount of monomer (MAA/EG or MAA/NVP).  
In order to eventually initiate the polymerization, the photoinitiator 1-
hydroxycyclohexyl phenyl ketone (Irgacure 184, Sigma-Aldrich Inc., St. Louis, MO) was 
added to the polymerization mixture in the amount of 1 wt% of the total monomer 
added (MAA/EG or MAA/NVP).  A solvent mixture consisting of 50:50 by weight 
deionized water (Milli-Q Plus system, Millipore) and ethanol (AAPER Alcohol, Shelbyville, 
KY) was added to the polymer mixture in the amounts of either 50:50, 60:40, or 67:33 
by weight polymer mixture to solvent mixture.  The presence of the solvent is essential 
to carry out the polymerization in solution, to prevent autopolymerization, and to 
produce a workable thin polymer film. 
To ensure all components dissolved and went into a homogenous solution, the 
polymer mixture was sonicated for 15 minutes.  After sonication, nitrogen was bubbled 
through the polymer solution within a nitrogen environment to eliminate oxygen.  
Oxygen is a free radical scavenger and significant oxygen levels could prematurely end 
the polymerization process.  After removal of oxygen by nitrogen purging, the polymer 
mixture is poured between two glass slides (153 x 153 x 3 mm) separated by a Teflon 
spacer (0.7 mm) while still in a nitrogen environment.  The glass slide apparatus 
containing the polymer solution spread into a thin film was then placed under a UV light 
source while still in a nitrogen environment.  The solution was allowed to polymerize 
under the light source within an intensity range of 16-17 mW/cm2 for 30 minutes.  After 
the polymerization was completed, the polymer gels were removed from the nitrogen 
environment, separated from the glass slides, and placed in deionized water.  The 
polymer films were washed in the deionized water for 7 days to remove excess 
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monomer and contaminants.  After washing was completed, the polymers were dried in 
a vacuum oven at approximately 30° C for 2 days. 
After completely drying the polymer films, they were removed from the vacuum 
oven and crushed into microparticles using a mortar and pestle.  The crushed 
microparticles were then sieved into appropriate size ranges of either less than 75 
microns, 90-150 microns, or 150-212 microns.  The crushed and sieved microparticles 
were then stored in a vial within a desiccator to prevent moisture entering until further 
use. 
 
6.2.2 Loading Time Determination for Large Molecules (Transferrin) 
Diffusion into the polymer network is largely based upon the size of the molecule 
being loaded.  Because P(MAA-g-EG) and P(MAA-co-NVP) were largely designed for 
smaller therapeutic proteins such as insulin, the loading of a larger molecule such as 
transferrin or insulin-transferrin conjugates would take significantly longer than the 
typical insulin loading period (2 hours).  Instead of using expensive insulin-transferrin 
conjugates for this determination, transferrin was used as an analog to represent a size 
similar to insulin-transferrin conjugates. 
Transferrin (Sigma-Aldrich Inc., St. Louis, MO) stock solutions were prepared by 
dissolving transferrin in 20 mL PBS buffer (pH 7.4, Fisher Scientific, Fair Lawn, NJ) at a 
concentration of 1 mg/mL.  To initiate the loading process, 140 mg of P(MAA-g-EG) 
microparticles were added to each transferrin stock solution to reach a concentration of 
7 mg/mL.  Two different formulations of P(MAA-g-EG), differing by crosslinker length, 
were added to two separate transferrin stock solutions.  The concentrated transferrin 
solutions were allowed to load into the microparticles through equilibrium partitioning 
for an extended period of time.  Small samples of 0.2 mL were withdrawn using syringes 
(1 mL, Norm-Ject, Henke Sass Wolf, Tuttlingen, Germany) at time points of 0.25, 0.5, 1, 2, 
3, 6, 12 hours for subsequent analysis by HPLC (Waters Corporation, Milford, MA).  Also, 
a final sample was taken for analysis the following day.  All withdrawn samples were 
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filtered through syringe filters (PVDF, 0.22 μm, Millipore, Jaffrey, NH) to ensure only free 
protein is being analyzed.  Transferrin loading was carried out in siliconized glass 
beakers using Sigmacote (Sigma-Aldrich Inc., St. Louis, MO) to prevent any inaccurate 
concentration values due to protein adhesion to the glass.   
To determine initial concentration, an initial sample was taken before addition of 
microparticles and analyzed by HPLC.  Based on the concentration of the initial sample, 
the calculated concentrations of free transferrin in solution at each time point provided 
a comparison or ratio to determine percentage transferrin loaded at that specific time.  
Based on the loading efficiencies at each interval, the time point at which the loading 
efficiency had reached a value close to the equilibrium loading efficiency was chosen as 
the ideal loading period for large molecules similar to transferrin. 
 
6.2.3 Loading of Transferrin into Polymer Microparticles 
After determination of an ideal loading time for large molecules, the protocols 
for loading and releasing insulin-transferrin conjugates were sufficiently corrected.  
However, before performing any loading and release tests on the insulin-transferrin 
conjugate, the molecule transferrin was tested in loading and release scenarios to 
determine if the polymer microparticles were capable of effectively loading and 
releasing large molecules similar to transferrin.  While the loading time for transferrin 
was already determined, it was also necessary to determine if transferrin could remain 
within the particle after collapse as well as through the filtering and lyophilization 
processes. 
Transferrin stock solutions were prepared by dissolving the protein in 20 mL PBS 
buffer at a concentration of 1 mg/mL.  The stock solutions were placed in glass beakers 
which were siliconized using Sigmacote to reduce protein adhesion to the glass.  To 
initiate the loading process, 140 mg of P(MAA-g-EG) microparticles were added to each 
transferrin stock solution to reach a concentration of 7 mg/mL.  Two different 
formulations of P(MAA-g-EG), differing by crosslinker length, were added to two 
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separate transferrin stock solutions.  The transferrin in each solution was allowed to 
load by equilibrium partitioning for 4 hours under constant stirring.  At the conclusion of 
the loading period, 20 mL of 0.1 N HCl (Fisher Scientific, Fair Lawn, NJ) was added to the 
solution to lower the pH and collapse the particles.  After allowing the particles to fully 
collapse, the loaded microparticles were filtered by passing the solution through filter 
paper.  The particles were then washed using 10 mL deionized water (Milli-Q Plus 
system, Millipore) to remove any excess transferrin adhered to the surface of the 
particle.  The collected microparticles are then frozen at -80° C and lyophilized overnight 
to remove any excess water content.  Once the lyophilization process has completed, 
the loaded microparticles are stored in desiccator in a freezer until further use. 
To determine initial concentration, an initial sample was taken before addition of 
microparticles and analyzed by HPLC.  In order to calculate loading efficiencies at various 
time points of the loading process, additional samples were withdrawn after the end of 
the loading period, after the addition of HCl, and after the filtering of microparticles.  
Sampling at the end of the loading period gives an initial loading efficiency based solely 
on equilibrium partitioning.  Taking a sample after the addition of HCl allows 
observation of the difference in loading from expulsion of protein molecules due to 
particle collapse.  The final sample after filtering is used to determine a final loading 
percentage and also to determine the initial amount of transferrin being introduced in 
the release study.  All withdrawn samples were filtered through syringe filters (PVDF, 
0.22 μm) to ensure only free protein is being analyzed.  All four samples for each loading 
procedure were analyzed using HPLC. 
 
6.2.4 Transferrin Release Studies 
In preparing P(MAA-g-EG) and P(MAA-co-NVP) microparticles for use with 
insulin-transferrin conjugates, it was important to know if a large molecule such as 
transferrin could be released from the microparticles effectively and in a timely manner, 
or if the transferrin would simply be too large to diffuse out in an appreciable amount.  
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Release studies using transferrin-loaded microparticles were performed to determine if 
large molecules would release in a desirable manner, creating potential for the system 
to achieve high bioavailability. 
Transferrin release studies were performed by placing approximately 10 mg of 
transferrin-loaded microparticles in 50 mL of PBS buffer (pH 7.4) in a dissolution 
apparatus (Distek Model 2100B, Distek Inc., North Brunswick, NJ).  The dissolution 
apparatus water bath was maintained at 37° C and the experimental solutions were 
kept under constant stirring using impellers at 100 rpm.  As the microparticles began to 
swell and release transferrin after addition to neutral buffer, small samples of 0.2 mL 
were taken at time points of 5, 10, 15, 30, 60, and 120 minutes to obtain release profiles 
versus time.  The volume of the solution was maintained at 50 mL by addition of 0.2 mL 
of PBS buffer after each sample withdrawal.  Needles were used with the syringes to 
minimize particle uptake and the sample volume was passed through syringe filters 
(PVDF, 0.22 μm) to ensure only free transferrin was being analyzed. 
The initial amount of transferrin in the mass of particles added to the release 
study was determined by the data obtained from loading experiments.  Based on this 
initial mass of transferrin available for release, the free transferrin concentration at each 
time point was used to calculate a percentage of transferrin released up to that point.  
By analyzing several time points using HPLC to determine transferrin concentration in 
solution, it was possible to generate a release profile which indicates the rate at which 
transferrin is released as well as the total overall amount released. 
 
6.2.5 Loading of Insulin-Transferrin Conjugates into Polymer Microparticles 
Loading and release studies performed on transferrin verified the possibility of 
incorporating large molecules such as insulin-transferrin conjugates into the synthesized 
hydrogel carriers.  Based on the success of P(MAA-g-EG) being able to load large 
molecules, insulin-transferrin conjugates were loaded into a number of polymer 
formulations.  The polymer formulations included P(MAA-g-EG) and P(MAA-co-NVP) and 
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varied by synthesis parameters such as crosslinker length, monomer-to-solvent ratio, 
and particle size.  Due to transferrin previously being effectively loaded and release, a 
similar protocol was used to load insulin-transferrin conjugates with only slight 
modifications. 
As a result of the previous conjugation reaction, insulin-transferrin conjugates 
were already dissolved in a PBS buffer (pH 7.4) at a known concentration as measured 
by HPLC.  Insulin-transferrin stock solutions were prepared by diluting the conjugate 
solutions with PBS buffer (pH 7.4) to a concentration of 1 mg/mL and a volume of 40 mL.  
The stock solutions were placed in glass beakers which were siliconized using Sigmacote 
to reduce protein adhesion to the glass.  To initiate the loading process, 280 mg of 
P(MAA-g-EG) or P(MAA-co-NVP) microparticles were added to each insulin-transferrin 
stock solution to reach a concentration of 7 mg/mL.  Within the insulin-transferrin 
loading experiments, the conjugates were loaded into numerous different polymer 
formations which differed by crosslinker length, monomer-to-solvent ratio, particle size, 
and comonomer used.  The insulin-transferrin conjugates in each solution were allowed 
to load by equilibrium partitioning for 4 hours under constant stirring.  At the conclusion 
of the loading period, 40 mL of 0.1 N HCl was added to the solution to lower the pH and 
collapse the particles.  After allowing the particles to fully collapse, the loaded 
microparticles were filtered by passing the solution through filter paper.  The particles 
were then washed using 2 mL deionized water to remove any excess insulin-transferrin 
conjugates adhered to the surface of the particle.  The collected microparticles were 
then frozen at -80° C and lyophilized overnight to remove any excess water content.  
Once the lyophilization process had completed, the loaded microparticles were stored 
in a desiccator in a freezer until further use. 
To determine initial concentration, an initial sample was taken before addition of 
microparticles and analyzed by HPLC.  In order to calculate loading efficiencies at various 
time points of the loading process, additional samples were withdrawn after the end of 
the loading period, after the addition of HCl, and after the filtering of microparticles.  
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Sampling at the end of the loading period gives an initial loading efficiency based solely 
on equilibrium partitioning.  Taking a sample after the addition of HCl allows 
observation of the difference in loading from expulsion of protein molecules due to 
particle collapse.  The final sample after filtering is used to determine a final loading 
percentage and also to determine the initial amount of insulin-transferrin conjugate 
being introduced in the release study.  All withdrawn samples were filtered through 
syringe filters (PVDF, 0.22 μm) to ensure only free protein is being analyzed.  All four 
samples for each loading procedure were analyzed using HPLC. 
 
6.2.6 Insulin-Transferrin Conjugate Release Studies 
Release studies for a therapeutic protein loaded into a polymer carrier are 
essential to understanding the dynamics of the system as well as to gain insight on the 
possible performance of the formulation when administered to human subjects.  
Specifically, release studies are necessary to shed light on two different properties of 
the system.  The first property is the speed at which the conjugate is released.  If 
diffusion is too slow and significant release takes over an hour, then very little conjugate 
will be absorbed because of a finite residence time in the small intestine due to 
intestinal motility.  Also, the overall amount of conjugate released into solution is very 
important as well.  If a significant portion of loaded conjugate is not released from the 
microparticle within the residence time at the site of absorption, the chances for 
achieving a useful bioavailability in the bloodstream drops significantly. 
Insulin-transferrin conjugate release studies were performed by placing 
approximately 10 mg of conjugate-loaded microparticles in 50 mL of PBS buffer (pH 7.4) 
in a dissolution apparatus.  The dissolution apparatus water bath was maintained at 37° 
C and the experimental solutions were kept under constant stirring using impellers at 
100 rpm.  As the microparticles began to swell and release insulin-transferrin conjugates 
after addition to neutral buffer, small samples of 0.2 mL were taken at time points of 5, 
10, 15, 30, 60, and 120 minutes to obtain release profiles versus time.  The volume of 
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the solution was maintained at 50 mL by addition of 0.2 mL of PBS buffer after each 
sample withdrawal.  Needles were used with the syringes to minimize particle uptake 
and the sample volume was passed through syringe filters (PVDF, 0.22 μm) to ensure 
only free insulin-transferrin conjugates were being analyzed. 
The initial amount of insulin-transferrin conjugates in the mass of particles 
added to the release study was determined by the data obtained from the previous 
insulin-transferrin loading experiments.  Based on this initial mass of conjugate available 
for release, the free insulin-transferrin concentration at each time point was used to 
calculate a percentage of insulin-transferrin released up to that point.  By analyzing 
several time points using HPLC to determine conjugate concentration in solution, it was 
possible to generate a release profile which indicates the rate at which insulin-
transferrin is released as well as the total overall amount released. 
 
6.2.7 Protein Sample Concentration Analysis by HPLC 
High Performance Liquid Chromatography (HPLC) was used to analyze samples 
containing either transferrin or insulin-transferrin conjugates dissolved in PBS buffer (pH 
7.4).   The samples analyzed came from nearly every procedure listed in this chapter 
including determination of loading time for large molecules, transferrin loading and 
release, and insulin-transferrin conjugate loading and release.  HPLC analysis was used 
for each sample to determine concentration based on absorbance values relative to 
absorbances of standard samples of known concentrations.  Determining sample 
concentrations allows for the calculation of free protein in solution as well as loading 
efficiencies and release profiles. 
The HPLC equipment used consists of a Waters 2695 Separation Module (Waters 
Corporation, Milford, MA) attached to a Waters 2487 Dual λ Absorbance Detector 
(Waters Corporation, Milford, MA).  Analysis is performed using a reverse-phase 
analytical HPLC method designed to elute a wide range of proteins within a specified 
time period.  The method includes the use of water (HPLC Grade, Fisher Scientific, Fair 
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Lawn, NJ) with 0.1% by volume trifluoroacetic acid (TFA, ACROS Organics, Geel, Belgium) 
as Solvent A and acetonitrile (Optima, Fisher Scientific, Fair Lawn, NJ) with 0.08% by 
volume TFA as Solvent B.  During the separation process, the mobile phase begins at a 
composition of 70% Solvent A and 30% Solvent B.  The mobile phase changes 
composition using a gradient to 40% Solvent A and 60% Solvent B within 6 minutes.  The 
mobile phase composition is then returned to initial conditions of 70% Solvent A and 
30% Solvent B for the next sample to be analyzed.  The mobile phase was introduced at 
a constant flow rate of 0.6 mL/min.  All separations are performed using a 
Symmetry300TM C4 column (particle size 5 µm, 3.9 mm I.D. x 150 mm length, Waters 
Corporation, Milford, MA) held at a constant temperature of 40°C.  After separation of 
proteins, absorbance of the solution was detected at a wavelength of 220 nm.  All 
instrument and processing methods were controlled and specified using the Empower 
software. 
 
6.3 Results and Discussion 
6.3.1 Polymer Microparticle Formation by UV Polymerization 
A number of different systems of polymer microparticles were synthesized for 
use in the loading and release experiments conducted in this chapter.  Many different 
polymers were created including P(MAA-g-EG) and P(MAA-co-NVP) while also varying 
synthesis parameters such as crosslinker length (4 repeat units and 23 repeat units), 
monomer-to-solvent ratio (67:33, 60:40, and 50:50), and particle size (less than 75 
microns, 90-150 microns, and 150-212 microns).  The use of different systems yielded a 
range of results based on the effect of the synthesis parameters on loading and release 
studies.  At the conclusion of the studies, a specific polymer formulation was chosen as 
the optimal formulation for use with insulin-transferrin conjugates. All formulations 
were successfully synthesized and determined to be usable for demonstrating loading 
and release characteristics of insulin-transferrin conjugates in conditions which mimic 
physiological environments. 
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6.3.2 Loading Time Determination for Large Molecules (Transferrin) 
Transferrin was used as a model protein analog for the insulin-transferrin 
conjugate based on its similar size and properties.  Before performing loading and 
release on transferrin, it was necessary to determine a suitable loading period which 
would allow the molecule to diffuse into the polymer network for subsequent 
incorporation.  The loading period for a molecule is very much dependent on its 
diffusion coefficient within the polymer network, which in turn is very dependent on 
molecule size and surface properties.  Using transferrin as a model analog, the loading 
time determination experiment consisted of loading transferrin for an extended period 
over 24 hours.  Samples were taken at various time points to determine free transferrin 
concentration in solution as well as the loading efficiency at each time point.  The graph 
showing the loading efficiency profiles versus time is shown as Figure 6.1. 
As seen in Figure 6.1, the percentage of transferrin loaded sharply increases 
within the first few hours of the loading period.  The goal of the experiment was to 
select a cutoff at which point the percentage of transferrin loaded would be a stable 
value which would not differ greatly from the equilibrium value.  Based on this criteria, 
the selected loading period for future loading experiments with insulin-transferrin 
conjugates was chosen to be 4 hours.  As evident in Figure 6.1, the cutoff at four hours is 
well after the initial sharp increase and also occurs at a value which is within 10-15% of 
the equilibrium value.  Four hours allows sufficient time for a large molecule such as 
insulin-transferrin conjugates to diffuse far enough into the polymer network to not be 
removed with washing but still be able to release in a reasonable amount of time.   
If one were to attempt to have a longer loading period, it would indeed translate 
to more efficient loading, but loading for too long, or overloading, typically has an 
adverse effect on release of the protein.  In fact, the microparticles loaded with 
transferrin from Figure 6.1 for over 29 hours were collapsed, filtered, and lyophilized for 
use in a subsequent release study.  The results from the release study using the 
overloaded microparticles are shown as Figure 6.2.  As seen in Figure 6.2, there is a 
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significant delay in the release of transferrin using the overloaded microparticles.  It 
appears as if it takes at least 15 minutes for the system to release any appreciable 
amount of encapsulated protein.  The lag in release can most likely be attributed to 
increased time for diffusion during loading, allowing transferrin to diffuse deeper into 
the network from which it takes more time and a more tortuous path to diffuse out.  
The ramifications of loading for too long are evident in that even if the release of 
protein is satisfactory but delayed only 15 minutes, the chance for absorption will still 
be greatly decreased due to intestinal motility and the brevity of the residence time at 
the site of absorption.  Because of the disadvantages of loading for too short of a period 
(bad loading) and loading for too long (bad release), the ideal loading time was found to 
be approximately 4 hours. 
 
6.3.3 Loading of Transferrin into Polymer Microparticles 
Transferrin was used as an analog protein to determine if a large molecule could 
be effectively loaded and released with P(MAA-g-EG), a polymer system previously used 
in this laboratory for loading and release of much smaller proteins.  Before performing 
loading and release studies on transferrin, the ideal loading time for large molecules 
such as transferrin was first investigated and found to be 4 hours.  After appropriately 
modifying the protocol to reflect the longer loading period, the protein transferrin was 
loaded into two different formulations of P(MAA-g-EG) to test its loading capabilities.  
Loading efficiencies can be calculated by taking the ratio of the difference between 
initial protein concentration in solution (C0) and the final free protein concentration in 
solution (Cf) to the initial protein concentration.  The loading efficiencies were 
calculated using Equation 6.1 as shown below: 
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The loading efficiencies of transferrin in the two different formulations are shown as 
Figure 6.3. 
 As seen in Figure 6.3, P(MAA-g-EG) microparticles are capable of effectively 
loading large molecules such as transferrin.  Also, modification of synthesis parameters 
such as crosslinker length can have a significant effect on the results of the loading 
experiments.  The graph also shows that a significant portion of protein is lost due to 
particle collapse and surface washing.  Particle collapse often squeezes out a significant 
amount of protein and surface washing removes the majority of any surface-adhered 
protein, greatly reducing the loading efficiency.  However, while a high final loading 
efficiency makes for a more efficient overall process, it is the subsequent release 
performance that is the most important when deciding an ideal polymer carrier.  Protein 
which is not loaded can still potentially be recovered and reused in an industrial process 
where protein which is not released in the body is considered wasted therapeutics.  The 
important results obtained from the transferrin analog loading experiment are that an 
appreciable amount is loaded into the network, meaning it will not require a huge mass 
of polymer to deliver a relatively small amount of insulin-transferrin conjugate.  Also, 
the performance appears to depend significantly on the synthesis parameters of the 
polymer carriers. 
 Another indication of performance in loading studies is the polymer weight 
fraction of transferrin, or the weight fraction of the loaded microparticles which can be 
attributed to the presence of transferrin molecules.  Because of the nature of loading 
protocols, the polymer weight fraction for most proteins is typically somewhat low 
(0.04-0.14).  However, if the polymer weight fraction of a protein is extremely low, then 
it would take a large amount of polymer to deliver a small amount of therapeutic 
protein, translating to an increased materials cost as well as large dosage forms.  
Polymer weight fractions were calculated by taking the difference between the initial 
mass of protein in solution (M0) and the final mass of protein in the solution (Mf) and 
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dividing by the same difference (M0 – Mf) added to the weight of polymer in the solution 
(Mp).  Polymer weight fractions were calculated using Equation 6.2 as shown below: 
 
 
 
The polymer weight fractions of transferrin in each formulation are shown as Figure 6.4. 
 Figure 6.4 gives additional insight into the performance of P(MAA-g-EG) with 
respect to loading of large molecules.  The polymer weight fractions generally reflect 
trends observed in loading efficiencies but are also very important because the specific 
values of the polymer weight fraction of a protein determine if delivering the protein 
will be cost-effective as well as mass-effective.  In this case, the graph shows that 
P(MAA-g-EG) have potential to act as carriers for a large molecule such as insulin-
transferrin conjugates.  The calculation of exact mass of dosage form required also 
depends on other factors such as amount released, epithelial transport, and 
bioavailability.  However, the polymer weight fractions of transferrin are within a 
reasonable range, indicating potential use of P(MAA-g-EG) with insulin-transferrin 
conjugates and allowing for progression of the project into observing large molecule 
performance in release studies. 
 
6.3.4 Transferrin Release Studies 
Transferrin-loaded P(MAA-g-EG) microparticles were placed in PBS buffer (pH 
7.4) to determine if transferrin, acting as a protein analog for insulin-transferrin, could 
be effectively released from the polymer carriers in a reasonable period of time.  After 
successfully loading transferrin into the P(MAA-g-EG), it was expected that the 
transferrin could diffuse out of the polymer network just as easily.  However, the extent 
to which it diffuses out is still an important factor in selecting a system for use.  Release 
studies were performed with transferrin inside two different formulations of P(MAA-g-
EG) to determine the potential effect on synthesis parameters on overall release.  The 
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percentage released at any time point during the experiment is simply a ratio of the free 
transferrin in solution to the amount of transferrin initially present in the mass of 
microparticles added.  The generated release profiles of transferrin in the two 
formulations of P(MAA-g-EG) are shown in Figure 6.5. 
As evident in Figure 6.5, P(MAA-g-EG) microparticles are capable of effectively 
releasing large molecules similar to transferrin from within the polymer network.  Also, 
it can be observed that synthesis parameters such as crosslinker length have a 
significant effect on the overall results of the release study.  The graph shows that 
approximately 75% of the transferrin is released from one of the formulations within 
one hour.  A one hour window is a conservative representation of the useful residence 
time at the site of absorption before intestinal motility causes the removal of the 
microparticles from the mucus.  Under the right conditions, the residence time can be 
more than one hour, but 1-1.5 hours is a fair time range to use to judge the release 
study results.  With 75% of the transferrin released in the first hour, P(MAA-g-EG) 
microparticles demonstrate potential to deliver large amounts of insulin-transferrin 
conjugate to the small intestine.  The protein which remains trapped in the polymer 
network at the end of the useful residence time continues through the digestive tract 
and is considered wasted therapeutics.  Therefore, in a system that achieves 75% 
release the maximum bioavailability is also 75%.  The 1:1 ratio of amount released to 
maximum bioavailability illustrates the importance of the release properties of the 
system.  Also, it is advantageous for the release properties of a system to be easily 
manipulated simply through the changing of various synthesis parameters.  The 
transferrin release studies performed in this section have demonstrated that the 
potential bioavailability of the system will not be seriously hindered by the limited 
diffusion and release kinetics of large molecules such as insulin-transferrin conjugates 
and also that the system can be fine-tuned using synthesis parameters to achieve the 
best possible release and thus the highest potential bioavailability. 
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6.3.5 Loading of Insulin-Transferrin Conjugates into Polymer Microparticles 
The viability of P(MAA-g-EG) microparticles for loading and release of large 
molecules such as insulin-transferrin conjugates was demonstrated through loading and 
release of transferrin as a protein analog.  To determine the performance of insulin-
transferrin conjugates, they were loaded into P(MAA-g-EG) formulations.  Several 
formulations were investigated to determine the effect of various synthesis parameters 
on loading and release characteristics of the system.  The polymer microparticles tested 
included varying crosslinker lengths (4 repeat units and 23 repeat units), monomer-to-
solvent ratios (67:33, 60:40, and 50:50), particle size (less than 75 microns, 90-150 
microns, and 150-212 microns), and comonomer used (to form both P(MAA-g-EG) and 
P(MAA-co-NVP)).  Based on the results from the investigation of each synthesis 
parameter, an ideal formulation in terms of loading can be identified for use with 
insulin-transferrin conjugates. 
 
Analysis of the Effect of Crosslinker Length on Insulin-Transferrin Loading:  Insulin-
transferrin conjugates were loaded into two different P(MAA-g-EG) formulations which 
differed only in the length of the crosslinker.  The crosslinkers used were TEGDMA (4 
ethylene glycol repeat units) and PEGDMA1000 (approximately 23 ethylene glycol 
repeat units).  Loading efficiencies were calculated at specific points throughout the 
loading process for both formulations using Equation 6.1 shown above.  The loading 
efficiencies for insulin-transferrin in the specified formulations are shown as Figure 6.6. 
 Figure 6.6 shows that a significant portion of the insulin-transferrin conjugate 
was loaded using the experimental protocol designated for large molecules.  Also, it 
shows that the presence of a longer crosslinker had a significant effect on the amount of 
conjugate loaded into the polymer network.  Specifically, the use of a shorter crosslinker 
resulted in a final loading efficiency that is well over double the loading efficiency 
obtained using a much longer crosslinker.  The reason for the noticeable difference is 
twofold.  The use of a shorter crosslinker creates a tighter, more rigid polymer network, 
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forcing conjugate which has diffused into the network to most likely remain in the 
polymer network due to the tortuous path to diffuse out.  Also, upon particle collapse 
and surface rinsing, the longer crosslinker network is more open and loose, allowing 
more protein to be squeezed out due to deswelling.  However, as previously mentioned, 
conjugate which is not loaded can potentially be recovered in an industrial process.  The 
full analysis of crosslinker length with respect to optimization of the system can only 
occur after examining the subsequent release studies.  While release studies have a 
major effect on maximum potential bioavailability, loading studies theoretically do not.  
However, loading efficiencies are important to understand and these experiments 
demonstrate that a significant portion of conjugate can be loaded. 
 Additional insight into the effect of crosslinker length on loading of insulin-
transferrin conjugates was gained by observing the polymer weight fractions as 
calculated by Equation 6.2 shown above.  The polymer weight fractions for insulin-
transferrin loaded in both formulations are shown in Figure 6.7.  The graph shows that a 
larger fraction of the hypothetical dosage form will be comprised of therapeutic insulin-
transferrin conjugates in systems which contain shorter crosslinkers.  While this trend 
mirrors the trend seen in the graph of loading efficiencies, it also brings to the forefront 
the possibility of having to create larger dosage forms if the use of a longer crosslinker 
proves optimal based on release studies.  However, based on the value of the polymer 
weight fraction for the longer crosslinked system, a significant portion of the total 
dosage form is still insulin-transferrin, albeit reduced from the shorter crosslinked 
system.  While adjusting synthesis parameters, the benefits and drawbacks are often 
linked in such a way that the optimal system requires a balance of specific synthesis 
parameters. 
 
Analysis of the Effect of Monomer-to-Solvent Ratios on Insulin-Transferrin Loading:  
Loading studies were performed by loading insulin-transferrin conjugates into three 
P(MAA-g-EG) polymer formulations which differed only by monomer-to-solvent ratios 
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used during the synthesis procedure.  The formulations included monomer-to-solvent 
ratios of 67:33, 60:40, and 50:50.  Loading efficiencies were calculated at specific points 
throughout the loading process for all formulations using Equation 6.1.  The loading 
efficiencies for insulin-transferrin conjugates in the specified formulations are shown as 
Figure 6.8. 
As can be seen in Figure 6.8, all three formulations were able to successfully load 
a large portion of the insulin-transferrin conjugates.  Also, it is clear that the monomer-
to-solvent ratio had little pronounced effect on the obtained loading efficiencies.  
Changing the monomer-to-solvent ratio during the synthesis of the polymer in effect 
changes the way in which diffusion occurs within the system.  If a polymer network is 
formed with very little solvent and mostly monomer, such as in the 67:33 formulation, 
then the diffusion is based solely on the effective mesh size of the network and the 
conjugate must be able to diffuse between the crosslinked polymer strands.  However, if 
the synthesis is carried out with the presence of more solvent, such as in the 50:50 
formulation, the polymer network is forced to form around the solvent molecules, 
creating a more porous and open network.  The additional solvent increases the 
“effective mesh size” of the system by allowing conjugates to diffuse through larger 
spaces, or pores, created by the presence of solvent.  However, it appears that the 
different types of diffusion had little influence in the loading of insulin-transferrin 
conjugates but may still play a role in release of the conjugate molecules. 
The effect of the monomer-to-solvent ratios on loading of insulin-transferrin 
conjugates was observed further by examining the polymer weight fractions of the 
conjugate-loaded microparticles as calculated by Equation 6.2.  The polymer weight 
fractions for insulin-transferrin loaded in all three formulations are shown in Figure 6.9.  
Similar to the loading efficiencies, there is little variation between the polymer weight 
fractions of insulin-transferrin conjugates in the three formulations.  However, it is 
important to note that roughly 7-8% of the weight of the loaded microparticle can be 
attributed to the presence of the conjugate, indicating its potential to be used in a 
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practical therapeutic dosage form.  While release characteristics remain the most direct 
contributor to potential bioavailability, the three formulations examined in this section 
performed extremely well throughout the loading process. 
 
Analysis of the Effect of Particle Size on Insulin-Transferrin Loading:  Insulin-transferrin 
conjugates were loaded into three P(MAA-g-EG) formulations differing only in the 
average size of the microparticles.  The three particle size ranges of formulations tested 
include less than 75 microns, 90-150 microns, and 150-212 microns.  Loading efficiencies 
were calculated at specific points throughout the loading process for all formulations 
using Equation 6.1.  The loading efficiencies for insulin-transferrin conjugates in the 
specified formulations are shown as Figure 6.10. 
 Figure 6.10 illustrates that a significant portion of insulin-transferrin conjugates 
were successfully loaded into all three formulations.  Also, the difference in particle size 
appears to have a slight effect in initial loading efficiencies, but little to no pronounced 
effect on the final loading efficiencies.  The effect of changing the particle size of 
polymer formulations can be described in terms of volume or in terms of diffusion path 
length.  As the diameter of the particle is increased, the volume of the particle increases 
exponentially and is able to carry more conjugate molecules.  However, conjugate 
molecules which are loaded into the center of the polymer network of a larger particle 
have a longer diffusion path length in order to diffuse out of the system.  The longer 
diffusion path means a more tortuous journey for the molecule and thus a slower and 
less complete release.  In terms of loading, the effect of particle size is mostly directly 
related to the volume that the particle can hold.  Specifically, the surface area-to-
volume ratio has some effect on the amount of conjugate loaded in each formulation.  
Among the three formulations, the smallest particles achieved the lowest initial loading 
efficiency compared to the other larger particles.  This can be most readily explained by 
volume considerations and surface area-to-volume ratios.  However, it is interesting to 
note that after particle collapse and surface rinsing, the final loading efficiencies were 
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nearly identical.  The minimization of differences among the formulations in terms of 
final loading efficiencies can most likely be attributed to the decreasing differences in 
particle size in the collapsed state.  Because the final loading efficiency is the most 
important practical value for industrial processes, the particle size had minimal effect on 
the loading process. 
Additional insight into the effect of particle size on the loading of insulin-
transferrin conjugates in P(MAA-g-EG) microparticles was gained by analyzing the 
polymer weight fractions of the conjugate as calculated by Equation 6.2.  The polymer 
weight fractions for insulin-transferrin conjugates loaded in all three formulations are 
shown in Figure 6.11.  As evident in the figure, the polymer weight fraction which can be 
attributed to the presence of the insulin-transferrin conjugate decreased as the particle 
size was increased.  Based on these results, use of smaller microparticles as carriers for 
insulin-transferrin conjugates is preferential due to the practical advantage of being able 
to formulate smaller dosage forms.  Also, the final loading efficiencies of the three 
particle size ranges were nearly identical, eliminating any informed selection based on 
loading efficiencies alone.  In contrast, the effect of particle size on the release of 
conjugate will most likely stem from factors related to diffusion path length within the 
particle and will also be the determining factor when optimizing particle size due to the 
direct relationship between release studies and potential bioavailability. 
 
Analysis of the Effect of the Replacement of PEG Comonomer with NVP Comonomer on 
Insulin-Transferrin Loading:  Loading studies were performed by loading insulin-
transferrin conjugates into P(MAA-g-EG) and P(MAA-co-NVP) polymer microparticles 
which differed only by the comonomer used.  Loading efficiencies were calculated at 
specific points throughout the loading process for both formulations using Equation 6.1.  
The loading efficiencies for insulin-transferrin conjugates in P(MAA-g-EG) and P(MAA-co-
NVP) are shown as Figure 6.12. 
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 As can be seen in Figure 6.12, both P(MAA-g-EG) and P(MAA-co-NVP) were able 
to effectively load the majority of insulin-transferrin conjugates placed in solution.  Also, 
the difference between the two formulations with respect to loading efficiencies was 
only evident in the initial loading efficiencies.  After the particles were collapsed and 
surface rinsed, the difference in loading efficiencies between the systems became 
minimal.  Differences in loading between the systems can be attributed to interactions 
between the insulin-transferrin conjugate and either the PEG tethers or NVP repeat 
units.  Interactions which may have an effect include surface charge interactions, 
physical hindrance, hydrophilicity, and interpolymer interactions.  However, because the 
loading efficiencies were very similar between the systems, it is reasonable to conclude 
that the interactions based on the presence of the comonomer had little effect on the 
loading process.  However, the presence of a specific comonomer is more likely to play a 
role in the subsequent release studies because of the importance of the interpolymer 
interactions governing the rate of swelling as well as the hydrophilicity of each group 
significantly affecting the release properties. 
 The effect of the presence of the PEG and NVP comonomers on the loading of 
insulin-transferrin conjugates was further investigated by determining the polymer 
weight fractions of insulin-transferrin as calculated by Equation 6.2.  The polymer weight 
fractions for insulin-transferrin conjugates loaded in both P(MAA-g-EG) and P(MAA-co-
NVP) are shown in Figure 6.13.  Similar to the final loading efficiencies, little difference 
could be observed between the polymer weight fraction of the insulin-transferrin 
conjugate in P(MAA-g-EG) and P(MAA-co-NVP).  However, it is important to note that 
both polymer formulations had polymer weight fractions within the range of 0.07-0.08, 
indicating that both polymers could serve as potential carriers for insulin-transferrin 
conjugates in a dosage form.  As with all four synthesis parameters investigated, the 
selection of the optimal system will most likely depend on the release characteristics in 
simulated physiological conditions because of the direct link to potential bioavailability.  
However, loading studies are important to perform with respect to each synthesis 
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parameter in order to verify loading of a significant amount of conjugate, to determine 
if the polymer weight fraction is enough to warrant a practical dosage form, and to 
better understand how each manipulated synthesis parameter affects the diffusion of 
the conjugate within the polymer network. 
 
6.3.6 Insulin-Transferrin Conjugate Release Studies 
Insulin-transferrin conjugates were loaded into a number of different polymer 
formulations including P(MAA-g-EG) and P(MAA-co-NVP) synthesized using a number of 
different synthesis parameters.  The formulations were found to all be able to load an 
appreciable amount of insulin-transferrin conjugate in solution as well as having a 
significant polymer weight fraction attributed to the protein.  The conjugate-loaded 
microparticles from each formulation were then investigated using release studies.  The 
formulations included systems with varying crosslinker lengths (4 repeat units and 23 
repeat units), monomer-to-solvent ratios (67:33, 60:40, and 50:50), particle size (less 
than 75 microns, 90-150 microns, and 150-212 microns), and comonomer used (to form 
both P(MAA-g-EG) and P(MAA-co-NVP)).  Based on the results obtained from the 
investigation of the loading and release studies for each synthesis parameter, an 
optimal polymer formulation to achieve maximum potential bioavailability was 
identified and chosen for future use with insulin-transferrin conjugates. 
 
Analysis of the Effect of Crosslinker Length on the Release of Insulin-Transferrin:  Insulin-
transferrin conjugates were previously loaded into two different P(MAA-g-EG) 
formulations which differed only in the length of the crosslinker.  The crosslinkers used 
were TEGDMA (4 ethylene glycol repeat units) and PEGDMA1000 (approximately 23 
ethylene glycol repeat units).  Release studies were performed by placing the conjugate-
loaded microparticles in PBS buffer (pH 7.4) and measuring the conjugate concentration 
in solution over time.  The percentage released at each time point was calculated by 
taking a ratio of the amount of conjugate at the specified time to the initial amount of 
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conjugate present in the loaded particles.  The release profiles for insulin-transferrin as 
released from the specified formulations are shown as Figure 6.14. 
Figure 6.14 shows that while both formulations released a significant amount of 
conjugate within 2 hours, the system which was crosslinked with PEGDMA1000 released 
approximately 10% more than the system crosslinked with TEGDMA by the conclusion 
of the release period.  The difference in release is a result of the effect of a longer 
crosslinker on the polymer network.  The crosslinker PEGDMA1000 is significantly longer 
than TEGDMA, creating a polymer network with a larger mesh size which is more open 
to diffusion of a large molecule such as the conjugate.  The increased distance between 
polymer strands allows loaded conjugate in the PEGDMA1000 crosslinked formulation 
to diffuse out of the system quicker and in a higher quantity over a short time period.  
Even though the loading and polymer weight fraction is preferential for the TEGDMA 
crosslinked system, the release profile clearly justifies the use of longer crosslinkers for 
polymer carriers for insulin-transferrin conjugates.  Because of the improved release 
using a longer crosslinker, even longer crosslinkers such as PEGDA4000 were used as 
crosslinkers in some experimental systems.  However, the resultant polymer films were 
not rigid enough and were unmanageable due to the introduction of an extremely long 
crosslinker.  However, the additional insulin-transferrin conjugate released in the case of 
the PEGDMA1000 crosslinked formulation relative to the TEGDMA crosslinked 
formulation equates to higher potential bioavailability and increased potential efficacy 
of a possible oral formulation. 
 
Analysis of the Effect of Monomer-to-Solvent Ratios on the Release of Insulin-
Transferrin:  Insulin-transferrin conjugates were previously loaded into three different 
P(MAA-g-EG) formulations which differed only in the monomer-to-solvent ratios used 
during synthesis.  The formulations included monomer-to-solvent ratios of 67:33, 60:40, 
and 50:50.  Release studies were performed by placing the conjugate-loaded 
microparticles in PBS buffer (pH 7.4) and measuring the conjugate concentration in 
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solution over time.  The percentage released at each time point was calculated by taking 
a ratio of the amount of conjugate at the specified time to the initial amount of 
conjugate present in the loaded particles.  The release profiles for insulin-transferrin as 
released from the specified formulations are shown as Figure 6.15. 
 Figure 6.15 illustrates that all three formulations were able to release at least a 
sizable portion of the loaded insulin-transferrin conjugates.  However, the data also 
clearly shows that as more solvent relative to monomer is introduced to the prepolymer 
mixture, the release characteristics benefit greatly.  Changing the balance of the 
monomer-to-solvent ratio in the prepolymer mixture in effect changes the way in which 
diffusion occurs throughout the system.  If a large amount of monomer relative to 
solvent is used, such as in the 67:33 formulation, then diffusion characteristics are based 
solely on the effective mesh size of the network, forcing the conjugate to diffuse within 
the spaces created between the crosslinked polymer strands.  However, if the 
monomer-to-solvent ratio is changed to favor adding more solvent, such as in the 50:50 
formulation, the polymer network forms around the solvent molecules, creating a more 
porous and open network.  The additional solvent increases the “effective mesh size” of 
the system by allowing conjugates to diffuse through larger spaces, or pores, created by 
the presence of solvent in the prepolymer mixture.  The loading characteristics varied 
very little between the three formulations, but the release profiles clearly require that 
the monomer-to-solvent ratio of the prepolymer mixture must be as low as possible to 
achieve an optimal system.  Because more solvent present in the synthesis led to better 
release, experimental systems were synthesis with monomer-to-solvent ratios of 40:60 
and 33:67.  However, the syntheses produced films which were gel-like and 
unmanageable in terms of washing excess monomer and subsequent crushing.  The 
formulation successfully synthesized using the lowest monomer-to-solvent ratio, which 
was 50:50, was chosen as the optimal system because of the significantly more probable 
prospect of achieving high bioavailability versus the other two formulations. 
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Analysis of the Effect of Particle Size on the Release of Insulin-Transferrin:  Insulin-
transferrin conjugates were previously loaded into three different P(MAA-g-EG) 
formulations which differed only in particle size.  The formulations included P(MAA-g-
EG) microparticles in size ranges of less than 75 microns, 90-150 microns, and 150-212 
microns.  Release studies were performed by placing the conjugate-loaded 
microparticles in PBS buffer (pH 7.4) and measuring the conjugate concentration in 
solution over time.  The percentage released at each time point was calculated by taking 
a ratio of the amount of conjugate at the specified time to the initial amount of 
conjugate present in the loaded particles.  The release profiles for insulin-transferrin as 
released from the specified formulations are shown as Figure 6.16. 
 As can be seen in Figure 6.16, all three formulations were able to release at least 
a small portion of the loaded insulin-transferrin conjugate.  However, there is a large 
increase in the overall amount of conjugate released as the particle size decreases.  The 
relationship between amount of conjugate released and particle size of the carrier can 
best be described by the concept of diffusion path length.  In smaller particles, the 
loaded conjugate has a shorter distance to diffuse before being completely released 
from the system.  In contrast, a large molecule presents a more tortuous and longer 
path for the release of conjugate, translating to slower release and a reduction in overall 
release over a short period.  The diffusion path length plays a considerable role in the 
release characteristics of the conjugate whereas the particle size effect on loading is 
best described by volume considerations as mentioned previously.  Based on the results, 
the ideal particle size for polymer carriers for insulin-transferrin conjugates was 
determined to be less than 75 microns.  It is difficult to reduce the upper end of the size 
range due to the difficulty in creating smaller particles using the crushing method of 
using a mortar and pestle.  If a different type of polymerization were used which could 
control the size down to a smaller range, the release of conjugates would likely see even 
greater benefit.  However, using the specific protocol outlined in Chapter 4, the 
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microparticles of size range of less than 75 microns were used to achieve the highest 
potential bioavailability. 
 
Analysis of the Effect of the Replacement of PEG Comonomer with NVP Comonomer on 
the Release of Insulin-Transferrin:  Insulin-transferrin conjugates were previously loaded 
into P(MAA-g-EG) and P(MAA-co-NVP) formulations which differed only by the 
comonomer used.  Release studies were performed by placing the conjugate-loaded 
microparticles in PBS buffer (pH 7.4) as well as PBS buffer (pH 3.2) and measuring the 
conjugate concentration in solution over time.  The release studies performed under 
acidic conditions were performed to examine how the particles would perform in the 
collapsed state, or to observe if any conjugate was prematurely released in conditions 
mimicking the stomach.  The percentage released at each time point was calculated by 
taking a ratio of the amount of conjugate at the specified time to the initial amount of 
conjugate present in the loaded particles.  The release profiles for insulin-transferrin as 
released from the specified formulations are shown as Figure 6.17. 
 Figure 6.17 illustrates that both P(MAA-g-EG) and P(MAA-co-NVP) polymer 
formulations were able to release a portion of the loaded insulin-transferrin conjugate 
under neutral pH conditions and that both formulations were able to prevent any 
release of conjugate under acidic conditions.  Also, while no free conjugate could be 
detected in solution under acidic conditions for both formulations, the P(MAA-g-EG) 
polymer formulation far outperformed the P(MAA-co-NVP) formulation by releasing 
much more conjugate under neutral conditions.  The major difference between these 
two comonomers is the interpolymer interactions and the resultant degree of 
complexation.  NVP is thought to have a higher degree of complexation with MAA than 
PEG does, allowing for the interpolymer bonds in P(MAA-co-NVP) to be stronger than 
those in P(MAA-g-EG).  The selection of NVP as a possible replacement for the PEG 
comonomer was based on its degree of complexation and such a property was 
determined to have an advantageous effect on protection of the conjugate under acidic 
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conditions.  However, it was the strong interpolymer interactions which most likely 
limited the release of conjugate from P(MAA-co-NVP) particles.  While the degree of 
complexation in the collapsed state may have been higher in P(MAA-co-NVP), the 
P(MAA-g-EG) particles also prevented any release of conjugate under acidic conditions.  
Therefore, the additional complexation in the collapsed state was unnecessary for 
protection of a large molecule such as the insulin-transferrin conjugate.  In fact, the 
strong complexation most likely limited the release of the conjugate under neutral 
conditions.  If the therapeutic were a smaller protein, such as insulin by itself, the 
additional protection from the complexation of P(MAA-co-NVP) may be necessary.  
Moreover, in the less complexed system of P(MAA-g-EG), the insulin may be able to 
diffuse out under acidic conditions.  However, for the specific case of the insulin-
transferrin conjugate, the P(MAA-g-EG) microparticles were found to be the desired 
formulation as a carrier for the conjugate because of the much improved release and 
concurrently the much improved potential bioavailability of an oral formulation. 
 
Determination of an Optimal Polymer Formulation for the Delivery of Insulin-Transferrin 
Conjugates:  Several polymer formulations were synthesized in an effort to determine 
an optimal polymer formulation to achieve high bioavailability of orally delivered 
insulin-transferrin conjugates.  The polymer formulations included P(MAA-g-EG) and 
P(MAA-co-NVP) while also varying synthesis parameters such as crosslinker length (4 
repeat units and 23 repeat units), monomer-to-solvent ratio (67:33, 60:40, and 50:50), 
and particle size (less than 75 microns, 90-150 microns, and 150-212 microns).  Each 
formulation was loaded with insulin-transferrin conjugates and subsequently released 
to determine loading efficiencies and release profiles.  As each synthesis parameter was 
investigated, all other synthesis parameters and values were held constant.  At the 
conclusion of the studies, the release characteristics were the determining factor in 
selecting an optimal carrier.  The loading efficiencies and polymer weight fractions were 
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determined to verify that each formulation could indeed load a significant portion of 
conjugate. 
 The investigation of the effect of crosslinker length yielded that the longest 
crosslinker (PEGDMA1000) would provide the best release characteristics.  After testing 
monomer-to-solvent ratios, it was found necessary to include as much solvent as 
possible in the prepolymer mixture (50:50 monomer-to-solvent) to achieve desirable 
release profiles.  The experiments on the effect of particle size of the carrier 
demonstrated that the smallest particles (less than 75 microns) achieved the highest 
overall release.  The studies in which the PEG comonomer was replaced with the NVP 
comonomer illustrated that while NVP may complex better under acidic conditions, the 
extra protection in unnecessary in the case of a large molecule such as insulin-
transferrin conjugates and that P(MAA-g-EG) particles are preferred as carriers due to 
the much improved release characteristics.  Within the parameters specified in this 
chapter and manipulation only to the extent that polymers could be successfully 
synthesized, the ideal polymer carrier for oral delivery of insulin-transferrin conjugates 
was found to be P(MAA-g-EG) particles synthesized using a monomer-to-solvent ratio of 
50:50, crosslinked with PEGDMA1000, and having a particle size of less than 75 microns. 
 
6.3.7 Protein Sample Concentration Analysis by HPLC 
All samples obtained from loading and release studies were analyzed by HPLC.  
The concentration of each sample was determined by comparisons to standards of 
known concentrations.  The experimental concentration of each sample was used to 
calculate the free protein concentration in the solution at the time the sample was 
withdrawn.  In the cases of values of zero concentration as in the release studies 
performed under acidic conditions, the free protein in the samples was at a 
concentration low enough to be undetectable by HPLC. 
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6.4 Conclusions 
Insulin-transferrin conjugates were successfully synthesized and required 
investigation into the in vitro characteristics with relation to loading and release in 
polymer microparticle carriers.  To determine if polymer carriers typically used for 
smaller proteins such as insulin were able to carry large molecules, a protocol was 
designed for transferrin and it was tested as a protein analog to determine its loading 
and release characteristics.  The polymer carriers were found to perform well with a 
large molecule, allowing for investigation into the loading and release of insulin-
transferrin conjugates in the polymer carriers.  To determine the ideal polymer 
formulation to use as a carrier for the conjugate, several polymer formulations were 
tested using loading and release studies to gauge performance.  The polymer 
formulations included P(MAA-g-EG) and P(MAA-co-NVP) and also differed in synthesis 
parameters such as crosslinker length, monomer-to-solvent ratio, and particle size.  
Loading studies performed on all formulations confirmed that each formulation was 
capable of loading a significant amount of insulin-transferrin conjugates.  Upon 
performing release studies, the optimal release characteristics for obtaining high 
bioavailability upon administration were obtained using the specific optimal formulation 
of P(MAA-g-EG) microparticles less than 75 microns in size, crosslinked with 
PEGDMA1000, and synthesized using a 50:50 monomer-to-solvent ratio.  The selected 
optimized polymer carrier along with the synthesized insulin-transferrin conjugate 
received further investigation into their properties and potential to achieve high 
bioavailability upon administration by evaluation via cell studies performed in a later 
chapter. 
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Figure 6.1 Loading profiles versus time for transferrin loading in P(MAA-g-EG) in 
PBS buffer (pH 7.4). 
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Figure 6.2 Release profiles for transferrin-loaded microparticles from an extended 
loading experiment incorporating transferrin in P(MAA-g-EG) for over 29 hours. 
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Figure 6.3 Loading efficiencies of transferrin in P(MAA-g-EG) before and after 
particle collapse and surface washing. 
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Figure 6.4 Polymer weight fractions of transferrin in loaded P(MAA-g-EG) 
microparticles. 
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Figure 6.5 Release profiles of transferrin loaded in P(MAA-g-EG) microparticles 
and placed in PBS buffer (pH 7.4). 
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Figure 6.6 Loading efficiencies of insulin-transferrin conjugates in P(MAA-g-EG) 
microparticles of differing crosslinker lengths before and after particle collapse and 
surface washing. 
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Figure 6.7 Polymer weight fractions of insulin-transferrin conjugates in P(MAA-g-
EG) formulations of differing crosslinker lengths. 
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Figure 6.8 Loading efficiencies of insulin-transferrin conjugates in P(MAA-g-EG) 
formulations of differing monomer-to-solvent ratios before and after particle collapse 
and surface washing. 
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Figure 6.9 Polymer weight fractions of insulin-transferrin conjugates in P(MAA-g-
EG) formulations synthesized using different monomer-to-solvent ratios. 
  186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
< 75 90-150 150-212
Particle Size Range (μm)
In
su
li
n
-T
ra
n
sf
e
rr
in
 L
o
a
d
e
d
 (
%
)
Initial
Final
Figure 6.10 Loading efficiencies of insulin-transferrin conjugates in P(MAA-g-EG) 
formulations of differing particle sizes before and after particle collapse and surface 
washing. 
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Figure 6.11 Polymer weight fractions of insulin-transferrin conjugates in P(MAA-g-
EG) formulations of different particle size ranges. 
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Figure 6.12 Loading efficiencies of insulin-transferrin conjugates in P(MAA-g-EG) 
and P(MAA-co-NVP) polymer formulations before and after particle collapse and 
surface washing. 
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Figure 6.13 Polymer weight fractions of insulin-transferrin conjugates in P(MAA-g-
EG) and P(MAA-co-NVP) polymer formulations. 
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Figure 6.14 Release profiles of insulin-transferrin conjugates loaded in P(MAA-g-EG) 
microparticles of differing crosslinker lengths and placed in PBS buffer (pH 7.4). 
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Figure 6.15 Release profiles of insulin-transferrin conjugates loaded in P(MAA-g-EG) 
microparticles of differing monomer-to-solvent ratios and placed in PBS buffer (pH 
7.4). 
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Figure 6.16 Release profiles of insulin-transferrin conjugates loaded in P(MAA-g-EG) 
microparticles of differing particle sizes and placed in PBS buffer (pH 7.4). 
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Figure 6.17 Release profiles of insulin-transferrin conjugates loaded in P(MAA-g-EG) 
and P(MAA-co-NVP) microparticles and placed in either PBS buffer (pH 7.4) or PBS 
buffer (pH 3.2). 
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CHAPTER 7 
EVALUATION OF CALCITONIN-TRANSFERRIN CONJUGATES BY INVESTIGATION INTO 
LOADING AND RELEASE PROPERTIES FROM COMPLEXATION HYDROGELS 
 
 
7.1 Introduction 
In determining the potential efficacy of a new drug formulation being released 
from a polymer carrier, it is first necessary to investigate the interactions that occur 
between the carrier and the drug formulations as well as to understand the effect in will 
have on final bioavailability.  Investigation into the interactions can consist of several 
different approaches.  To determine how effectively the drug formulation will be 
incorporated into the polymer network, studies can be performed to load the 
formulation into the carrier in a manner similar to the way it would be carried out in 
preparation of the dosage form in an industrial setting.  Once present within the 
polymer network, further studies can be performed to examine drug-polymer 
interactions with relation to release of the formulation from the carrier.  Such 
investigations would typically be performed under conditions which are made to closely 
mimic the physiological conditions that would be relevant at the time of release within 
actual patients.  Based on the results from the studies, either the formulation or the 
polymer carrier can be altered in such a way as to propagate the positive results and to 
create an optimal system for achieving maximum efficacy. 
In Chapter 5, the therapeutic protein calcitonin was bound to transferrin to 
create a protein-transporter conjugate designed to improve specificity of the uptake as 
well as to increase transport of calcitonin into the bloodstream.  The addition of 
transferrin to the therapeutic calcitonin offers a couple of advantages.  Transferrin is 
resistant to tryptic and chymotryptic degradation [1], thereby protecting calcitonin and 
making the conjugate itself also resistant to degradation.  Also, the ligand-receptor 
interaction which exists between transferrin and the transferrin receptor can be used to 
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increase specificity of the uptake as well to improve overall transport.  However, the 
addition of transferrin to calcitonin also drastically increases the size of the molecule 
being loaded and released from the polymer carriers.  In most cases, the increase in size 
of the encapsulated entity will have an adverse effect on the loading and release 
characteristics of the system.  To determine the effect of the incorporation of the 
calcitonin-transferrin conjugate on the system properties, loading and release studies 
need to be performed to gain insight on potential performance of the conjugates under 
relevant conditions.  Ideally, a large portion of the conjugate can be easily loaded into 
the network over a reasonable loading period and nearly all of the conjugate would be 
released within an hour upon introduction of the loaded particles into liquid simulating 
the small intestine. 
The process of loading refers to the incorporation of the conjugate into or onto 
the polymer component to form a single system.  Loading can occur in a number of 
different ways depending on the properties and requirements of the system.  In some 
systems, therapeutic molecules are bound to polymers to enhance system properties 
such as improved transport and better stealth characteristics [2-4].  If the therapeutic 
drug needs to be protected, such as with most proteins, some systems will contain a 
larger polymer component such as a carrier network.  In this case, the conjugate could 
still be covalently bound but are often times loaded into the polymer using diffusion.  
However, once loaded into the polymer network, it is also a lack of diffusion under 
certain conditions which keeps the conjugate molecule contained within the carrier [5, 
[6, 7].  Because the diffusion characteristics of the calcitonin-transferrin conjugate 
within the polymer network can be significantly altered using pH-responsive hydrogel 
carriers, the loading explored in this chapter is based on diffusion and occurs through 
equilibrium partitioning. 
Release of the loaded therapeutic entity could also occur in a number of 
different ways.  Most times, the release mechanism is simply the reverse process of the 
loading mechanism.  In the case of covalently bound therapeutic drugs, the bond is 
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typically broken by the presence of certain conditions or molecules and the drug can be 
released freely.  In the case of systems in which the drug was loaded using diffusion, the 
release also occurs based on diffusion but can be categorized in one of two ways.  The 
mechanism of release can be initiated from a contraction or deswelling of the polymer 
carrier, resulting in a burst release of loaded therapeutics [8-11].  In contrast, the 
mechanism of release can also be triggered by an expansion or swelling of the polymer 
system, increasing the effective diffusion in and out of the system and allowing the 
therapeutic entity to diffuse out.  In this chapter, release of calcitonin-transferrin 
conjugates from the polymer carriers is triggered by an expansion of the hydrogel 
carrier and subsequent increase in the effective diffusion of the conjugate. 
Analysis of the loading and release processes for calcitonin-transferrin 
conjugates presents a unique challenge based on the properties of the calcitonin 
molecule.  Unlike other therapeutic proteins such as insulin, calcitonin has an unusually 
high isoelectric point (pI) of approximately 8.0 [12].  In a loading process using calcitonin 
and anionic polymer hydrogels such as P(MAA-g-EG), the calcitonin molecules will 
contain a net positive charge due to the isoelectric point and the polymer carriers would 
contain overall negative charges in neutral media.  The opposite charge interaction that 
exists between calcitonin and the polymer carriers would make loading incredibly 
effective and fast.   
However, in release studies which are also performed in neutral media, the 
opposite charges create an attractive force which causes the calcitonin to remain in the 
polymer network, preventing any significant release.  Modification of calcitonin by 
conjugation to a molecule such as transferrin can help to overcome this unique 
challenge inherent to calcitonin.  Because of the drastically increased size and volume of 
transferrin relative to calcitonin, the addition of transferrin to calcitonin translates to a 
new molecule which takes on properties more similar to the original properties of 
transferrin.  As demonstrated in earlier chapters, transferrin can be easily loaded and 
released from anionic hydrogels.  The formation of calcitonin-transferrin conjugates, 
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while intended to increase specificity and overall transport, also serves the purpose of 
allowing efficient loading and release of therapeutic calcitonin with hydrogel carriers. 
The loading and release characteristics of calcitonin-transferrin conjugates in 
complexation hydrogels are affected by a number of factors inherent to the system 
design.  For example, it is essential to have an understanding of the possible interactions 
which may occur between the polymer and the conjugate when selecting materials on 
which to base a system.  A common interaction which has a profound effect on loading 
and release characteristics is the surface charge interaction of both the polymer and the 
conjugate.  The electrostatic forces which occur due to opposite charge attraction or like 
charge repulsion will have a significant effect on the rate and efficiency with which the 
conjugate loads and releases as well as how much is loaded and released.  Also 
important in selecting materials for use is the hydrophilicity of both materials.  Because 
loading and release is performed in solution, the respective hydrophilicities of both the 
polymer and conjugate play a significant role in whether the conjugate can load into the 
polymer properly. 
Another set of factors which can influence the loading and release of calcitonin-
transferrin conjugates are factors which relate to the diffusivity of the conjugate into 
and out of the polymer network.  A major factor affecting diffusion within the system is 
the mesh size of the polymer network.  The mesh size refers to the average space 
between crosslinks of the polymer network, or how much space there is for the 
conjugate to diffuse.  The mesh size of the polymer is a direct function of the synthesis 
parameters of the polymer formation and can be easily controlled.  Another factor 
affecting diffusion is the size of the conjugate molecule itself.  The larger the molecule, 
the more difficult it is for it to diffuse through a given space based on a known mesh size.  
While the size of the calcitonin-transferrin conjugate is mostly limited by the choice of 
therapeutic and transporter proteins, it can be partially controlled by limiting the 
number of calcitonin molecules that attach to each transferrin molecule.  The calcitonin 
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to transferrin ratio can be easily controlled by using specific protocol during the 
combination of the two modified proteins during the conjugate synthesis. 
The factors which affect loading and release of a system can generally be 
controlled by modifying specific design specifications.  For example, the diffusion within 
the system can be either enhanced or limited by controlling a number of specifications.  
Diffusion of the calcitonin-transferrin conjugate within the system can be increased by 
increasing the effective mesh size of the polymer network.  A method to accomplish 
increasing the mesh size is to lengthen the crosslinker used to connect the polymer 
network, which will ultimately make the mesh size larger and can lead to better overall 
release.  Also, by lowering the monomer-to-solvent ratio, the system becomes more 
porous and open and also leads to better overall release.  Diffusion can also be 
increased by limiting the final size of the synthesized conjugate product.  During the 
conjugation reaction of calcitonin-transferrin, the conjugate size is limited by stopping 
the reaction within 90 minutes.  Crosslinker length, monomer-to-solvent ratio, and 
conjugate size are all controllable synthesis parameters which can be manipulated to 
achieve optimal diffusivity of the conjugate within the system. 
Apart from factors affecting diffusivity within the system, other controllable 
parameters can also affect loading and release.  Manipulation of the carrier particle size 
has an effect on diffusion as well.  However, particle size does not affect the rate at 
which the conjugate diffuses, but rather the diffusion path length necessary for the 
conjugate to be released.  Smaller particle sizes translate to a shorter, less tortuous path 
to release, leading to a quicker release and a better overall release in a given time [13].  
Interactions which occur between the conjugate and polymer network can also have an 
effect on loading and release and can be controlled by the selection of materials for use 
in the system.   
In this chapter, calcitonin-transferrin conjugates are tested with both P(MAA-g-
EG) and P(MAA-co-NVP) polymer networks to determine which system has more 
desirable interactions with the conjugate molecule.  In fact, P(MAA-co-NVP) polymers 
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are thought to have a stronger interpolymer complexation [14] but it is relatively 
unknown if they will have a desirable interaction with calcitonin-transferrin conjugates.  
Particle size and the materials selected for use with the system are two controllable 
synthesis parameters which have an effect on overall loading and release but are not 
related to changing the diffusivity of the calcitonin-transferrin conjugate. 
The overall objectives of the studies performed in this chapter are to determine 
the performance with respect to loading and release of the calcitonin-transferrin 
conjugates with the hydrogel carriers already synthesized and also to optimize the 
system based on the results.  In a previous chapter, the polymer carriers which are 
typically used to load and release smaller proteins such as insulin were tested with 
transferrin, a large protein, and the protocols were sufficiently adjusted to achieve 
desirable loading and release characteristics.  In this chapter, calcitonin-transferrin 
conjugates will be loaded and released from a variety of polymer networks to examine 
performance and efficiency as well as determine which synthesis parameters lead to an 
optimal system.  At the conclusion of the studies in this chapter, the goal is to find a 
polymer network which can successfully load calcitonin-transferrin conjugates and can 
also quickly release a large portion of the loaded conjugate in conditions simulating the 
small intestine.  The ideal polymer for use with the calcitonin-transferrin conjugate will 
consist of specially selected materials and will be a precise combination of a number of 
synthesis parameters based on loading and release experiments performed in this 
chapter. 
 
7.2 Materials and Methods 
7.2.1 Polymer Microparticle Formation by UV Polymerization 
P(MAA-g-EG) and P(MAA-co-NVP) were prepared using a free radical UV 
polymerization in solution.  P(MAA-g-EG) was prepared by mixing MAA (Sigma-Aldrich 
Inc., St. Louis, MO) with poly(ethylene glycol) monomethyl ether monomethacrylate 
with a approximate molecular weight of 1000 (PEGMA1000, Polysciences Inc., 
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Warrington, PA) in a 1:1 molar ratio of MAA:EG.  P(MAA-co-NVP) was prepared by 
mixing MAA with NVP (Sigma-Aldrich Inc., St. Louis, MO) in a 1:1 molar ratio of 
MAA:NVP.  Crosslinking agents were then added into the monomer mixtures consisting 
of MAA/EG or MAA/NVP.  The crosslinking agents used within this study were 
tetraethylene glycol dimethacrylate (TEGDMA, Sigma-Aldrich Inc., St. Louis, MO) and 
poly(ethylene glycol) dimethacrylate with an approximately molecular weight of 1000 
(PEGDMA1000, Polysciences Inc., Warrington, PA).  The amount of crosslinker added to 
each monomer mixture was equal to 1 mol% of the total amount of monomer (MAA/EG 
or MAA/NVP).  In order to eventually initiate the polymerization, the photoinitiator 1-
hydroxycyclohexyl phenyl ketone (Irgacure 184, Sigma-Aldrich Inc., St. Louis, MO) was 
added to the polymerization mixture in the amount of 1 wt% of the total monomer 
added (MAA/EG or MAA/NVP).  A solvent mixture consisting of 50:50 by weight 
deionized water (Milli-Q Plus system, Millipore) and ethanol (AAPER Alcohol, Shelbyville, 
KY) was added to the polymer mixture in the amounts of either 50:50, 60:40, or 67:33 
by weight polymer mixture to solvent mixture.  The presence of the solvent solution is 
essential to prevent autopolymerization as well as to produce a workable thin polymer 
film. 
To ensure all components dissolved and went into a homogenous solution, the 
polymer mixture was sonicated for 15 minutes.  After sonication, nitrogen was bubbled 
through the polymer solution within a nitrogen environment to eliminate oxygen.  
Oxygen is a free radical scavenger and significant oxygen levels could prematurely end 
the polymerization process.  After removal of oxygen by nitrogen purging, the polymer 
mixture is poured between two glass slides (153 x 153 x 3 mm) separated by a Teflon 
spacer (0.7 mm) while still in a nitrogen environment.  The glass slide apparatus 
containing the polymer solution spread into a thin film was then placed under a UV light 
source while still in a nitrogen environment.  The solution was allowed to polymerize 
under the light source within an intensity range of 16-17 mW/cm2 for 30 minutes.  After 
the polymerization was completed, the polymer gels were removed from the nitrogen 
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environment, separated from the glass slides, and placed in deionized water.  The 
polymer films were washed in the deionized water for 7 days to remove excess 
monomer and contaminants.  After washing was completed, the polymers were dried in 
a vacuum oven at approximately 30° C for 2 days. 
After completely drying the polymer films, they were removed from the vacuum 
oven and crushed into microparticles using a mortar and pestle.  The crushed 
microparticles were then sieved into appropriate size ranges of either less than 75 
microns, 90-150 microns, or 150-212 microns.  The crushed and sieved microparticles 
were then stored in a vial within a desiccator to prevent moisture entering until further 
use. 
 
7.2.2 Loading of Calcitonin-Transferrin Conjugates into Polymer Microparticles 
Based on the previously established success of P(MAA-g-EG) being able to load 
large molecules, calcitonin-transferrin conjugates were loaded into a number of 
polymer formulations.  The polymer formulations included P(MAA-g-EG) and P(MAA-co-
NVP) and varied by synthesis parameters such as crosslinker length, monomer-to-
solvent ratio, and particle size.   
As a result of the previous conjugation reaction, calcitonin-transferrin conjugates 
were already dissolved in a PBS buffer (pH 7.4) at a known concentration as measured 
by HPLC.  Calcitonin-transferrin stock solutions were prepared by diluting the conjugate 
solutions with PBS buffer (pH 7.4) to a concentration of 1 mg/mL and a volume of 40 mL.  
The stock solutions were placed in glass beakers which were siliconized using Sigmacote 
to reduce protein adhesion to the glass.  To initiate the loading process, 280 mg of 
P(MAA-g-EG) or P(MAA-co-NVP) microparticles were added to each calcitonin-
transferrin stock solution to reach a concentration of 7 mg/mL.  Within the calcitonin-
transferrin loading experiments, the conjugates were loaded into numerous different 
polymer formations which differed by crosslinker length, monomer-to-solvent ratio, 
particle size, and comonomer used.  The calcitonin-transferrin conjugates in each 
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solution were allowed to load by equilibrium partitioning for 4 hours under constant 
stirring.  At the conclusion of the loading period, 40 mL of 0.1 N HCl was added to the 
solution to lower the pH and collapse the particles.  After allowing the particles to fully 
collapse, the loaded microparticles were filtered by passing the solution through filter 
paper.  The particles were then washed using 2 mL deionized water to remove any 
excess calcitonin-transferrin conjugates adhered to the surface of the particle.  The 
collected microparticles were then frozen at -80° C and lyophilized overnight to remove 
any excess water content.  Once the lyophilization process had completed, the loaded 
microparticles were stored in a desiccator in a freezer until further use. 
To determine initial concentration, an initial sample was taken before addition of 
microparticles and analyzed by HPLC.  In order to calculate loading efficiencies at various 
time points of the loading process, additional samples were withdrawn after the end of 
the loading period, after the addition of HCl, and after the filtering of microparticles.  
Sampling at the end of the loading period gives an initial loading efficiency based solely 
on equilibrium partitioning.  Taking a sample after the addition of HCl allows 
observation of the difference in loading from expulsion of protein molecules due to 
particle collapse.  The final sample after filtering is used to determine a final loading 
percentage and also to determine the initial amount of calcitonin-transferrin conjugate 
being introduced in the release study.  All withdrawn samples were filtered through 
syringe filters (PVDF, 0.22 μm) to ensure only free protein is being analyzed.  All four 
samples for each loading procedure were analyzed using HPLC. 
 
7.2.3 Calcitonin-Transferrin Conjugate Release Studies 
Release studies for a therapeutic protein loaded into a polymer carrier are 
essential to understanding the dynamics of the system as well as to gain insight on the 
possible performance of the formulation when administered to human subjects.  
Specifically, release studies are necessary to shed light on two different properties of 
the system.  The first property is the speed at which the conjugate is released.  If 
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diffusion is too slow and significant release takes over an hour, then very little conjugate 
will be absorbed because of a finite residence time in the small intestine due to 
intestinal motility.  Also, the overall amount of conjugate released into solution is very 
important as well.  If a significant portion of loaded conjugate is not released from the 
microparticle within the residence time at the site of absorption, the chances for 
achieving a useful bioavailability in the bloodstream drops significantly. 
Calcitonin-transferrin conjugate release studies were performed by placing 
approximately 10 mg of conjugate-loaded microparticles in 50 mL of PBS buffer (pH 7.4) 
in a dissolution apparatus.  The dissolution apparatus water bath was maintained at 37° 
C and the experimental solutions were kept under constant stirring using impellers at 
100 rpm.  As the microparticles began to swell and release calcitonin-transferrin 
conjugates after addition to neutral buffer, small samples of 0.2 mL were taken at time 
points of 5, 10, 15, 30, 60, and 120 minutes to obtain release profiles versus time.  The 
volume of the solution was maintained at 50 mL by addition of 0.2 mL of PBS buffer 
after each sample withdrawal.  Needles were used with the syringes to minimize particle 
uptake and the sample volume was passed through syringe filters (PVDF, 0.22 μm) to 
ensure only free calcitonin-transferrin conjugates were being analyzed. 
The initial amount of calcitonin-transferrin conjugates in the mass of particles 
added to the release study was determined by the data obtained from the previous 
calcitonin-transferrin loading experiments.  Based on this initial mass of conjugate 
available for release, the free calcitonin-transferrin concentration at each time point 
was used to calculate a percentage of calcitonin-transferrin released up to that point.  
By analyzing several time points using HPLC to determine conjugate concentration in 
solution, it was possible to generate a release profile which indicates the rate at which 
calcitonin-transferrin is released as well as the total overall amount released. 
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7.2.4 Protein Sample Concentration Analysis by HPLC 
High Performance Liquid Chromatography (HPLC) was used to analyze samples 
containing calcitonin-transferrin conjugates dissolved in PBS buffer (pH 7.4).   The 
samples analyzed came from the loading and release studies for the calcitonin-
transferrin conjugate.  HPLC analysis was used for each sample to determine 
concentration based on absorbance values relative to absorbances of standard samples 
of known concentrations.  Determining sample concentrations allows for the calculation 
of free protein in solution as well as loading efficiencies and release profiles. 
The HPLC equipment used consists of a Waters 2695 Separation Module (Waters 
Corporation, Milford, MA) attached to a Waters 2487 Dual λ Absorbance Detector 
(Waters Corporation, Milford, MA).  Analysis is performed using a reverse-phase 
analytical HPLC method designed to elute a wide range of proteins within a specified 
time period.  The method includes the use of water (HPLC Grade, Fisher Scientific, Fair 
Lawn, NJ) with 0.1% by volume trifluoroacetic acid (TFA, ACROS Organics, Geel, Belgium) 
as Solvent A and acetonitrile (Optima, Fisher Scientific, Fair Lawn, NJ) with 0.08% by 
volume TFA as Solvent B.  During the separation process, the mobile phase begins at a 
composition of 70% Solvent A and 30% Solvent B.  The mobile phase changes 
composition using a gradient to 40% Solvent A and 60% Solvent B within 6 minutes.  The 
mobile phase composition is then returned to initial conditions of 70% Solvent A and 
30% Solvent B for the next sample to be analyzed.  The mobile phase was introduced at 
a constant flow rate of 0.6 mL/min.  All separations are performed using a 
Symmetry300TM C4 column (particle size 5 µm, 3.9 mm I.D. x 150 mm length, Waters 
Corporation, Milford, MA) held at a constant temperature of 40°C.  After separation of 
proteins, absorbance of the solution was detected at a wavelength of 220 nm.  All 
instrument and processing methods were controlled and specified using the Empower 
software. 
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7.3 Results and Discussion 
7.3.1 Polymer Microparticle Formation by UV Polymerization 
A number of different formulations of polymer microparticles were synthesized 
for use in the loading and release experiments conducted in this chapter.  Many 
different formulations were created including P(MAA-g-EG) and P(MAA-co-NVP) while 
also varying synthesis parameters such as crosslinker length (4 repeat units and 23 
repeat units), monomer-to-solvent ratio (67:33, 60:40, and 50:50), and particle size (less 
than 75 microns, 90-150 microns, and 150-212 microns).  The use of different systems 
yielded different results based on the effect of the synthesis parameters on loading and 
release studies.  At the conclusion of the studies, a specific polymer formulation was 
chosen as the optimal formulation for use with calcitonin-transferrin conjugates. All 
formulations were successfully synthesized and determined to be usable for 
demonstrating loading and release characteristics of calcitonin-transferrin conjugates in 
conditions which mimic physiological environments. 
 
7.3.2 Loading of Insulin-Transferrin Conjugates into Polymer Microparticles 
To determine the performance characteristics of calcitonin-transferrin 
conjugates, they were loaded into P(MAA-g-EG) formulations.  Several formulations 
were investigated to determine the effect of various synthesis parameters on loading 
and release characteristics of the system.  The polymer microparticles tested included 
varying crosslinker lengths (4 repeat units and 23 repeat units), monomer-to-solvent 
ratios (67:33, 60:40, and 50:50), particle size (less than 75 microns, 90-150 microns, and 
150-212 microns), and comonomer used (to form both P(MAA-g-EG) and P(MAA-co-
NVP)).  Based on the results from the investigation of each synthesis parameter, an ideal 
formulation in terms of loading can be identified for use with calcitonin-transferrin 
conjugates. 
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Analysis of the Effect of Crosslinker Length on Calcitonin-Transferrin Loading:  
Calcitonin-transferrin conjugates were loaded into two different P(MAA-g-EG) 
formulations which differed only by the length of the crosslinker.  The crosslinkers used 
were TEGDMA (4 ethylene glycol repeat units) and PEGDMA1000 (approximately 23 
ethylene glycol repeat units).  Loading efficiencies were calculated at specific points 
throughout the loading process for both formulations using Equation 7.1 as shown 
below: 
 
 
 
The loading efficiencies for calcitonin-transferrin in the specified formulations are 
shown as Figure 7.1. 
Figure 7.1 shows that a significant portion of the calcitonin-transferrin 
conjugates were effectively loaded into the P(MAA-g-EG) microparticles.  Also, it shows 
that the presence of a longer crosslinker had a significant effect on the amount of 
conjugate loaded into the polymer network.  The system that is crosslinked with the 
much shorter crosslinker TEGDMA achieves a final loading efficiency that is well over 
double the loading efficiency of the PEGDMA1000 crosslinked system.  The reason for 
the noticeable difference is twofold.  The use of a shorter crosslinker creates a more 
rigid network, forcing conjugate already loaded into the network to most likely remain 
in the polymer network due to the difficult path to diffuse out of the network.  Also, 
upon particle collapse and surface rinsing, the longer crosslinker network is more open 
and loose, allowing more protein to be squeezed out due to contraction of the network.  
It is also interesting to note that a slightly higher loading efficiency in the TEGDMA 
crosslinked system is achieved after addition of acid.   
The additional loaded conjugate can most likely be attributed to an increased 
charge interaction due to the presence of calcitonin and the significant lowering of 
solution pH.  However, the increase is only minimal and is within the error of the data 
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samples.  In comparing the two polymer formulations, the loading efficiencies are 
important to obtain but less important in choosing an ideal polymer for carrying 
calcitonin-transferrin conjugates.  As previously mentioned, conjugate which is not 
loaded can potentially be recovered in an industrial process.  The full analysis of 
crosslinker length with respect to optimization of the system can only occur after 
examining the subsequent release studies.  While release studies have a major effect on 
maximum potential bioavailability, loading studies theoretically do not.  However, 
loading efficiencies are important to understand and these experiments demonstrate 
that a significant portion of conjugate can be loaded. 
 Another indication of performance in loading studies is the polymer weight 
fraction of calcitonin-transferrin conjugates, or the weight fraction of the loaded 
microparticles which can be attributed to the presence of calcitonin-transferrin 
molecules.  Because of the nature of loading protocols, the polymer weight fraction for 
most proteins is typically somewhat low (0.04-0.14) relative to the weight of the 
polymer.  However, if the polymer weight fraction of a protein is even lower, then it 
would take a large amount of polymer to deliver a small amount of therapeutic protein, 
translating to an increased materials cost as well as larger dosage forms.  Polymer 
weight fractions were calculated by taking the difference between the initial mass of 
protein in solution (M0) and the final mass of protein in the solution (Mf) and dividing by 
the same difference (M0 – Mf) added to the weight of polymer in the solution (Mp).  
Polymer weight fractions were calculated using Equation 7.2 as shown below: 
 
 
The polymer weight fractions of calcitonin-transferrin in each formulation previously 
mentioned are shown as Figure 7.2. 
 Figure 7.2 demonstrates that a larger fraction of a possible dosage form will be 
comprised of therapeutic calcitonin-transferrin conjugates in systems which contain 
shorter crosslinkers.  A similar tendency can be observed in the loading efficiencies, but 
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the polymer weight fraction analysis also demonstrates the need to create larger dosage 
forms if the use of a longer crosslinker proves optimal based on release studies.  
However, the value of the polymer weight fraction for the longer crosslinked system 
indicates that a significant portion of the total dosage form is still calcitonin-transferrin, 
even though it is a reduced fraction relative to the shorter crosslinked system.  While 
adjusting synthesis parameters, the benefits and drawbacks are often linked in such a 
way that the optimal system requires a balance of specific synthesis parameters. 
 
Analysis of the Effect of Monomer-to-Solvent Ratios on Calcitonin-Transferrin Loading:  
Loading studies were performed by loading calcitonin-transferrin conjugates into three 
P(MAA-g-EG) polymer formulations which differed only by monomer-to-solvent ratios 
used during the synthesis procedure.  The formulations included monomer-to-solvent 
ratios of 67:33, 60:40, and 50:50.  Loading efficiencies were calculated at specific points 
throughout the loading process for all formulations using Equation 7.1.  The loading 
efficiencies for calcitonin-transferrin conjugates in the specified formulations are shown 
as Figure 7.3. 
As can be seen in Figure 7.3, all three of the polymer formulations were able to 
successfully load a large portion of the calcitonin-transferrin conjugates.  Also, it is clear 
that the monomer-to-solvent ratio had a significant effect on the loading efficiencies of 
calcitonin-transferrin.  The effect of monomer-to-solvent ratio on conjugate loading 
differs significantly in the case of the calcitonin-transferrin conjugate compared to the 
insulin-transferrin conjugate where there was no effect.  In the case of calcitonin-
transferrin conjugates, it appears that the addition of more monomer relative to solvent 
significantly decreases the loading efficiencies, particularly the final loading efficiency 
values.  Changing the monomer-to-solvent ratio during the synthesis of the polymer in 
effect changes the way in which diffusion occurs within the system.  If a polymer 
network is formed with very little solvent and mostly monomer, such as in the 67:33 
formulation, then the diffusion is based solely on the effective mesh size of the network 
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and the conjugate must be able to diffuse between the crosslinked polymer strands.  
However, if the synthesis is carried out with the presence of more solvent, such as in the 
50:50 formulation, the polymer network is forced to form around the solvent molecules, 
creating a more porous and open network.  The additional solvent increases the 
“effective mesh size” of the system by allowing conjugates to diffuse through larger 
spaces, or pores, created by the presence of solvent.  In this case, the system in which 
diffusion is based on porosity of the network achieved higher loading of calcitonin-
transferrin conjugates than the systems where diffusion is based primarily on a smaller 
mesh size.  In order to optimize the polymer carriers with respect to monomer-to-
solvent ratios, it is necessary to examine the effect of the monomer-to-solvent ratio on 
release of the conjugates from the polymer carriers. 
The effect of the monomer-to-solvent ratios on loading of calcitonin-transferrin 
conjugates was observed further by examining the polymer weight fractions of the 
conjugate-loaded microparticles as calculated by Equation 7.2.  The polymer weight 
fractions for calcitonin-transferrin loaded in all three formulations are shown in Figure 
7.4.  Similar to the loading efficiencies, there a significant effect of the monomer-to-
solvent ratio on the polymer weight fraction.  The highest polymer weight fraction exists 
in the system which used the most solvent in the prepolymer mixture.  The use of a 
system with high polymer weight fraction attributed to the conjugate translates to a 
more practical therapeutic dosage form. 
 
Analysis of the Effect of Particle Size on Calcitonin-Transferrin Loading:  Calcitonin-
transferrin conjugates were loaded into three P(MAA-g-EG) formulations differing only 
in the average size of the microparticles.  The three particle size ranges of formulations 
tested include less than 75 microns, 90-150 microns, and 150-212 microns.  Loading 
efficiencies were calculated at specific points throughout the loading process for all 
formulations using Equation 7.1.  The loading efficiencies for calcitonin-transferrin 
conjugates in the specified formulations are shown as Figure 7.5. 
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 Figure 7.5 illustrates that a significant portion of calcitonin-transferrin conjugates 
were successfully loaded into all three polymer formulations.  Also, the difference in 
particle size appears to have an effect on both the initial and final loading efficiencies.  
The effect of the particle size of a polymer carrier can be described in terms of volume 
or in terms of diffusion path length.  As the diameter of the particle is increased, the 
volume of the particle increases exponentially and is able to carry or load more 
conjugate molecules.   
However, conjugate molecules which are loaded into the center of the polymer 
network of a larger particle have a longer diffusion path length in order to diffuse out of 
the system.  The longer diffusion path means a more tortuous journey for the conjugate 
molecules and thus a slower and less complete release.  In terms of loading, the effect 
of particle size is most directly related to the volume that the particle can hold.  
Specifically, the surface area-to-volume ratio has some effect on the amount of 
conjugate loaded in each formulation.  Among the three formulations, the smallest 
particles achieved the both the highest initial and final loading efficiencies compared to 
the larger particles.  In the case of loading calcitonin-transferrin conjugates, the initial 
loading efficiencies were similar, indicating that volume considerations and surface 
area-to-volume ratios have little to do with the initial loading of this particular conjugate.  
However, the effect of particle size can be observed after collapse and surface washing 
of the microparticles.  With respect to final loading efficiencies, the smaller particles 
exhibited more desirable loading characteristics for loading calcitonin-transferrin 
conjugates.  To fully optimize the system with respect to particle size, release studies 
must be performed to determine the full effect of the particle size of the carrier. 
Additional insight into the effect of particle size on the loading of calcitonin-
transferrin conjugates in P(MAA-g-EG) microparticles was gained by analyzing the 
polymer weight fractions of the conjugate as calculated by Equation 7.2.  The polymer 
weight fractions for calcitonin-transferrin conjugates loaded in all three formulations are 
shown in Figure 7.6.  As evident in the figure, the polymer weight fraction due to the 
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calcitonin-transferrin conjugate decreased as the particle size was increased.  Therefore, 
use of smaller microparticles as carriers for calcitonin-transferrin conjugates is more 
desirable due to the practical advantage of being able to administer smaller dosage 
forms.  Also, the polymer weight fractions attributed to the conjugate in the cases of the 
two larger particle sizes are low (<0.035), which means an effective dosage form would 
require much more polymer and consequently would be much larger, decreasing 
effectiveness and potential profit margins. 
 
Analysis of the Effect of the Replacement of PEG Comonomer with NVP Comonomer on 
Calcitonin-Transferrin Loading:  Loading studies were performed by loading calcitonin-
transferrin conjugates into P(MAA-g-EG) and P(MAA-co-NVP) polymer microparticles 
which differed only by the comonomer used.  Loading efficiencies were calculated at 
specific points throughout the loading process for both formulations using Equation 7.1.  
The loading efficiencies for calcitonin-transferrin conjugates in P(MAA-g-EG) and 
P(MAA-co-NVP) are shown as Figure 7.7. 
 As can be seen in Figure 7.7, both P(MAA-g-EG) and P(MAA-co-NVP) were able to 
effectively load a significant portion of calcitonin-transferrin conjugates placed in 
solution.  Also, the difference between the two formulations with respect to loading 
efficiencies was evident in both the initial and final loading efficiencies.  While P(MAA-g-
EG) had higher initial and final loading efficiencies, it is interesting to note that there 
was virtually no decrease in loading efficiency before and after particle collapse and 
surface washing for P(MAA-co-NVP).  The differences in loading between the systems 
can be attributed to the different interactions between the calcitonin-transferrin 
conjugate and either the PEG tethers or NVP repeat units.  Interactions which may have 
an effect include surface charge interactions, physical hindrance, hydrophilicity, and 
interpolymer interactions.  Based on the results, the loading efficiencies were 
significantly affected by the interactions based on the presence of the comonomer both 
before and after particle collapse and surface washing.  The presence of a specific 
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comonomer is likely to have an even more significant role in the subsequent release 
studies because of the importance of the interpolymer interactions governing the rate 
of swelling as well as the hydrophilicity of each group significantly affecting the release 
properties. 
 The effect of the presence of the PEG and NVP comonomers on the loading of 
calcitonin-transferrin conjugates was further investigated by determining the polymer 
weight fractions of calcitonin-transferrin as calculated by Equation 7.2.  The polymer 
weight fractions for calcitonin-transferrin conjugates loaded in both P(MAA-g-EG) and 
P(MAA-co-NVP) are shown in Figure 7.8.  Similar to the loading efficiencies, a significant 
difference was observed between the polymer weight fractions of the calcitonin-
transferrin conjugate in P(MAA-g-EG) and P(MAA-co-NVP).  The polymer weight fraction 
of calcitonin-transferrin in P(MAA-g-EG) was well over double of the polymer weight 
fraction of the conjugate in P(MAA-co-NVP).  Also, it is important to note that P(MAA-g-
EG) had a polymer weight fraction above 0.08, indicating that the polymer could serve 
as a potential carrier for calcitonin-transferrin conjugates in a dosage form.  As with all 
four synthesis parameters investigated, system optimization will most likely depend 
more on the release characteristics in simulated physiological conditions because of the 
increased effect on potential bioavailability.  However, loading studies are important to 
perform with respect to each synthesis parameter in order to verify loading of a 
significant amount of conjugate, to obtain polymer weight fractions to better envision 
the possibility of an effective and practical dosage form, and to better understand how 
each manipulated synthesis parameter affects the diffusion of the conjugate within the 
polymer network.  
 
7.3.3 Calcitonin-Transferrin Conjugate Release Studies 
Calcitonin-transferrin conjugates were loaded into a number of different 
polymer formulations including P(MAA-g-EG) and P(MAA-co-NVP) synthesized using a 
number of different synthesis parameters.  The formulations were found to all be able 
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to load an appreciable amount of calcitonin-transferrin conjugate in solution as well as 
having a significant polymer weight fraction attributed to the protein.  The conjugate-
loaded microparticles from each formulation were then investigated using release 
studies.  The formulations included systems with varying crosslinker lengths (4 repeat 
units and 23 repeat units), monomer-to-solvent ratios (67:33, 60:40, and 50:50), particle 
size (less than 75 microns, 90-150 microns, and 150-212 microns), and comonomer used 
(to form both P(MAA-g-EG) and P(MAA-co-NVP)).  Based on the results obtained from 
the investigation of the loading and release studies for each synthesis parameter, an 
optimal polymer formulation to achieve maximum potential bioavailability was 
identified and chosen for future use with calcitonin-transferrin conjugates. 
 
Analysis of the Effect of Crosslinker Length on the Release of Calcitonin-Transferrin:  
Calcitonin-transferrin conjugates were previously loaded into two different P(MAA-g-
EG) formulations which differed only in the length of the crosslinker.  The crosslinkers 
used were TEGDMA (4 ethylene glycol repeat units) and PEGDMA1000 (approximately 
23 ethylene glycol repeat units).  Release studies were performed by placing the 
conjugate-loaded microparticles in PBS buffer (pH 7.4) and measuring the conjugate 
concentration in solution over time.  The percentage released at each time point was 
calculated by taking a ratio of the amount of conjugate at the specified time to the 
initial amount of conjugate present in the loaded particles.  The release profiles for 
calcitonin-transferrin as released from the specified formulations are shown as Figure 
7.9. 
Figure 7.9 shows that while both formulations released a significant amount of 
conjugate within 2 hours, the longer crosslinked system released approximately 30% 
more than the system crosslinked with TEGDMA by the conclusion of the release period.  
The significant difference in release is a result of the effect of incorporation of a longer 
crosslinker within the polymer network.  The crosslinker PEGDMA1000 is over 5 times 
longer than TEGDMA, creating a polymer network with a larger mesh size which 
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consequently is more open to diffusion of a large molecule such as the conjugate.  The 
increased space between polymer strands allows loaded conjugate in the PEGDMA1000 
crosslinked formulation to diffuse out of the system much quicker and in a higher 
quantity over a specified time period.  The loading and polymer weight fraction results 
demonstrate a preference for using the TEGDMA crosslinked system, but the release 
profiles clearly justify the use of longer crosslinkers for polymer carriers for insulin-
transferrin conjugates.  From within 10 minutes into the study to the conclusion, the 
amount of calcitonin-transferrin conjugate released from the PEGDMA1000 crosslinked 
system is an additional 50% relative to the amount released from the TEGDMA 
crosslinked system.  Because of the improved release using a longer crosslinker, even 
longer crosslinkers such as PEGDA4000 were used as crosslinkers in some experimental 
systems.  However, the resultant polymer films were not rigid enough and were 
unmanageable due to the introduction of an extremely long crosslinker.  However, the 
additional calcitonin-transferrin conjugate released in the case of the PEGDMA1000 
crosslinked formulation relative to the TEGDMA crosslinked system equates to higher 
potential bioavailability and increased potential efficacy of a possible oral formulation. 
 
Analysis of the Effect of Monomer-to-Solvent Ratios on the Release of Calcitonin-
Transferrin:  Calcitonin-transferrin conjugates were previously loaded into three 
different P(MAA-g-EG) formulations which differed only in the monomer-to-solvent 
ratios used during synthesis.  The formulations included monomer-to-solvent ratios of 
67:33, 60:40, and 50:50.  Release studies were performed by placing the conjugate-
loaded microparticles in PBS buffer (pH 7.4) and measuring the conjugate concentration 
in solution over time.  The percentage released at each time point was calculated by 
taking a ratio of the amount of conjugate at the specified time to the initial amount of 
conjugate present in the loaded particles.  The release profiles for calcitonin-transferrin 
as released from the specified formulations are shown as Figure 7.10. 
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 Figure 7.10 illustrates that all three formulations were able to release at least a 
sizable portion of the loaded calcitonin-transferrin conjugates.  The data also shows that 
changing the monomer-to-solvent ratio has very little effect on release of calcitonin-
transferrin other than a quicker initial release in the case of the system which contained 
the most solvent (50:50).  Changing the balance of the monomer-to-solvent ratio in the 
prepolymer mixture in effect changes the way in which diffusion occurs throughout the 
system.  If a large amount of monomer relative to solvent is used, such as in the 67:33 
formulation, then diffusion characteristics are based solely on the effective mesh size of 
the network, forcing the conjugate to diffuse within the spaces created between the 
crosslinked polymer strands.  However, if the monomer-to-solvent ratio is changed to 
favor adding more solvent, such as in the 50:50 formulation, the polymer network forms 
around the solvent molecules, creating a more porous and open network.  The 
additional solvent increases the “effective mesh size” of the system by allowing 
conjugates to diffuse through larger spaces, or pores, created by the presence of solvent 
in the prepolymer mixture.  In the case of the release of calcitonin-transferrin, the 
increased “effective mesh size” and increased diffusion only generated the small effect 
of increasing the amount released with 10-15 minutes.  However, even though the 
release characteristics varied very little between the three formulations, the loading 
studies combined with a higher initial release clearly require that the monomer-to-
solvent ratio of the prepolymer mixture must be as low as possible to achieve an 
optimal system.  Because more solvent present in the synthesis led to preferable system 
properties, experimental systems were synthesis with monomer-to-solvent ratios of 
40:60 and 33:67.  However, the syntheses produced films which were gel-like and 
unmanageable in terms of washing excess monomer and subsequent crushing.  The 
formulation successfully synthesized using the lowest monomer-to-solvent ratio, which 
was 50:50, was chosen as the optimal system because of the significantly better loading 
characteristics as well as the prospect of delivering more calcitonin-transferrin to the 
site of absorption over a short time period. 
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Analysis of the Effect of Particle Size on the Release of Calcitonin-Transferrin:  
Calcitonin-transferrin conjugates were previously loaded into three different P(MAA-g-
EG) formulations which differed only in particle size.  The formulations included P(MAA-
g-EG) microparticles in size ranges of less than 75 microns, 90-150 microns, and 150-212 
microns.  Release studies were performed by placing the conjugate-loaded 
microparticles in PBS buffer (pH 7.4) and measuring the conjugate concentration in 
solution over time.  The percentage released at each time point was calculated by taking 
a ratio of the amount of conjugate at the specified time to the initial amount of 
conjugate present in the loaded particles.  The release profiles for calcitonin-transferrin 
as released from the specified formulations are shown as Figure 7.11. 
 As can be seen in Figure 7.11, all three formulations were able to release a 
significant portion of the loaded calcitonin-transferrin conjugate.  However, there is a 
substantial increase in the overall amount of conjugate released as the particle size 
becomes smaller and smaller.  The relationship between amount of conjugate released 
and particle size of the carrier can best be described by the concept of diffusion path 
length.  In smaller particles, the loaded conjugate has a shorter distance to diffuse 
before being completely released from the system.  In contrast, a large molecule 
presents a more tortuous and longer path for the release of conjugate, translating to 
slower release and a reduction in overall release over a short period.  The diffusion path 
length plays a considerable role in the release characteristics of the conjugate and can 
drastically change the release profiles of the dosage form.  Based on the results, the 
ideal particle size for polymer carriers for calcitonin-transferrin conjugates was 
determined to be less than 75 microns.  It is difficult to reduce the upper end of the size 
range due to the difficulty in creating smaller particles using the crushing method which 
uses a mortar and pestle.  If a different type of polymerization were used which could 
control the size down to a smaller range, the release of conjugates would likely see even 
greater benefit.  However, using the specific protocol outlined in Chapter 4, the 
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microparticles of size range of less than 75 microns were used to achieve the highest 
potential bioavailability. 
 
Analysis of the Effect of the Replacement of PEG Comonomer with NVP Comonomer on 
the Release of Calcitonin-Transferrin:  Calcitonin-transferrin conjugates were previously 
loaded into P(MAA-g-EG) and P(MAA-co-NVP) formulations which differed only by the 
comonomer used.  Release studies were performed by placing the conjugate-loaded 
microparticles in PBS buffer (pH 7.4) as well as PBS buffer (pH 3.2) and measuring the 
conjugate concentration in solution over time.  The release studies performed under 
acidic conditions were performed to examine how the particles would perform in the 
collapsed state, or to observe if any conjugate was prematurely released in conditions 
mimicking the stomach.  The percentage released at each time point was calculated by 
taking a ratio of the amount of conjugate at the specified time to the initial amount of 
conjugate present in the loaded particles.  The release profiles for calcitonin-transferrin 
as released from the specified formulations are shown as Figure 7.12. 
 Figure 7.12 illustrates that both P(MAA-g-EG) and P(MAA-co-NVP) polymer 
formulations were able to release a portion of the loaded calcitonin-transferrin 
conjugate under neutral pH conditions.  However, release studies performed under 
acidic conditions showed that P(MAA-g-EG) released a minute fraction of the loaded 
conjugate while P(MAA-co-NVP) did not release any conjugate under acidic conditions. 
Also, the release studies performed under neutral conditions showed that the P(MAA-g-
EG) polymer formulation far outperformed the P(MAA-co-NVP) formulation by releasing 
much more conjugate over the entire release period.  The major difference between 
these two comonomers is the interpolymer interactions and the resultant degree of 
complexation.  NVP is thought to have a higher degree of complexation with MAA than 
PEG does, allowing for the interpolymer bonds in P(MAA-co-NVP) to be stronger than 
those in P(MAA-g-EG).  The selection of NVP as a possible replacement for the PEG 
comonomer was based on its degree of complexation and such a property was 
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determined to have an advantageous effect on protection of the conjugate under acidic 
conditions.  However, it was the strong interpolymer interactions which also most likely 
limited the release of conjugate from P(MAA-co-NVP) particles.  While the degree of 
complexation in the collapsed state may have been higher in P(MAA-co-NVP), the 
P(MAA-g-EG) particles released very little of the conjugate under acidic conditions, 
demonstrating that the P(MAA-g-EG) system also has a suitably high degree of 
complexation.  Therefore, the additional complexation in the collapsed state in the 
P(MAA-co-NVP) system was deemed unnecessary for protection of a large molecule 
such as the calcitonin-transferrin conjugate.  In fact, the strong complexation in the 
P(MAA-co-NVP) system most likely limited the release of the conjugate under neutral 
conditions while the relatively weaker complexation allowed for greater release in the 
P(MAA-g-EG) system.  If the therapeutic were a smaller protein, such as insulin by itself, 
the additional protection from the complexation of P(MAA-co-NVP) may be necessary.  
Moreover, in the less complexed system of P(MAA-g-EG), the insulin may be able to 
diffuse out under acidic conditions.  However, for the specific case of the calcitonin-
transferrin conjugate, the P(MAA-g-EG) microparticles were found to be the preferred 
formulation as a carrier for the conjugate because of the significantly improved release 
and concurrently the improved potential bioavailability of a possible oral formulation. 
 
Determination of an Optimal Polymer Formulation for the Delivery of Calcitonin-
Transferrin Conjugates:  Several polymer formulations were synthesized in an effort to 
determine an optimal polymer formulation to achieve high bioavailability of orally 
delivered calcitonin-transferrin conjugates.  The polymer formulations included P(MAA-
g-EG) and P(MAA-co-NVP) while also varying synthesis parameters such as crosslinker 
length (4 repeat units and 23 repeat units), monomer-to-solvent ratio (67:33, 60:40, and 
50:50), and particle size (less than 75 microns, 90-150 microns, and 150-212 microns).  
Each formulation was loaded with calcitonin-transferrin conjugates and subsequently 
released to determine loading efficiencies and release profiles.  As each synthesis 
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parameter was investigated, all other synthesis parameters and values were held 
constant.  At the conclusion of the studies, the release characteristics were the primary 
determining factor in selecting an optimal carrier.  The loading efficiencies and polymer 
weight fractions were determined to verify that each formulation could indeed load a 
significant portion of conjugate and also the loading studies were used as a secondary 
criteria for selecting the optimal polymer carrier for calcitonin-transferrin conjugates. 
 The investigation of the effect of crosslinker length yielded that the longest 
crosslinker (PEGDMA1000) would provide the best release characteristics.  After testing 
monomer-to-solvent ratios, it was determined that release profiles differed very little 
but including as much solvent as possible in the prepolymer mixture (50:50 monomer-
to-solvent) was chosen to obtain a quicker initial release and more desirable loading 
characteristics.  The experiments on the effect of particle size of the carrier 
demonstrated that the smallest particles (less than 75 microns) achieved the highest 
overall release.  The studies in which the PEG comonomer was replaced with the NVP 
comonomer illustrated that while NVP may complex better under acidic conditions, the 
extra protection in mostly unnecessary in the case of a large molecule such as 
calcitonin-transferrin conjugates and that P(MAA-g-EG) particles are preferred as 
carriers due to the much improved release characteristics.  Within the parameters 
specified in this chapter and manipulation only to the extent that polymers could be 
successfully synthesized, the ideal polymer carrier for oral delivery of calcitonin-
transferrin conjugates was found to be P(MAA-g-EG) particles synthesized using a 
monomer-to-solvent ratio of 50:50, crosslinked with PEGDMA1000, and having a 
particle size of less than 75 microns. 
 
7.3.4 Protein Sample Concentration Analysis by HPLC 
All samples obtained from loading and release studies were analyzed by HPLC.  
The concentration of each sample was determined by comparisons to standards of 
known concentrations.  The experimental concentration of each sample was used to 
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calculate the free protein concentration in the solution at the time the sample was 
withdrawn.  In the cases of values of zero concentration as in the release studies 
performed under acidic conditions, the free protein in the samples was at a 
concentration low enough to be undetectable by HPLC. 
 
7.4 Conclusions 
Calcitonin-transferrin conjugates were successfully synthesized and required 
investigation into the in vitro characteristics with relation to loading and release in 
polymer microparticle carriers.  To determine the ideal polymer formulation to use as a 
carrier for the conjugate, several polymer formulations were tested using loading and 
release studies to obtain performance characteristics.  The polymer formulations 
included P(MAA-g-EG) and P(MAA-co-NVP) and also differed in synthesis parameters 
such as crosslinker length, monomer-to-solvent ratio, and particle size.  Loading studies 
performed on all formulations verified that each formulation was capable of loading a 
significant amount of calcitonin-transferrin conjugates and that a few polymer 
formulations were marginally better at loading calcitonin-transferrin conjugates.  Upon 
performing release studies, the selected polymer formulation for optimal release 
characteristics for obtaining high bioavailability upon administration was P(MAA-g-EG) 
microparticles less than 75 microns in size, crosslinked with PEGDMA1000, and 
synthesized using a 50:50 monomer-to-solvent ratio.  The selected optimized polymer 
carrier along with the synthesized calcitonin-transferrin conjugates received further 
investigation into their properties and potential to achieve high bioavailability upon 
administration by evaluation via cell studies performed in a later chapter. 
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Figure 7.1 Loading efficiencies of calcitonin-transferrin conjugates in P(MAA-g-EG) 
microparticles of differing crosslinker lengths before and after particle collapse and 
surface washing. 
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Figure 7.2 Polymer weight fractions of calcitonin-transferrin in loaded P(MAA-g-
EG) formulations of differing crosslinker lengths. 
  225 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
50/50 60/40 67/33
Monomer-to-Solvent Ratio
C
a
lc
it
o
n
in
-T
ra
n
sf
e
rr
in
 L
o
a
d
e
d
 (
%
)
Initial
Final
Figure 7.3 Loading efficiencies of calcitonin-transferrin conjugates in P(MAA-g-EG) 
formulations of differing monomer-to-solvent ratios before and after particle collapse 
and surface washing. 
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Figure 7.4 Polymer weight fractions of calcitonin-transferrin conjugates in P(MAA-
g-EG) formulations synthesized using different monomer-to-solvent ratios. 
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Figure 7.5 Loading efficiencies of calcitonin-transferrin conjugates in P(MAA-g-EG) 
formulations of differing particle sizes before and after particle collapse and surface 
washing. 
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Figure 7.6 Polymer weight fractions of calcitonin-transferrin conjugates in P(MAA-
g-EG) formulations of different particle size ranges. 
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Figure 7.7 Loading efficiencies of calcitonin-transferrin conjugates in P(MAA-g-EG) 
and P(MAA-co-NVP) polymer formulations before and after particle collapse and 
surface washing. 
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Figure 7.8 Polymer weight fractions of calcitonin-transferrin conjugates in P(MAA-
g-EG) and P(MAA-co-NVP) polymer formulations. 
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Figure 7.9 Release profiles of calcitonin-transferrin conjugates loaded in P(MAA-g-
EG) microparticles of differing crosslinker lengths and placed in PBS buffer (pH 7.4). 
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Figure 7.10 Release profiles of calcitonin-transferrin conjugates loaded in P(MAA-g-
EG) microparticles of differing monomer-to-solvent ratios and placed in PBS buffer (pH 
7.4). 
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Figure 7.11 Release profiles of calcitonin-transferrin conjugates loaded in P(MAA-g-
EG) microparticles of differing particle sizes and placed in PBS buffer (pH 7.4). 
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Figure 7.12 Release profiles of calcitonin-transferrin conjugates loaded in P(MAA-g-
EG) and P(MAA-co-NVP) microparticles and placed in either PBS buffer (pH 7.4) or PBS 
buffer (pH 3.2). 
  235 
REFERENCES 
 
1. Azari, P. R., and Feeney, R. E., Resistance of Metal Complexes of Conalbumin and 
Transferrin to Proteolysis and to Thermal Denaturation. J. Biol. Chem., 1958. 
232(1): p. 293-302. 
2. Khandare, J., and Minko, T., Polymer-drug conjugates: Progress in polymeric 
prodrugs. Prog. Polym. Sci., 2006. 31(4): p. 359-397. 
3. Li, C., and Wallace, S., Polymer-drug conjugates: Recent development in clinical 
oncology. Adv. Drug Deliver. Rev., 2008. 60(8): p. 886-898. 
4. Pasut, G., and Veronese, F.M., Polymer-drug conjugation, recent achievements 
and general strategies. Prog. Polym. Sci., 2007. 32(8-9): p. 933-961. 
5. Nakamura, K., Morishita, M., Ehara, J., Onuki, Y., Yamagata, T., Kamei, N., 
Lowman, A.M., Peppas, N.A., and Takayma, K., Key functions in polymer carriers 
for intestinal absorption of insulin. Int. J. Pharm., 2008. 354(1-2): p. 135-142. 
6. Wood, K.M., Stone, G., and Peppas, N.A., Lectin functionalized complexation 
hydrogels for oral protein delivery. J. Control. Release, 2006. 116(2): p. e66-e68. 
7. Lowman, A.M., Morishita, M., Kajita, M., Nagai, T., and Peppas, N.A., Oral 
delivery of insulin using pH-responsive complexation gels. J. Pharm. Sci., 1999. 
88(9): p. 933-937. 
8. Duncan, G., Jess, T.J., Mohamed, F., Price, N.C., Kelly, S.M., and van der Walle, 
C.F., The influence of protein solubilisation, conformation and size on the burst 
release from poly(lactide-co-glycolide) microspheres. J. Control. Release, 2005. 
110(1): p. 34-48. 
9. Hasan, A.S., Socha, M., Lamprecht, A., Ghazouani, F.E., Sapin, A., Hoffman, M., 
Maincent, P., and Ubrich, N., Effect of the microencapsulation of nanoparticles 
on the reduction of burst release. Int. J. Pharm., 2007. 344(1-2): p. 53-61. 
10. Huang, X., and Brazel, C.S., On the importance and mechanisms of burst release 
in matrix-controlled drug delivery systems. J. Control. Release, 2001. 73(2-3): p. 
121-136. 
  236 
11. Luan, X., Skupin, M., Siepmann, J., and Bodmeier, R., Key parameters affecting 
the initial release (burst) and encapsulation efficiency of peptide-containing 
poly(lactide-co-glycolide) microparticles. Int. J. Pharm., 2006. 324(2): p. 168-175. 
12. Tobler, P.H., Jöhl, A., Born, W., Maier, R., and Fishcer, J.A., Identity of calcitonin 
extracted from normal human thyroid glands with synthetic human calcitonin-(1-
32). BBA-Protein Struct. M., 1982. 707(1): p. 59-65. 
13. Morishita, M., Goto, T., Peppas, N.A., Joseph, J.I., Torjman, M.C., Munsick, C., 
Nakamura, K., Yamagata, T., Takayama, K., and Lowman, A.M., Mucosal insulin 
delivery systems based on complexation polymer hydrogels: effect of particle size 
on insulin enteral absorption. J. Control. Release, 2004. 97(1): p. 115-124. 
14. Lowman, A.M., and Peppas, N.A., Molecular analysis of interpolymer 
complexation in graft copolymer networks. Polymer, 2000. 41(1): p. 73-80. 
 
 
  237 
CHAPTER 8 
EVALUATION OF INSULIN-TRANSFERRIN CONJUGATES BY INVESTIGATION 
USING CELLULAR MODELS AND IN VIVO ANIMAL MODELS 
 
 
8.1 Introduction 
When evaluating the potential of a novel oral dosage form for oral delivery, it is 
necessary to examine cellular interactions with the therapeutic entity using cellular 
models as well as to determine performance of the drug in vivo using animal models.  
Investigation of the insulin-transferrin conjugate using cellular and animal models can 
give insight into a number of important factors governing efficacy and bioavailability of 
the potential drug formulation.   
The mechanism of absorption of insulin-transferrin conjugate can be determined 
by comparing the permeability alone and in the presence of excess transferrin which 
would act as a competitive binding agent.  Verification of transcellular transport of the 
insulin-transferrin conjugate is essential towards demonstrating the potential for use of 
protein-transporter conjugates for oral delivery.   
Cellular models can be used to compare the permeability and transport of 
insulin-transferrin conjugates to native insulin.  If comparison of the two reveals 
increased transport in the case of the insulin-transferrin conjugate, then transcellular 
transport holds greater potential to achieve high bioavailability than systems based on 
paracellular transport.   
Cellular studies performed in the presence of the P(MAA-g-EG) microparticles 
will also give insight into the effect of complexation hydrogels on the integrity of the 
epithelial cell monolayer.  Also, preliminary studies performed using animal models can 
be used to verify the synthesis of insulin-transferrin conjugates as well as to confirm the 
therapeutic bioactivity of insulin.  As a result from evaluation of the insulin-transferrin 
conjugate using cellular and animal models, it can be determined whether the use of 
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protein-transporter conjugates as a strategy to increase bioavailability of orally 
delivered proteins is a viable concept and whether the system design deserves 
consideration for further testing and implementation into other existing pharmaceutical 
processes. 
In previous chapters, insulin-transferrin conjugates were synthesized, 
characterized, and then loaded and released from complexation hydrogel carriers to 
determine the optimal carrier for the conjugates.  Assuming optimal release 
characteristics are achieved, a large portion of therapeutic conjugate will arrive in the 
small intestine at the site of absorption upon administration.  However, to determine 
the nature and degree of the absorption of the conjugate into the bloodstream, it is 
necessary to examine the interaction between the conjugate and the cell monolayer 
which lines the small intestine.  The epithelium lining the small intestine contains a cell 
monolayer which consists of six different types of cells:  enterocytes (absorptive cells), 
goblet cells (produce mucus), endocrine cells, paneth cells, M cells, and tuft and cup 
cells [1].  To investigate epithelial cellular interactions with therapeutics, cell monolayers 
can be constructed in vitro to simulate interactions which may occur in the small 
intestine of a typical patient.  However, it is extremely difficult to form cellular models 
using all six types of intestinal epithelial cells in the proper proportions, forcing most 
cellular models to be designed as a simplified system while still being representative of 
in vivo characteristics and interactions. 
A common cellular model used to evaluate therapeutics is the Caco-2 cell line.  
Caco-2 cells, extracted from a human colon, act as an analog to intestinal epithelial 
enterocyte cells and are the most widely used cells for determining permeability of a 
specified molecule [2-5].  More specifically, Caco-2 cell lines are used as a tool for rapid 
screening when comparing the transport or permeability of various drugs and 
therapeutics [6].  Caco-2 cell lines are generally used as cellular models by growing a 
monolayer of the cells on a permeable support.  After a rigid monolayer has formed, a 
drug or therapeutic can be placed on the apical (top) side of the monolayer.  Over time, 
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a portion of the drug will be transported to the basolateral (bottom) side, allowing for 
the calculation of permeability and the observation of transport characteristics. 
The use of Caco-2 cell lines for cellular studies also has some disadvantages.  
While Caco-2 cells accurately represent the absorptive enterocytes of the small intestine, 
the use of Caco-2 cells as a model does not account for contributions from the other five 
types of cells present in the intestinal epithelium.  For example, in the epithelium of the 
small intestine, the enterocytes are covered by mucus which is secreted by the goblet 
cells.  The presence of mucus has been found to have a profound effect on the diffusion 
of drugs across the epithelial cell barrier [7, 8].   
In an effort to create more realistic cellular models, co-cultures have been 
developed consisting of Caco-2 cells and HT29-MTX cells (mucus secreting goblet cells) 
[9].  Due to the large size of the insulin-transferrin conjugate, it is essential to provide 
accurate conditions for diffusion of the large molecule in order to calculate reasonable 
and meaningful permeability values.  To more closely mimic the conditions of the small 
intestine, a co-culture of Caco-2/HT29-MTX cells were used as the cellular model for all 
investigations. 
Transport of orally administered therapeutics into the bloodstream can occur 
through a number of different mechanisms of absorption [10] as shown in Figure 8.1.  
Drug molecules can be absorbed either through the cell membranes (transcellular 
transport) or through the tight junctions between the cells (paracellular transport).   
Transcellular transport can be further classified as either passive diffusion, efflux 
transport, carrier-mediated transcytosis, or receptor-mediated endocytosis.  Past work 
involving oral delivery of insulin using P(MAA-g-EG) hydrogels has relied on paracellular 
transport for the absorption of insulin.  Furthermore, the presence of the hydrogels has 
been to shown to approximately double paracellular transport of insulin due to the 
capacity of the hydrogels to bind calcium, which is vital to maintenance of the tight 
junctions [11].  However, paracellular transport of insulin has a few inherent 
disadvantages.   
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Even with increased absorption due to the presence of the hydrogels, the 
bioavailability of insulin is still low in most cases.  Also, paracellular transport is not 
specific to insulin molecules, allowing the possible introduction of viruses or toxins into 
the bloodstream during the period in which the integrity of the tight junctions is 
lowered.  The development of protein-transporter conjugates allows for utilization of 
transcellular pathways.  Specifically, binding therapeutic proteins to transporter ligands 
utilizes the specificity of the receptor-ligand interaction to transport the therapeutic 
protein using receptor-mediated endocytosis.  Increased specific targeting of the 
protein-transporter conjugate should minimize risk of introduction of viruses or toxins 
as well as to potentially increase bioavailability in the bloodstream. 
Important information about the insulin-transferrin conjugate can be 
ascertained by simulating cellular transport under a number of different conditions.  By 
placing only the protein on the apical side of the chamber, it is possible to compare the 
permeability of insulin and insulin-transferrin conjugates as to determine if the presence 
of transferrin increases absorption.  By performing similar tests but in the presence of 
P(MAA-g-EG) microparticles, it is also possible to determine if the calcium binding effect 
of the hydrogel will change the amount of drug transported in either/both cases.  Lastly, 
by performing a transport study with excess transferrin in solution with the conjugate, 
insight can be gained as to the mechanism of absorption.   If the permeability of insulin-
transferrin conjugates is significantly lowered because of the introduction of excess 
transferrin, transcellular transport must be occurring to some degree due to the drop in 
conjugate transport from competitive binding at receptor sites.  By comparing transport 
studies, valuable information related to potential bioavailability of insulin-transferrin 
conjugates can be obtained. 
While cellular models are designed to mimic physiological conditions within the 
small intestine, they cannot predict the reaction of a living organism to the therapeutic 
drug and they cannot help to validate the efficacy or bioactivity of the therapeutic 
protein.  To validate the potential use of insulin-transferrin conjugates, studies were 
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performed in vivo to verify the synthesis of the bioconjugate and to evaluate bioactivity 
of the insulin molecule.  Upon administration of insulin-transferrin conjugates into the 
bloodstream, subsequent reduction of blood-glucose level would demonstrate that 
insulin-transferrin conjugates were successfully synthesized (insulin alone would have 
been dialyzed out) and that insulin is still bioactive despite having undergone an 
extensive conjugation reaction.  Animal studies designed to evaluate efficacy and 
bioactivity are an essential step towards gaining the necessary level of understanding 
needed to further pursue the investigation of a novel therapeutic for practical 
applications. 
The overall objectives of the studies performed in this chapter are to evaluate 
the performance of insulin-transferrin conjugates using in vitro cellular models and in 
vivo animal models.  In this chapter, insulin-transferrin conjugates will be evaluated 
using a Caco-2/HT29-MTX co-culture under differing conditions such as using pure 
insulin versus using insulin-transferrin conjugates, introducing the P(MAA-g-EG) 
microparticles, and introducing excess transferrin for competitive binding.  Also, this 
chapter will determine the in vivo reaction of animal models to administration of insulin-
transferrin conjugates.  The cellular studies will shed light on the degree of increased 
transport due to transferrin, the effect of the presence of the microparticles, and the 
mechanism of absorption.  The animal studies will give some idea as to the potential 
efficacy of the drug as well as to determine if the therapeutic insulin is still bioactive.  If 
the data from this chapter and the previous chapters proves that the use of insulin-
transferrin conjugates is a significant improvement to previously designed systems for 
oral insulin delivery, then the concept of protein-transporter conjugates merits further 
investigation and possible implementation into other pharmaceutical designs as well. 
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8.2 Materials and Methods 
8.2.1 Development of Caco-2/HT29-MTX Monolayers 
To effectively perform the transport studies using insulin-transferrin conjugates, 
monolayers consisting of a co-culture of Caco-2/HT29-MTX cells had to be formed.  To 
form the monolayer, both types of cells were initially cultured in culturing flasks (75 cm2, 
VWR Scientific, West Chester, PA) with 10 mL of culture media (DMEM, Biofluids Inc., 
Rockville, MD).  The DMEM culture media was also supplemented with 10% fetal bovine 
serum and 1% non-essential amino acids (penicillin, streptomycin, amphotericin B) 
(Mediatech, Inc., Manassas, VA).  Cultivation was performed at a seeding density of 2.5 
x 105 cells per flask for the Caco-2 cells and 1.25 x 105 cells per flask for the HT29-MTX 
cells.  During cultivation, the cells were incubated at 37° C, 95% relative humidity, and 
5% CO2 while the culture media was replaced every other day until the cells reached 70-
80% confluency.  After reaching the desired confluency, the cells were passaged by 
rinsing 3 times with DPBS and subsequent trypsinization via exposure to a trypsin-EDTA 
solution (0.05% w/v trypsin, 0.02% w/v EDTA, MP Biomedical, Solon, OH) for 5 minutes.  
Both types of cells were passaged at least once prior to combination of the cell types.  
The Caco-2 cells had passage numbers between 77 and 78 while the HT29-MTX cells had 
passage numbers between 17 and 19.  After passaging, the Caco-2 and HT29-MTX cells 
were transferred at the desired seeding density to experimental wells in a 1:1 ratio as to 
obtain a 50% Caco-2/50% HT29-MTX experimental co-culture monolayer. 
For the transport studies, a co-culture of Caco-2/HT29-MTX cells was grown in 6-
well Transwell® plates (4.71 cm2/well, Costar Corning Inc., Corning, NY).  The cell density 
in the experimental wells was approximately 3 x 105 cells/well with the composition 
being 50% of each cell type.  The co-culture was grown in the culture medium for 
approximately 21-23 days until the monolayer achieved a constant transepithelial 
electrical resistance (TEER) as measured by a chopstick electrode (World Precision 
Instrument, Sarasota, FL).  Typically, a constant TEER value indicates that the monolayer 
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has formed tight junctions [12, 13].  During the formation of the monolayer, the culture 
media was changed every other day and the TEER was monitored regularly.   
Each experimental well is composed of two compartments:  an apical (top) side 
which represents the small intestine, and a basolateral (bottom) side which potentially 
represents transport to the bloodstream.  The apical and basolateral compartments 
were separated only by the cell monolayer which was grown on a porous membrane 
support.  The experiment setup for transport studies for each well can be seen as Figure 
8.2. 
Upon the formation of tight junctions, the transport studies began by allowing 
the cells to equilibrate with Hank’s Balanced Salt Solution (HBSS, HyClone, Logan, UT), 
the experimental medium for the study.  The HBSS also contained Ca2+ ions to ensure 
regulation of intracellular Ca2+ ions, which are instrumental in maintaining the integrity 
of the tight junctions.  A volume of 1.5 mL of HBSS was added to both the apical and 
basolateral chambers.  The TEER of the cell monolayer was monitored for the next hour 
with samples withdrawn at 0, 15, 30, 45, and 60 minutes.  At the conclusion of the 
equilibration period, the TEER had achieved and maintained a constant value, indicating 
adjustment to the HBSS solution as well as the ability to begin the transport studies. 
 
8.2.2 Protein Transport Across the Cell Monolayer 
Three transport studies were performed using only protein in the apical chamber.  
An insulin control study was performed to determine the permeability of insulin alone.  
A study using insulin-transferrin conjugates was performed to determine if there is 
increased transport due to the presence of transferrin.  A final transport study was 
performed with insulin-transferrin conjugates in the presence of excess transferrin as to 
determine the mechanism of absorption of the conjugate.  Excess transferrin should 
serve as a competitive binding entity, thus lowering the permeability of insulin-
transferrin conjugates if the transport is indeed transcellular. 
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For the studies, insulin or insulin-transferrin was dissolved in warm HBSS at a 
concentration of 0.2 mg/mL.  For the study with excess transferrin, insulin-transferrin 
was dissolved at a concentration of 0.2 mg/mL while transferrin was dissolved at a 
concentration of 2.0 mg/mL.  To begin the study, the previous HBSS solution was 
removed from the apical chamber.  Approximately 1.5 mL of the solution containing 
either the insulin, insulin-transferrin, or conjugate and excess transferrin was then 
placed in the apical chamber.  The Transwell® plates were then placed in an incubator at 
37° C.  Samples of 100 μL were withdrawn from the basolateral chambers at time points 
of 0, 0.5, 1, 2, and 3 hours after the addition of protein solution to the well.  Also, 
samples of 100 μL were withdrawn from the apical chambers at time points of 0 and 3 
hours to observe any change in apical protein concentration.  The TEER of the 
monolayer was also measured at the withdrawal of each sample.  Throughout the 
course of the transport study, all measurements were taken while maintaining the 
Transwell® plate at 37° C, ensuring no changes in the integrity of the tight junctions or in 
the amount of transcellular transport as both vary significantly as temperature varies.  
The samples were placed in small vials and refrigerated until they could be analyzed.  
Analysis of protein concentration of the apical chamber was performed by HPLC and 
protein concentration in the basolateral chamber was determined by use of an ELISA kit. 
 
8.2.3 Protein Transport Across the Cell Monolayer in the Presence of P(MAA-g-EG) 
Microparticles 
In addition to transport studies using only proteins, more transport studies were 
performed to determine the effect of the presence of P(MAA-g-EG) microparticles on 
the cellular transport of both insulin and insulin-transferrin conjugates.  Because the 
P(MAA-g-EG) microparticles are anionic, the local negative charges throughout the 
polymer network attract positively charged extracellular Ca2+ ions, thereby lowering 
intracellular Ca2+ concentrations.  Intracellular Ca2+ is vital to maintaining the integrity of 
the tight junctions, thus causing P(MAA-g-EG) microparticles to act as a transport 
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enhancer for paracellular transport.  Since the mechanism of absorption for insulin is 
thought to be paracellular, insulin transport should benefit from the presence of anionic 
polymer microparticles.  However, because insulin-transferrin conjugates are thought to 
undergo transcellular transport, the presence of P(MAA-g-EG) microparticles should 
have no effect on the transcellular transport of the conjugate.  Alternatively, there may 
be a combinatorial effect of transcellular transport as well as paracellular transport due 
to the presence of the microparticles. 
The polymer microparticles used in this study are the exact same microparticles 
which were determined optimal for the loading and release of insulin-transferrin 
conjugates in Chapter 6.  As with the previous transport studies, solutions of either 
insulin or insulin-transferrin conjugates were prepared at a concentration of 0.2 mg/mL 
in warm HBSS.  After removing the HBSS used for equilibration of the monolayer from 
the apical chamber, approximately 1.5 mL of either of the protein solutions was added 
to refill the apical chamber with sample.  Immediately after addition of the protein 
solutions to the apical side, dry P(MAA-g-EG) microparticles were added to the apical 
chamber at a concentration of 1 mg/mL.  Sampling of both the apical and basolateral 
chambers occurred in the same manner as previously described and all samples were 
analyzed by either HPLC (apical samples) or using an ELISA kit (basolateral samples). 
 
8.2.4 Apical Sample Protein Concentration Analysis by HPLC 
High Performance Liquid Chromatography (HPLC) was used to analyze samples 
from the apical chamber containing either insulin or insulin-transferrin conjugates 
dissolved in HBSS.  HPLC analysis was used for each sample to determine concentration 
based on absorbance values relative to absorbances of standard samples of known 
concentrations.  Protein concentrations in the apical chamber as determined by HPLC 
are values used to calculate permeability values of the transported protein. 
The HPLC equipment used consists of a Waters 2695 Separation Module (Waters 
Corporation, Milford, MA) attached to a Waters 2487 Dual λ Absorbance Detector 
  246 
(Waters Corporation, Milford, MA).  Analysis is performed using a reverse-phase 
analytical HPLC method designed to elute a wide range of proteins within a specified 
time period.  The method includes the use of water (HPLC Grade, Fisher Scientific, Fair 
Lawn, NJ) with 0.1% by volume trifluoroacetic acid (TFA, ACROS Organics, Geel, Belgium) 
as Solvent A and acetonitrile (Optima, Fisher Scientific, Fair Lawn, NJ) with 0.08% by 
volume TFA as Solvent B.  During the separation process, the mobile phase begins at a 
composition of 70% Solvent A and 30% Solvent B.  The mobile phase changes 
composition using a gradient to 40% Solvent A and 60% Solvent B within 6 minutes.  The 
mobile phase composition is then returned to initial conditions of 70% Solvent A and 
30% Solvent B for the next sample to be analyzed.  The mobile phase was introduced at 
a constant flow rate of 0.6 mL/min.  All separations are performed using a 
Symmetry300TM C4 column (particle size 5 µm, 3.9 mm I.D. x 150 mm length, Waters 
Corporation, Milford, MA) held at a constant temperature of 40°C.  After separation of 
proteins, absorbance of the solution was detected at a wavelength of 220 nm.  All 
instrument and processing methods were controlled and specified using the Empower 
software. 
 
8.2.5 Measurement of Transported Insulin and Insulin-Transferrin Conjugate Using 
ELISA Assay Kits 
The concentration of free insulin as well as transferrin-bound insulin transported 
across the cell monolayer was determined using an enzyme-linked immunosorbent 
assay (ELISA) for detection of bovine insulin (Mercodia AB, Uppsala, Sweden).  ELISA 
uses the direct sandwich technique in which two monoclonal antibodies are directed 
towards two different antigenic determinants on the insulin molecule.  Insulin in the 
sample initially reacts with peroxidase-conjugated anti-insulin antibodies bound to the 
bottom of each well.  After washing out unbound antibody, the insulin-antibody 
complex is detected by reaction with 3,3’-5,5’-tetramethylbenzidine (TMB).  The 
reaction can be stopped with the addition of an acidic stop solution which gives a 
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colorimetric endpoint which can be read using spectrophotometry.  A standard curve 
can be generated using the provided calibrator solutions of known concentrations. 
Preliminary experiments were performed to determine the dilution factors 
necessary to adjust the sample concentrations within a detectable range for the assay.  
The basolateral samples were diluted using HBSS to several different concentrations and 
then analyzed spectrophotometrically.  Based on the results of the experiments, all 
samples were diluted by a factor of 300 times to ensure proper measurement of the 
sample insulin concentration. 
The experimental process for using the ELISA assay to determine insulin 
concentration was performed using the materials provided in the assay kit and 
according to the provided instructions.  A volume of 25 µL of either calibrator solutions 
or basolateral samples was placed in each well for analysis.  Approximately 100 µL of 
enzyme conjugate solution containing peroxidase-conjugated anti-insulin antibodies 
was added to each well and the entire plate was incubated on a plate shaker (Model 
4625, Lab-Line Instruments Inc., Melrose Park, IL) for 2 hours at room temperature.  
After incubation, the wells were washed 6 times using a wash buffer to remove excess 
unreacted antibody.  After emptying all excess fluid, 200 µL of the substrate TMB was 
added to each well and the plate was incubated for 15 minutes at room temperature.  
At the conclusion of the incubation period, 50 µL of acidic stop solution was added to 
each well and placed on the plate shaker for 5 seconds to reach the colorimetric 
endpoint.  Each well was analyzed using a microplate reader (Synergy HT, Bio-Tech 
Instruments, Winooski, VT) at a wavelength of 450 nm.  The absorbance of each sample 
was compared to calibrator absorbances to determine the concentration of each sample 
well. 
 
8.2.6 In Vivo Animal Studies 
Preliminary animal studies were performed to measure the bioactivity and to 
verify the synthesis of insulin-transferrin conjugates.  The animal studies were 
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performed under compliance with the regulations of the Committee on Ethics in the 
Care and Use of Laboratory Animals. The animal models were male Sprague–Dawley 
rats (Tokyo Laboratory Animals Science Co., Ltd., Tokyo, Japan) weighing between 180–
220 g and were housed in rooms controlled between 23 ± 1 °C and 55 ± 5% relative 
humidity.  The rats also had free access to water and food during acclimatization.  
Following anesthetization by intraperitoneal injection of sodium pentobarbital (50 
mg/kg of body weight; Dainippon Pharmaceutical Co., Ltd., Osaka, Japan), rats were held 
in a supine position on a thermostatically controlled board at 37 °C.  Additional 
intraperitoneal injections of sodium pentobarbital (12.5 mg/kg) were used every hour to 
maintain the appropriate level of anesthesia. 
The studies were performed by administering insulin-transferrin conjugates 
through the subcutaneous route.  Subcutaneous injection ensures reasonable 
bioavailability of the conjugates in the bloodstream such that the effect on blood 
glucose level can be observed.  Solutions for injection of insulin-transferrin conjugates 
were prepared at approximate conjugate concentrations of 0.125 mg, 0.25 mg, and 0.5 
mg per kilogram of rat body weight.  The three concentrations of conjugates in solution 
roughly correspond to insulin dosages of 0.5 IU/kg, 1.0 IU/kg, and 2.0 IU/kg respectively 
under ideal conjugation reaction conditions.  As a control, recombinant human insulin 
was also injected at a dosage of 1.0 IU/kg. 
After injection of insulin-transferrin conjugates, a sample of 0.25 mL of blood 
was taken from the jugular vein at time points of 0, 5, 10, 15, 30, 60, 120, 180, and 240 
minutes.  Tuberculin syringes (1 mL) were preheparinized by coating the syringe wall 
with aspirating heparin and subsequently expelling all heparin by completely depressing 
the plunger.  Plasma was separated by centrifugation at 13,000 rpm for 1 minute.  Blood 
glucose concentration was measured using a glucose meter (Novo Assist Plus, Novo 
Nordisk Pharma Ltd., Tokyo, Japan) and was used to represent the biological activity of 
the bound insulin within the insulin-transferrin conjugates.  The hypoglycemic response 
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was quantified by examining the blood glucose concentration curve and calculating the 
area above the curve (AAC) using the trapezoidal method for the first 4 hours. 
 
8.3 Results and Discussion 
8.3.1 Development of Caco-2/HT29-MTX Monolayers 
Cell monolayers consisting of a co-culture of 50% Caco-2 cells and 50% HT29-
MTX cells were formed for the use of five separate transport studies.  The transport 
studies included measuring the cellular transport of insulin and insulin-transferrin with 
and without the presence of polymer microparticles as well as a study with insulin-
transferrin conjugates in the presence of excess transferrin.  The cell monolayers for 
each study were constructed identically as to allow comparison between the separate 
transport studies. 
The transepithelial electrical resistance (TEER) was monitored regularly during 
the formation of the cell monolayer.  After 21-23 days, an equilibrium TEER value was 
achieved, indicating the formation of tight junctions within the monolayer.  The 
monolayer was then allowed to equilibrate with warm HBSS, the solvent used for the 
transport studies.  The TEER values of the monolayer were monitored for the next hour 
to ensure equilibration with the fluid before starting the transport studies.  The average 
TEER values for all of the monolayers over the hour of the equilibration period are 
shown in Figure 8.3. 
After equilibrating with HBSS, the monolayers were used for transport studies.  
At the conclusion of the studies, the interaction of the protein with the cell monolayers 
and the amount of protein transported through the monolayers provided a basis of 
comparison between the samples as well as evidence to differentiate between the 
suggested approaches for the oral delivery of insulin and to determine which approach 
is the most effective and useful for drug delivery applications. 
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8.3.2 Protein Transport Across the Cell Monolayer 
Several samples including solutions of either insulin, insulin-transferrin 
conjugates, or insulin-transferrin conjugates with excess transferrin were investigated 
through transport studies.  Transport studies of the different protein solutions were 
conducted by placing dissolved protein in the apical chamber of a Transwell® plate with 
a monolayer of Caco-2/HT29-MTX cells grown on a porous membrane support.  Samples 
were withdrawn from the basolateral chamber at regular time points to determine the 
amount of protein transported over time.  The transport profiles were fit using a linear 
regression model and the slope of the fit was used to calculate apparent permeability 
values (Papp) for each of the protein samples. 
In order to calculate an apparent permeability for protein transport, several 
assumptions and simplifications must first be made.  For this analysis, the cellular 
monolayer is assumed to be similar to a chemically homogenous layer of known 
thickness.  Applying Fick’s first law of diffusion to the protein transport, a relationship 
can be derived between the rate of protein transport and the concentrations of both 
the apical and basolateral chamber.  The relationship is shown as Equation 8.1: 
 
 
 
where Q(t) is the cumulative amount of protein (ng) transported at time t, K is the 
partition of distribution coefficient of the protein within the cell monolayer, D is the 
diffusion coefficient (cm2/s), h is the height or thickness of the cell monolayer (cm), A is 
the area of the cell monolayer (cm2), and CA(t) and CB(t) are the protein concentrations 
(ng/mL or ng/cm3) of the apical and basolateral chambers respectively. 
 To simplify the expression, the first term of the expression was redefined as 
apparent permeability (Papp) using Equation 8.2 as shown below: 
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To further simplify the expression, the term [CA(t) – CB(t)] can be reworked based on the 
relationship between the terms.  Because the concentration in the apical chamber 
(CA(t)) is measured in milligrams and the concentration in the basolateral chamber 
(CB(t)) is measured in nanograms and is much smaller, the basolateral concentration is 
essentially zero.  Also, because very little transport occurs relative to the initial apical 
concentration (CA0), the term [CA(t) – CB(t)] can be replaced by the term CA0.  Using the 
reduced version of Equation 8.1 and solving for apparent permeability (Papp) yields a 
simplified expression for determining permeability values as shown in Equation 8.3: 
 
 
 
In Equation 8.3, the area of the monolayer (A) and the initial apical concentration (CA0) 
are known values.  The term dQ(t)/dt is the slope of the linear fit of the cellular 
transport profiles of each protein. 
As an experimental control, a solution of insulin dissolved in HBSS was added to 
the apical chamber and was allowed to interact with the cell monolayer.  The cellular 
transport profile of insulin from the apical to basolateral chamber for a period of 3 
hours is shown as Figure 8.4.  The data in Figure 8.4 confirms that insulin transport 
across the cell does occur.  In fact, the graph shows that there may be a burst transport 
of insulin across the monolayer, indicated by the high amount of insulin transported 
within 30 minutes and a leveling off of transport over the next few hours.  The apparent 
permeability (Papp) of the insulin relative to the cell monolayer was determined to be 
4.95 x 109 cm/s as calculated using Equation 8.3.  The extent of transport as well as the 
apparent permeability of the insulin control served as a standard of comparison for the 
experimental protein solutions. 
To determine the effect of the conjugation of a transporter protein to insulin, 
the transport of a solution of insulin-transferrin conjugates across the cell monolayer 
was measured and analyzed.  The cellular transport profile of insulin-transferrin 
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conjugates from the apical to basolateral chamber for a period of 3 hours is shown as 
Figure 8.5.  As evident in Figure 8.5, a significant amount of insulin-transferrin conjugate 
was transported across the Caco-2/HT29-MTX monolayer.  In comparison to the insulin 
control, the transport occurred to a much greater extent and also in a much more linear 
fashion.  The linearity of the transport can most likely be attributed to the timing of 
cellular mechanisms involved in transcellular transport, leading to a slower but more 
linear transport profile.  The apparent permeability (Papp) of the insulin-transferrin 
conjugates across the Caco-2/HT29-MTX monolayer was calculated using Equation 8.3 
and found to be 37.0 x 109 cm/s.  The increased permeability of insulin-transferrin 
conjugates compared to the insulin control suggests that the addition of a transporter 
protein such as transferrin will greatly increase the transport of a therapeutic protein 
like insulin across the cell monolayer.  Based on the cellular permeability, the 
conjugation of a transporter protein to a therapeutic protein may also drastically 
increase the bioavailability of the drug in the bloodstream. 
In an attempt to gain more knowledge about the mechanism of absorption of 
insulin-transferrin conjugates, transport studies were performed using a solution of 
insulin-transferrin conjugates with excess unmodified transferrin also in solution.  The 
cellular transport which occurred over a period of 3 hours using insulin-transferrin 
conjugates with excess transferrin is shown as Figure 8.6.  The data from Figure 8.6 
seems to suggest that more insulin-transferrin conjugate was transported due to the 
presence of unmodified transferrin.  However, the presence of excess transferrin was 
thought to have an inhibitory effect due to competitive binding of available transferrin 
receptors.  Moreover, the transferrin molecule has no known ability to increase 
paracellular transport or loosen tight junctions.   
The increased transport can most likely be attributed to unmodified transferrin 
being transported to the basolateral side as expected, but also causing non-specific 
binding between the transferrin in the sample solution and the antibodies lining the 
wells of the ELISA kit, giving a falsely high insulin-transferrin concentration.  However, 
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the graph does allow for some useful insight.  Because of the similarities between the 
transport profiles of the conjugate solution and the conjugate solution with excess 
transferrin, it seems likely that insulin-transferrin conjugates are transported using the 
same transcellular mechanisms as unmodified transferrin, indicating that the 
conjugation of insulin has little effect on the bioactivity of the transferrin molecule.  The 
apparent permeability (Papp) of the proteins across the Caco-2/HT29-MTX monolayer 
was calculated using Equation 8.3 and found to be 76.8 x 109 cm/s.  
While performing the transport studies, it was important to monitor the integrity 
of the cell monolayer and the tight junctions as to ensure that administration of such 
therapeutics would not cause the epithelial cell layer to have a lessened ability to expel 
dangerous viruses or toxins.  Over the course of each transport study, the transepithelial 
electrical resistance was measured as a means of monitoring tight junction integrity.  
The TEER values throughout the three transport studies are shown as Figure 8.7.  As 
evident in Figure 8.7, the TEER of the Caco-2/HT29-MTX monolayer stayed near 100% of 
the initial value throughout the course of each transport study.  The maintenance of 
steady TEER values indicates that the proteins (insulin, insulin-transferrin, transferrin) 
do not have a disruptive effect on the cell monolayer, ensuring their presence upon 
administration will not cause illness due to uptake of dangerous toxins or viruses 
through a weakened epithelial cell barrier. 
To compare the protein transport studies, the most simple and direct method is 
to compare the apparent permeability (Papp) values between the different protein 
solutions.  The apparent permeability values can be directly compared by referencing 
Table 8.1.  According to the values, the insulin-transferrin molecule has more than seven 
times the permeability compared to unmodified insulin.  Increasing transport of a 
potential therapeutic more than sevenfold has dramatic potential ramifications on the 
bioavailability of the drug in the bloodstream.  Based on the results of the transport 
studies conducted using solutions containing only protein, the transport of an orally 
administered therapeutic protein can be greatly increased by conjugating the drug to a 
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transporter molecule such as transferrin.  Upon investigation into a specific protein for 
oral delivery, the use of transporter molecules merits at least investigation and 
experimentation if not incorporation into the system design. 
 
8.3.3 Protein Transport Across the Cell Monolayer in the Presence of P(MAA-g-EG) 
Microparticles 
Several transport studies were conducted on protein solutions with P(MAA-g-EG) 
microparticles added to the solution.  The solutions investigated included a solution 
containing insulin in the presence of P(MAA-g-EG) microparticles and a solution 
containing insulin-transferrin conjugates in the presence of P(MAA-g-EG) microparticles.  
The studies were conducted by first preparing a solution of in which protein was 
dissolved in HBSS and a known mass of polymer microparticles was added.  The 
transport study began as the prepared solution was added to the apical chamber of a 
Transwell® plate with a monolayer of Caco-2/HT29-MTX cells grown on a porous 
membrane support.  Samples were withdrawn from the basolateral chamber at regular 
time points to determine the amount of protein transported over time.  The transport 
profiles were fit using a linear regression model and the slope of the fit was used to 
calculate apparent permeability values (Papp) for each of the protein samples using 
Equation 8.3. 
To determine the effect of the presence of polymer microparticles on cellular 
insulin transport, a prepared solution of insulin dissolved in HBSS with added P(MAA-g-
EG) microparticles was added to the apical chamber and was allowed to interact with 
the cell monolayer.  The cellular transport profile of insulin from the apical to 
basolateral chamber for a period of 3 hours in the presence of P(MAA-g-EG) 
microparticles is shown as Figure 8.8.  As can be seen in Figure 8.4, insulin transport still 
occurs in the presence of P(MAA-g-EG) microparticles.  In comparison to insulin 
transport with no microparticles present, the cumulative amount of insulin transported 
is similar and the initial burst transport of insulin within the first 30 minutes can also be 
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observed.  To quantitatively compare insulin transport with and without the presence of 
P(MAA-g-EG) microparticles, the apparent permeability (Papp) of each study was 
examined.  The apparent permeability (Papp) of the insulin in the presence of polymer 
microparticles was determined to be 5.20 x 109 cm/s as calculated using Equation 8.3.  
The apparent permeability of insulin in the presence of polymer microparticles is slightly 
higher than the value obtained for insulin alone, indicating that the presence of the 
microparticles may have a slight permeation enhancing effect for the paracellular 
transport of insulin.  A higher concentration of microparticles in solution would have 
most likely caused a greater increase in insulin transport due to concurrently increased 
calcium binding capacity, further loosening the tight junctions of the cell monolayer.  In 
addition to protection in the stomach and adhesion near the site of absorption, P(MAA-
g-EG) microparticles facilitate oral delivery of insulin even further by binding to 
extracellular calcium, thereby loosening the tight junctions and increasing the potential 
for paracellular transport. 
Similar transport studies were also conducted which used solutions of insulin-
transferrin conjugates in the presence of P(MAA-g-EG) microparticles to determine if 
the microparticles had a similar effect as was seen with insulin.  The cellular transport 
profile of insulin-transferrin conjugates from the apical to basolateral chamber for a 
period of 3 hours in the presence of P(MAA-g-EG) microparticles is shown as Figure 8.9.  
As can be seen in Figure 8.9, the magnitude of insulin-transferrin conjugates transported 
across the Caco-2/HT29-MTX cell monolayer is much higher than in the other transport 
studies.  To quantitatively compare the transport of conjugate in the presence of 
microparticles to the transport of conjugate alone or the transport of insulin in the 
presence of microparticles, it is essential to determine the apparent permeability (Papp) 
of the study.  The apparent permeability (Papp) of the insulin-transferrin conjugates 
across the Caco-2/HT29-MTX monolayer in the presence of polymer microparticles was 
calculated using Equation 8.3 and found to be 72.8 x 109 cm/s.  In comparison to the 
transport of insulin-transferrin conjugates alone, the permeability of the conjugate 
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nearly doubled in the presence of polymer microparticles.  Though it is not completely 
clear whether the presence of the microparticles enhanced transcellular transport of the 
conjugate or simply opened up paracellular pathways, it is evident that transport was 
greatly increased.  Earlier studies proved that the presence of polymer microparticles 
helped to enhance insulin transport slightly, increasing the apparent permeability by 
roughly 5% at the specified microparticle concentration.   
However, at the same concentration, the microparticles were able to enhance 
insulin-transferrin transport by nearly 100%.  The drastic difference in enhanced 
transport suggests that P(MAA-g-EG) microparticles act as better enhancers for 
transcellular transport than for paracellular transport.  In this study, while improved 
conjugate transport may be slightly attributable to newly opened paracellular pathways, 
it is clear that the microparticles facilitated transcellular transport, possibly through 
calcium binding, the consequent loss of intracellular calcium, and the resultant effect 
which lowered calcium has on transcytotic processes.  It is also useful to compare 
conjugate transport to insulin transport in the presence of microparticles.  Simply 
replacing insulin with insulin-transferrin conjugates at the same concentration but in the 
presence of microparticles increased the apparent permeability by a factor of nearly 
fourteen.  Assuming that a formulation of insulin-transferrin conjugates loaded into 
P(MAA-g-EG) microparticles could deliver the same amount of protein to the site of 
absorption as an insulin-loaded microparticle, the benefit of having potentially fourteen 
times the cellular transport would translate into a much more effective drug with 
significantly higher bioavailability. 
To gain a greater understanding of the effect of microparticles on the integrity of 
the tight junctions and the monolayer, the transepithelial electrical resistance (TEER) 
was measured over the course of the transport studies.  The TEER values throughout the 
two transport studies are shown as Figure 8.10.  As can be seen in Figure 8.10, the TEER 
of the Caco-2/HT29-MTX monolayer stayed near 100% of the initial value throughout 
the course of both transport studies.  Steady TEER values throughout the studies 
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indicate little to no disruption of the monolayer in the presence of both proteins and 
P(MAA-g-EG) microparticles. While previous studies have shown that the TEER values 
and the tight junctions will be affected by the presence of polymer microparticles [11, 
14], the microparticles used in this study were likely not introduced at a high enough 
concentration to achieve the significant disruptive effect that had been observed in 
previous studies. 
To compare all of the transport studies quantitatively, it is important to compare 
the apparent permeability (Papp) values.  The apparent permeability values for all of the 
transport studies can be directly examined in Table 8.1.  Based on the permeability 
values, the insulin-transferrin conjugate alone achieves more than seven times the 
transport of insulin alone.  Meanwhile, the addition of P(MAA-g-EG) microparticles 
increases insulin transport by approximately 5% while improving insulin-transferrin 
transport by nearly 100%.  Because of the ability of the polymer microparticles to 
facilitate transcellular transport to such a large extent, the insulin-transferrin conjugate 
achieves nearly fourteen times the transport that insulin does in the presence of the 
microparticles.  Considering all of the transport studies performed in this work, 
modification of therapeutic proteins by conjugation to transporter molecules remains 
an attractive option for increasing epithelial transport and achieving high bioavailability.   
 
8.3.4 Apical Sample Protein Concentration Analysis by HPLC 
All samples obtained during transport studies from the apical chamber were 
analyzed by HPLC.  The concentration of each sample was determined by comparisons 
to standards of known concentrations.  The experimental concentration of each sample 
was used to calculate the free protein concentration in the apical chamber at the time 
the sample was withdrawn.  The protein concentration as determined by HPLC was used 
to calculate apparent permeability (Papp) using Equation 8.3.  A table of apparent 
permeability values for each transport study is given as Table 8.1. 
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8.3.5 Measurement of Transported Insulin and Insulin-Transferrin Conjugate Using 
ELISA Assay Kits 
The concentrations of protein transported to the basolateral chamber for all 
transport studies were measured using ELISA assay kits.  The use of ELISA kits allows for 
detection of trace amounts of insulin as low as a 0.025 ng/mL.  Using the protocol 
outlined earlier, the ELISA analysis converts insulin concentration to a colorimetric 
endpoint which can be observed spectrophotometrically.  The insulin concentration of 
each sample was determined by comparison of the sample absorbance to absorbance of 
standards of known insulin concentration.  A calibration curve was constructed to 
determine a relationship between absorbance and concentration.  The calibration curve 
for all of the transport studies is shown as Figure 8.11 
In addition to providing a way to measure trace amounts of insulin, the use of 
ELISA kits also provided indirect evidence confirming the activity of the insulin molecule 
despite conjugation to transferrin.  Interaction with both the anti-insulin antibodies and 
the substrate TMB demonstrate that the active sites for both interactions remain intact 
and active. 
 
8.3.6 In Vivo Animal Studies 
Preliminary animal studies were conducted to test for the bioactivity of the 
insulin-transferrin conjugate as well as to verify the synthesis of the conjugate.  The rat 
specimens were injected with three different dosages of insulin-transferrin conjugates 
as well as recombinant human insulin as a control.  Following subcutaneous injection, 
the blood glucose level was monitored for four hours to determine the effect of the 
injected protein.  Reduction of blood glucose level by injection of insulin-transferrin 
conjugate not only confirms bioactivity of the conjugate but also indirectly verifies the 
synthesis reaction by recognizing the drop in blood glucose level as detection of insulin 
in the conjugate. 
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The blood glucose levels of the rat model following injection of experimental 
samples of insulin-transferrin as well as the insulin control are shown as Figure 8.12.  In 
the figure, it is clear that the two higher dosages of insulin-transferrin (1 IU/kg and 2 
IU/kg) both caused a reduction in blood glucose level.  In order to compare the 1 IU/kg 
dose of insulin-transferrin to the 1 IU/kg dose of the insulin control, the area above the 
curve (AAC) was calculated and the areas were compared.  Based on the analysis, 
insulin-transferrin was found to be approximately 15% active assuming a true 1 IU/kg 
dose of insulin within the conjugate.  However, the 1 IU/kg assumption for the insulin-
transferrin dosage is based on ideal conjugation reaction conditions in which every 
molecule of insulin supplied to the reaction was successfully bound to a transferrin 
molecule.  As the previously mentioned condition is the ideal reaction, it means that the 
insulin-transferrin dosage is at most 1 IU/kg and at least 15% active.  If it were assumed 
that the reaction yielded one insulin molecule bound to one transferrin molecule on 
average, then the measure of bioactivity would rise to approximately 40%.  Also, 
samples in this study were lyophilized as a requirement of overseas shipping, possibly 
denaturing a portion of the sample.   
The nature of this animal study was preliminary, and to determine the true 
extent of the bioactivity, a much more refined and controlled sample would have to be 
carefully examined.  However, based on the information available from the animal 
studies, relevant claims regarding the sample can be made.  The studies proved that 
bioactivity of the insulin can be retained throughout the conjugation reaction.  In other 
words, the insulin-transferrin conjugate can actually provide a therapeutic response 
similar to insulin.  Also, during the conjugation reaction, dialysis and purification is 
performed to remove any proteins smaller than transferrin (i.e. unreacted insulin).  An 
insulin-like response upon administration of insulin-transferrin conjugates suggests the 
presence of insulin, verifying the successful synthesis of a true protein-transporter 
conjugate.  Based on the animal studies, it has been shown that protein-transporter 
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conjugates can be synthesized successfully and can still serve as therapeutics while also 
offering improved characteristics such as increased cellular transport. 
 
8.4 Conclusions 
 Cellular evaluation of the insulin-transferrin conjugate was performed using a co-
culture Caco-2/HT29-MTX cell model.  The conjugate was investigated by conducting 
transport studies on both the insulin-transferrin conjugate and an insulin control with 
and without the presence of microparticles.  Also, a transport study in the presence of 
excess transferrin was performed.  Additionally, preliminary animal studies were 
performed by injecting the insulin-transferrin conjugate subcutaneously into rat models 
to verify the bioactivity of the insulin molecule within the conjugate complex.  The 
results of the transport studies indicated a sevenfold increase in transport by replacing 
insulin with insulin-transferrin conjugates.  Also, the presence of P(MAA-g-EG) 
microparticles enhanced transport for both insulin and the insulin-transferrin conjugate, 
but the increase in insulin transport was 5% while the increase in conjugate transport 
was found to be nearly 100%, indicating that the polymer microparticles may assist in 
transcytotic processes.  Finally, the transport studies also demonstrated that a 14-fold 
increase in transport can be achieved by switching from insulin in the presence of 
polymer microparticles to insulin-transferrin conjugates in the presence of polymer 
microparticles.  Upon administration of the insulin-transferrin conjugates to rat subjects 
through subcutaneous injection, the blood-glucose level was noticeably lowered, 
demonstrating the insulin-like therapeutic response of the conjugate as well as 
confirming the bioactivity of the insulin portion of the insulin-transferrin conjugate.  The 
specific targeting, increased transport, and insulin-like therapeutic response of the 
insulin-transferrin conjugate in combination with the protection and site-specific release 
capabilities of P(MAA-g-EG) microparticles combine synergistically to form a potential 
dosage form which could effectively deliver therapeutics to the small intestine and 
across the epithelium, resulting in high bioavailability in the bloodstream. 
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Transport Sample Apparent Permeability (Papp) 
Insulin (control) 4.95 x 109 cm/s 
Insulin with P(MAA-g-EG) Particles 5.20 x 109 cm/s 
Insulin-Transferrin Conjugate 37.0 x 109 cm/s 
Conjugate with P(MAA-g-EG) Particles 72.8 x 109 cm/s 
Conjugate with Excess Transferrin 76.8 x 109 cm/s 
 
 
 
 
 
 
 
 
 
 
 
Table 8.1 Apparent permeability values for each of the transport studies 
calculated using Equation 8.3 
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Figure 8.1  Cellular mechanisms of absorption in the small intestine. 
 
Schematic of (A) paracellular transport and (B) transcellular transport.  Specific types of 
transcellular transport include (B1) passive diffusion, (B2) carrier-mediated transcytosis, 
(B3) receptor-mediated transcytosis, and (B4) efflux transport.  
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Figure 8.2  Experimental setup for transport studies using Caco-2/HT29-MTX co-
culture cell models. 
 
The cell co-culture is grown as a monolayer on a porous membrane support.  Each well 
contains an apical (top) and a basolateral (bottom) chamber.  Protein which is 
transported through the cells can be measured in the basolateral chamber. 
Transepithelial electrical resistance (TEER) is measured by the chopstick electrode. 
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Figure 8.3 Average transepithelial electrical resistance (TEER) of cell monolayers 
for one hour after exposure to warm HBSS solution. 
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Figure 8.4 Cellular transport profile showing the cumulative amount of insulin 
transported across the monolayer of Caco-2/HT29-MTX cells over time. 
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Figure 8.5 Cellular transport profile showing the cumulative amount of insulin-
transferrin conjugates transported across the monolayer of Caco-2/HT29-MTX cells 
over time. 
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Figure 8.6 Cellular transport profile showing the cumulative amount of insulin-
transferrin conjugates transported across the monolayer of Caco-2/HT29-MTX cells 
while in the presence of excess unmodified transferrin. 
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Figure 8.7 Average transepithelial electrical resistance (TEER) values throughout 
the duration of transport studies involving protein solutions consisting of either 
insulin, insulin-transferrin conjugates, or insulin-transferrin conjugates with excess 
unmodified transferrin. 
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Figure 8.8 Cellular transport profile showing the cumulative amount of insulin 
transported across the monolayer of Caco-2/HT29-MTX cells while in the presence of 
P(MAA-g-EG) microparticles. 
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Figure 8.9 Cellular transport profile showing the cumulative amount of insulin-
transferrin conjugate transported across the monolayer of Caco-2/HT29-MTX cells 
while in the presence of P(MAA-g-EG) microparticles. 
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Figure 8.10 Average transepithelial electrical resistance (TEER) values throughout 
the duration of transport studies of insulin or insulin-transferrin conjugates in the 
presence of P(MAA-g-EG) microparticles. 
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Figure 8.11 Calibration curve consisting of known concentrations of insulin in 
solution.  Calibration curve used to determine insulin concentrations of unknown 
samples. 
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Figure 8.12 Blood glucose level of male Sprague-Dawley rats after injection of 
different dosages of insulin-transferrin conjugate or recombinant human insulin 
(control).  Reduction below 100% blood glucose level indicates insulin activity. 
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CHAPTER 9 
CONCLUSIONS 
 Research in the biomedical and pharmaceutical fields has increased drastically in 
recent years in an attempt to develop alternative methods to injection for delivering 
therapeutic proteins.  Research into different possible routes of administration has 
proved that each administration method has inherent advantages and disadvantages [1].  
Among the potential types of protein delivery, oral delivery has the greatest benefits 
including low cost, ease of administration, and high patient compliance.  Specifically, 
high patient compliance is essential to effective treatment because lack of proper 
medicine regimens can lead to serious complications in some diseases such as diabetes 
[2].  Lack of patient compliance is often attributed to fear or discomfort with injections 
[3], increasing the need for development of alternative routes of administration.  
However, oral delivery of proteins also has inherent challenges associated with 
development of a system.  Due to their sensitive nature, most therapeutic proteins will 
be degraded or denatured by the enzymes in the stomach [4].  Also, even if the protein 
survives transit through the stomach, there is a narrow window for absorption in the 
small intestine.  Finally, the epithelial cell layer lining the small intestine represents a 
challenging barrier to entry into the bloodstream.  A successful system design for oral 
delivery of proteins requires protection of the protein in the stomach, increased 
residence time at the site of absorption, and a driving force to enhance cellular 
transport across the epithelial cell barrier. 
 To address some of the challenges associated with oral protein delivery, systems 
have been developed in our laboratory involving the use of complexation hydrogels as 
carriers for therapeutic proteins to protect in the stomach and to release at the site of 
absorption in the small intestine.  While observing significantly increased bioavailability 
of therapeutic proteins in the bloodstream due to the use of hydrogels [5], the epithelial 
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transport barrier remains a major limiting factor for achieving bioavailability values 
similar to those obtained by injection.  Thus, in an effort to enhance the complexation 
hydrogel system design, further modifications were made to the system intended to 
drastically increase epithelial transport into the bloodstream. 
 Complexation hydrogels for the oral delivery of proteins act only as a delivery 
vehicle to the site of absorption, prompting the need for drug modification in order to 
increase epithelial transport.  The approach explored in this work was to conjugate a 
transporter molecule to the therapeutic protein to allow for specific targeting due to 
receptor-ligand interactions as well as increased overall epithelial transport.  The major 
objectives of the work included the synthesis of complexation hydrogel carriers, the 
synthesis and characterization of multiple protein-transporter conjugates, the 
optimization of the polymer carriers with respect to loading and release characteristics 
of the conjugate formulations, and the evaluation of the transport and bioactivity of the 
conjugate using cellular and animal models. 
Several variations of complexation hydrogel carriers were synthesized including 
P(MAA-g-EG) and P(MAA-co-NVP) of different crosslinker lengths, monomer-to-solvent 
ratios, and particle sizes.  The majority of the polymers were characterized by scanning 
electron microscopy to investigate the size variations, morphology, and surface features 
of each system.  Based on the characterizations, insight was gained on the type of visual 
differences that rigidity and tightness of the polymer network can create between 
systems as well as insight into mechanical properties which ultimately affect the 
performance of the polymer carriers.   
Novel protein-transporter conjugates consisting insulin bound to transferrin and 
calcitonin bound to transferrin were successfully synthesized using the protein 
crosslinker SPDP.  The final products insulin-transferrin and calcitonin-transferrin are 
both characterized by a disulfide bond connecting the two proteins.  Each conjugation 
reaction was analyzed using UV spectroscopy, HPLC for conjugate verification, and HPLC 
for quantification of overall reaction yield.  Based on the analyses, it was proven that 
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intact conjugates were indeed synthesized in a controlled, repeatable manner which 
also gave significant reaction yields.  The novel conjugates synthesized were intended to 
provide a greater specificity for drug uptake as well as to provide potential for increased 
transport. 
To specifically investigate the insulin-transferrin conjugates, studies were 
performed to gain insight into the in vitro characteristics with relation to loading and 
release in polymer microparticle carriers.  Specifically, a number of experiments were 
run to find the optimal polymer carrier to ensure sufficient release of insulin-transferrin 
conjugates in the small intestine.  To adjust the polymer carriers for the increased size of 
the conjugate relative to insulin, a protocol was designed for use with transferrin and it 
was tested as a protein analog to determine its loading and release characteristics.  The 
polymer carriers were found to perform well with a large molecule, allowing for 
investigation into the loading and release characteristics of the specific insulin-
transferrin conjugates.  To optimize the polymer carrier for use with insulin-transferrin, 
several polymer formulations including P(MAA-g-EG) and P(MAA-co-NVP) which differed 
in synthesis parameters such as crosslinker length, monomer-to-solvent ratio, and 
particle size were investigated.  Loading studies performed on all polymer systems 
confirmed that each system was capable of loading a significant amount of insulin-
transferrin conjugates.  Based on the release studies, the optimal polymer carrier for 
insulin-transferrin conjugates was found to be P(MAA-g-EG) microparticles less than 75 
microns in size, crosslinked with PEGDMA1000, and synthesized using a 50:50 
monomer-to-solvent ratio. 
The calcitonin-transferrin conjugates were also investigated with relation to 
finding an optimal carrier for their use in oral delivery applications.  The loading and 
release characteristics of calcitonin-transferrin conjugates in several polymer systems 
were examined.  The polymer systems tested for optimization included P(MAA-g-EG) 
and P(MAA-co-NVP) which differed in synthesis parameters such as crosslinker length, 
monomer-to-solvent ratio, and particle size.  Loading studies performed on all batches 
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of polymers showed that while most systems loaded a similar amount of conjugate, a 
few polymer formulations were marginally better at loading calcitonin-transferrin 
conjugate. By combining the results of the loading and release studies, the optimal 
polymer for use with calcitonin-transferrin conjugates was also found to be P(MAA-g-
EG) microparticles less than 75 microns in size, crosslinked with PEGDMA1000, and 
synthesized using a 50:50 monomer-to-solvent ratio. 
 After determining the optimal carrier for insulin-transferrin and calcitonin-
transferrin, the insulin-transferrin conjugate was chosen for evaluation of potential oral 
delivery characteristics using cellular and animal models.  The cellular model used for 
evaluation was a co-culture Caco-2/HT29-MTX cell model.  The insulin-transferrin 
conjugate was investigated by conducting transport studies on both the insulin-
transferrin conjugate and an insulin control with and without the presence of 
microparticles.  The results of the transport studies showed a sevenfold increase in 
transport by changing insulin to insulin-transferrin.  Also, the presence of P(MAA-g-EG) 
microparticles enhanced transport for insulin by 5% and insulin-transferrin by nearly 
100%, suggesting that the polymer may enhance transcytotic processes to some degree.  
The transport studies also showed that a 14-fold increase in transport can be achieved 
by replacing insulin in the presence of polymer microparticles with insulin-transferrin 
conjugates in the presence of polymer microparticles.  In addition to the cellular studies, 
preliminary animal studies were conducted by performing subcutaneous injections of 
the insulin-transferrin conjugate into rat subjects to verify the bioactivity of the insulin 
portion of the insulin-transferrin conjugate.  The animal studies showed that injection of 
insulin-transferrin conjugate causes the blood-glucose level to be noticeably lowered, 
demonstrating a therapeutic response similar to insulin as well as confirming the 
bioactivity of the insulin molecule within the conjugate complex.  The animal and 
cellular models used to evaluate the insulin-transferrin conjugate provide merit towards 
considering future implementation of protein-transporter conjugates into the design of 
new oral delivery systems. 
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 Throughout the investigations of researchers attempting to design oral protein 
delivery systems, the recurring factor which limits bioavailability most frequently is 
epithelial transport.  Within the chapters of this thesis, the idea of enhancing epithelial 
transport by the use of protein-transporter conjugates has been rigorously investigated.  
As seen in the cellular studies, the use of protein-transporter conjugates has the 
potential to increase epithelial transport several times over.  The probability is high that 
such a dramatic increase in epithelial transport would translate to a drastic increase in 
bioavailability of the therapeutic protein.  The implementation of protein-transporter 
conjugates into the majority of existing oral delivery system designs such as the use of 
complexation hydrogels certainly merits consideration if not action.  In the case of this 
specific system, the use of insulin-transferrin conjugates in P(MAA-g-EG) microparticles 
as an oral insulin delivery demonstrates extreme potential.  To create the most efficient 
system possible, more optimization experiments need to be performed with relation to 
some of the smaller details.  Also, further testing using animal models would provide 
feedback on which parameters need to be altered to further improve performance in 
vivo.  However, the research already performed identifies the use of protein-transporter 
conjugates as a viable strategy to improve epithelial transport.  The combination of the 
benefits of the polymer carriers (protection in the gastric environment, site-specific 
release) with the benefits of the protein-transporter conjugates (specific uptake, 
increased transport, insulin-like therapeutic response) allows for the systems 
investigated in this work to be considered as very promising candidates for the effective 
oral administration of insulin. 
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